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Chapter 1
Multiple Functions and 
Disordered Nature of 
Nucleocapsid Proteins of 
Retroviruses and Hepadnaviruses
Jean Luc Darlix and Hugues de Rocquigny
Abstract
This chapter aims at presenting small viral proteins that orchestrate replication of 
the human immunodeficiency virus type-1 (HIV-1) and the human hepatitis virus 
(HBV), two canonical examples of small human pathogens. HIV-1 nucleocapsid 
protein (NC) and the C-terminal domain (CTD) of the HBV core protein (HBc) 
are essential structural components of the virus capsid ensuring protection of the 
viral genome; they also chaperone replication of the HIV-1 genomic RNA and the 
HBV DNA by a reverse-transcription mode, and later, these proteins kick-start virus 
morphogenesis. HIV-1 NC and HBV CTD belong to the family of intrinsically disor-
dered proteins (IDP), a characteristic rendering possible a large number of molecular 
interactions. Although these viral proteins share little sequence homologies, they 
have in common to be rich in basic amino acids and endowed with RNA-binding and 
chaperoning activities. Similar viral RNA-binding proteins (vRBP) are also encoded 
for by other virus families, notably flaviviruses, hantaviruses, and coronaviruses. 
We discuss how these vRBPs function based on the abundant RBP family that plays 
key physiological roles via multiple interactions with non-coding RNA regulating 
immune defenses and cell stress. Moreover, these RBPs are flexible molecules allow-
ing dynamic interactions with many RNA and protein partners in a semi-solid milieu 
favoring biochemical reactions.
Keywords: RBP, HIV, HBV, IDP, RNA chaperoning, molecular crowding
1. Forewords on viruses and RNA chaperones
Viruses that replicate their genome by the process of reverse transcription 
(RTion) are common in animals, plants, algae, and fungi [1]. These so-called 
reverse-transcribing viruses have been classified into five different families, namely, 
Caulimoviridae, Hepadnaviridae, Metaviridae, Pseudoviridae, and Retroviridae to 
which was the recently added Belpaoviridae [2]. Among these widespread viruses, 
two are major human pathogens, the human immunodeficiency virus type 1 (HIV-1) 
and the human hepatitis B virus (HBV).
Retroviruses exist as infectious exogenous RNA viruses as well as endogenous 
retroelements (ERV) present at high copy numbers in the genome of vertebrates. 
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Hepadnaviruses can also integrate their genome in the host genome but at a much 
lower rate [3].
Replication of the genome of these two classes of virus necessitates a reverse 
transcription step. For HIV-1 the genomic RNA of 9600 nt in length has a structure 
similar to cellular mRNAs with a 5′ cap and 3′ poly A and contains 9 genes leading 
to the expression of 15 proteins. Retroviruses replicate their genome by a copy and 
paste mechanism, whereby the single-stranded positive-sense retroviral genomic 
RNA is converted into a double-stranded DNA by the virion reverse transcriptase 
(RT enzyme) [4], subsequently integrated into the host genome [5]. The integrated 
viral DNA called provirus is expressed by the host transcription machinery to syn-
thesize the full-length viral RNA (FL RNA), which after nuclear export in the cell 
cytoplasm is translated by the ribosomes to synthesize the major structural proteins 
and enzymes, the Gag and Gag-Pol precursors. Specific interactions of the genomic 
RNA with the Gag polyprotein precursor drive Gag polymerization and viral core 
assembly at the plasma membrane (PM) [6].
For hepadnaviruses the small double-stranded DNA genome in a relaxed circular 
form (rcDNA) is targeted to the nucleus after virus infection where it is converted 
into a covalently closed circular form (cccDNA) and expressed by the transcription 
machinery of the infected cell to synthesize the full-length RNA called pre-genomic 
RNA (pgRNA) [7]. Upon translation of the pgRNA, the newly made core protein 
and RT enzyme interact with the pgRNA to synthesize the ds DNA genome. The 
genome of this virus has unique features such as an extensive overlapping of the 
genes, namely, 3200 nt with four coding sequences leading to the expression of 
seven proteins for HBV, and a pseudo-circular structure [8]. In addition several of 
the HIV and HBV proteins were found to be multifunctional, notably NC, TAT, and 
VIF protein for HIV and the HBV core protein (HBc) [9, 10].
These two classes of viruses probably emerged during the early Paleozoic Era, 
some 450–520 million years ago, with a marine origin [11]. The HBVs seem to 
originate from non-enveloped progenitors called nackednaviruses present in fishes, 
some 400 million years ago [12].
In addition to an RNA/DNA-dependent DNA polymerase called reverse tran-
scriptase with an associated RNase H activity, these two classes of small viruses 
encode for a core protein endowed with RNA-binding, unwinding, annealing, and 
matchmaker activities and the ability to cause the formation of nucleoprotein com-
plexes with a gel-like milieu favoring molecular crowding and biochemical reactions 
such as reverse transcription.
This chapter will briefly review the multiple roles of the core proteins drawing a 
parallel between the HIV-1 Gag and the HBV core. In fact these viral core proteins 
turn out to be much more than a structural component forming a cage enveloping 
the genome since they provide assistance to the RT-RNase H enzyme at all steps of 
viral DNA synthesis and then ensure stability of the newly made viral DNA.
Despite common functions in HIV and HBV morphogenesis and replication, the 
core protein appears much different from Gag on an amino acid sequence basis, but 
taking a closer look at their activities and functions reveals that these viral proteins 
are similar.
2. The RNA folding problem and RNA chaperones
The need for RNA chaperones comes from the RNA folding problem whereby 
RNA molecules have to find their native functional structure in an extremely wide 
landscape of structures [13]. In fact, RNA chaperones are as diverse and abundant 
5
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as RNA molecules, coding and noncoding from prokaryotes to eukaryotes [14]. 
Recent findings highlight the fact that RNA chaperones are disordered in nature and 
function in a disordered state and do not require ATP as a source of energy to direct 
RNA folding [13]. Instead RNA chaperones seem to exploit a mechanism of an 
energy transfer during a rapid on-off RNA-binding kinetics. A number of standard 
assays are used to monitor RNA chaperoning activity; notably binding, fraying, 
and annealing of complementary sequences; activation of hammerhead ribozyme-
directed cleavage of an RNA substrate; and formation of a dense nucleoprotein 
complexes. Figure 1 illustrates assays aimed at describing the influence of NC on 
DNA strand transfers that occur during the process of reverse transcription result-
ing in the synthesis of cDNA.
3. The retroviral GAG polyprotein and its multiple roles
The major structural proteins of retroviruses are encoded for by Gag that 
is formed of several modular domains, namely, Map17, Cap24, NCp7, and p6; 
Figure 1. 
Standard assays for monitoring the nucleic acid chaperone activity. These in vitro chaperoning assays 
summarize several properties of nucleic acid chaperone proteins, notably their ability to rapidly anneal 
complementary nucleic acid sequences (top panel) and favor formation of the most stable duplex, in 
physiological-like conditions. Bottom panel: R+ and R− sequences represent the 5′ end repeats of the HIV-1 
genome of 96 nt in length. R− (mut) contains three mutated residues at its 3′ end in order to generate 3 nt 
mismatch upon annealing to R+; this was achieved by incubating R+ and R− mut at 66°C for 1 h. Next R− WT 
is added together with NC protein for 5 min at 30°C. The duplex and ss R− mut were resolved by native gel 
electrophoresis. Adapted from Darlix et al. [15].
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is formed of several modular domains, namely, Map17, Cap24, NCp7, and p6; 
Figure 1. 
Standard assays for monitoring the nucleic acid chaperone activity. These in vitro chaperoning assays 
summarize several properties of nucleic acid chaperone proteins, notably their ability to rapidly anneal 
complementary nucleic acid sequences (top panel) and favor formation of the most stable duplex, in 
physiological-like conditions. Bottom panel: R+ and R− sequences represent the 5′ end repeats of the HIV-1 
genome of 96 nt in length. R− (mut) contains three mutated residues at its 3′ end in order to generate 3 nt 
mismatch upon annealing to R+; this was achieved by incubating R+ and R− mut at 66°C for 1 h. Next R− WT 
is added together with NC protein for 5 min at 30°C. The duplex and ss R− mut were resolved by native gel 
electrophoresis. Adapted from Darlix et al. [15].
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in addition there are two small peptides p1 and p2 flanking NC in the Pr55 gag 
(Figure 2) [16]. The N-terminus is myristoylated, which, together with a row of 
basic residues within MA, targets Gag to the plasma membrane where assembly 
takes place [17].
In infected cells the full-length viral RNA is translated by the ribosome machin-
ery to produce the Gag and Gag-Pol polyprotein precursors. The present model of 
assembly stipulates that newly made Gag molecules accumulate in the cytoplasm, 
probably in the vicinity of the translating polysomes [18] where they kick-start 
virus assembly (Figure 3); this is achieved through two types of interactions (i) 
Gag-NC with the 5′ untranslated region (5′ UTR) of FL RNA [19] and (ii) the 
myristoylated matrix domain with phospholipids of the T-cell membrane [20]. 
These interactions target the Gag-RNA nucleoprotein complexes to the plasma 
membrane, causing Gag-oligomer formation; the nucleocapsid domain binds and 
selects the genomic RNA causing its dimerization and at the same time, together 
with the capsid domain, boosts Gag multimerization (Figure 3). These interactions 
between Gag and phospholipids as well as RNA lead to virus assembly that takes 
place at the plasma membrane. Subsequently, virus maturation occurs during the 
budding process, together with the  recruitment of the envelope glycoproteins by 
the matrix domain [21] (Figure 3).
Maturation is a complex process whereby the core of HIV-1 becomes coni-
cal and at the same time the genomic RNA dimer is condensed, thus leading 
to the formation of infectious particles [23]. However most HIV-1 virions and 
more generally retroviral particles are noninfectious. As a matter of fact, the 
ratio of infectious virus to noninfectious particles is from 1:10 to 1:104 [24, 25]. 
Thus a majority of particles are noninfectious most probably caused by the loss 
of envelope proteins, degradation of the genomic RNA, or else correspond to 
defective-interfering particles (DIP) that can lead to an underestimation of virus 
infectivity [26].
Figure 2. 
Structural model of the HIV-1 Gag polyprotein precursor. Left, the different domains of HIV-1 Gag, 
matrix (Map17), capsid (Cap24), nucleocapsid (NCp7), and p6; two small peptides flanking the NC 
domain, P2/SP1 and P1/SP2. Right: 2D presentation of the complete Gag Pr55. Adapted from Sundquist 
and Krausslich [16].
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4. Characteristics of retroviral nucleocapsid proteins
Retroviral nucleocapsid proteins are small basic proteins with either one (MuLV, 
gammaretrovirus) or two CCHC zinc fingers (HIV and FIV, lentiviruses; RSV 
an Alpharetrovirus) (Table 1). The zinc fingers are structured upon Zn2+ binding 
(in red), while the flanking domains are disordered and basic. Therefore, these 
viral proteins are members of the large family of intrinsically disordered proteins/
intrinsically disordered protein domains (IDPDs) [27–29]. Of note all these NC 
proteins are endowed with RNA-binding and chaperoning activities as shown using 
in vitro reconstituted systems [15, 30–32]. Other important characteristics are the 
ability of these NC proteins to cause the formation of nucleoprotein complexes 
capable of recruiting enzymes such as reverse transcriptase and integrase (IN) 
[33]. In this gel-like milieu, molecular crowding can take place, thus facilitating 
enzymatic reactions, such as cDNA synthesis by RT and integration by IN. Along 
this line, NC protein interacts with RT improving the fidelity of cDNA synthesis by 
several different ways: (i) inhibition of self-primed initiation of cDNA synthesis, 
(ii) chaperoning the obligatory minus- and plus-stranded transfers for the synthesis 
of the LTR flanking the viral DNA (Figure 1), and (iii) improving the processivity 
of RT as well as its excision repair activity resulting in a much higher fidelity of viral 
DNA synthesis (Figure 1 on chaperoning assays).
How is this achieved? According to Uversky, protein-RNA interfaces are most 
probably very large with the concomitant implications of basic, hydrophobic, and 
aromatic residues engaged, respectively, in ionic, hydrophobic, and intercalating 
interactions [34–36]. The interactions between NC and RT are poorly understood, 
but they appear to necessitate the RNA template as the scaffolding agent [37, 38]. 
Figure 3. 
Schematic representation of virus morphogenesis and the roles of Gag-NC. The genomic RNA is exported from 
the nucleus and translated by the cell ribosome machinery giving rise to the production of the Gag and Gag-Pol 
precursors. Gag-NC binds the packaging signal at the 5′ end of the genomic RNA causing the formation of 
the viral nucleoprotein complex (vRNP) and dimerization of the genomic RNA. Such vRNP are targeted to 
the plasma membrane where they accumulate to form immature viral particles. Next, the Gag molecules are 
processed by the viral protease causing core condensation. Adapted from Muriaux and Darlix [22].
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In that respect the RTp66 subunit with its active site appears to be extremely 
flexible with notably a large template-binding pocket. These observations favor 
the notion that the viral proteins NC and RT and the template RNA making up the 
replication machine exhibit a flexible nature in an active nucleoprotein complex 
in agreement with the proposal of Uversky [29]. These in vitro and ex vivo studies 
on retroviral Gag polyproteins and NC proteins have essentially been carried out 
using HIV-1 (Table 1); additional experiments performed with Alpharetrovirus RSV 
NCp12 with two zinc fingers flanked by basic residues; NCp10 of the gammaretro-
virus MuLV, with a unique zinc finger flanked by basic residues; and of the yeast 
retrotransposon Ty3 NCp9, with a unique zinc finger and basic residues, gave very 
similar results with respect to RNA binding, chaperoning, and ribonucleoprotein 
complex formation in vitro (Table 1).
5.  The core protein of HBV and its roles in virus assembly and viral DNA 
synthesis
HBV is an enveloped virus with a 3.2 kb partially double-stranded DNA genome 
referred to as rcDNA [7] that is synthesized by reverse transcription of the pgRNA 
[39]. The core protein contains 183–185 residues corresponding to two domains 
(Figure 4): the N-terminus (NTD) (residues 1–140) that oligomerizes in a capsid 
structure linked by a flexible sequence to the basic C-terminal domain (CTD) (resi-
dues 150–183) [40, 42, 43]. The core CTD interacts with nucleic acids and is endowed 
with nucleic acids annealing, matchmaker, and aggregating activities [8, 44].
The HBV core protein orchestrates virus assembly to form an icosahedral capsid 
[54] (Figure 5). During assembly, HBc specifically recognizes the Pol-pgRNA 
complex [55], promotes its packaging into nascent particles, and assists rcDNA syn-
thesis by the viral RT and cccDNA maintenance [56–58] (for review see Seeger and 
Mason [59]). The processes of RTion and capsid maturation are regulated by CTD 
phosphorylation/dephosphorylation [41, 60–62] together with structural rearrange-
ments of the capsid structure [63–65]; this influences capsid trafficking in virus-
producing cells and is driven by an unknown mechanism the viral ribonucleoprotein 
(vRNP) complex to the nucleus and thus the formation of cccDNA. Else the vRNP 
is targeted to cellular compartments where they interact with the envelope proteins 
Table 1. 
Sequences of retroviral nucleocapsid proteins and the C-terminus of HBV core protein. The one-letter code has 
been used, and the basic domains are in black, while the CX2CX4HX2C zinc fingers are in red. Note the low 
complexity basic domains flanking the NC zinc fingers. For the yeast retrotransposon Ty3, note the zinc finger 
essential for TY3 retrotransposition and the low complexity flanking sequences. The C-terminal domain of the 
HBV core protein has four R-rich sequences and is of low complexity.
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promoting virus egress [43, 66, 67] (for review see Blondot et al. [68]). HBV secre-
tion remains a challenging issue since different types of viral particles are found in 
the circulating blood of patients. Despite a heterogeneous distribution from patients 
Figure 4. 
HBV core primary sequence. The core protein is divided into two parts: the N-terminus (1–140) and the 
C-terminus (150–183). The N-terminus is sufficient in vitro for the process of self-assembly [8]. NTD monomer 
contains a series of five α helices, the third and the fourth helices associate in a four-helix bundle giving the 
characteristic spikes at the surface of assembled capsids [40]. The C-terminus contains arginine residues 
essential for the interaction of core with NA an activity that is regulated by the phosphorylation of the seven 
serine residues [41]. The effect of mutations in the flexible linker between NTD and CTD (141–149) suggests 
that the orientation of NTD respective to CTD is essential in the multistage process of HBV replication [42].
Figure 5. 
HBV replication cycle. (1) Virus attachment to the sodium-taurocholate cotransporting polypeptide (NTCP) 
and entry [45]. (2) Nucleocapsid release in the cytoplasm upon fusion of the cellular and viral membranes and 
trafficking to the nucleus [43]. This traffic is probably mediated by the CTD containing NLSs [46].  
(3) Nuclear pore attachment of the nucleocapsid and release of the rcDNA (relaxed circular) into the nucleus 
with reorganization of the capsid [47]. (4) Conversion of the rcDNA into cccDNA (covalently closed circular 
DNA) and formation of a nucleosome-bound minichromosome, possibly associated with HBx, core protein, 
histone, and nonhistone cellular proteins [7]. (5) Transcription generating the pre-genomic RNA, precore 
RNA, preS1/preS2/S mRNAs, and HBx mRNA [48]. (6) Synthesis of the viral proteins by the cell machinery. 
(7) Production of HBeAg and assembly of S alone with some L protein giving rise to subviral particles. 
(8) Formation of empty capsids or pgRNA-Pol containing capsids with immature nucleocapsids. Reverse 
transcription of pgRNA to generate rcDNA is concomitant with the maturation of the nucleocapsid. (9) Both 
empty and mature particles are embedded by L and S proteins and produced in the supernatant [49]. The egress 
of particles necessitates the endosomal sorting complexes required for transport (ESCRT) [50] even though naked 
capsids were shown to be released through the ALIX pathway [51]. (10) Alternatively, the rcDNA-containing 
particles recycle to the nucleus, amplifying the cccDNA copy numbers [52]. Adapted from Revill et al. [53].
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to patients, it is estimated that most of the particles are consisting of the sole enve-
lope proteins (HBsAg) as sphere and filaments also referred to as Australian antigen 
(1014/ml), empty particles (without genome, 1011/ml), RNA-containing virions 
(106/ml), and complete infectious particles (Dane particles, 109/ml)  
[49]. The low amount Dane particles remain unclear, and it has been proposed 
that reverse transcription of the pgRNA triggers a structural change of the capsid 
(maturation signal), which in turn causes the envelopment and secretion of com-
plete infectious virions [65, 69]. More recently the group of Hu et al. proposed a 
two-signal model, the first one exposed in the empty particles at the level of the 
NTD-CTD linker resulting in an interaction with the S protein and the second one 
exposed in maturate particles at the level of the MBD (matrix-binding domain) to 
cause an interaction with the L envelope [70, 71] (for review see Liu and Hu [72]). 
Even though the molecular bases of these two domains remain to be clarified, they 
both lie on the capsid structure in agreement with the large effect of capsid envel-
opment by single-point mutations around the hydrophobic pocket in the center of 
the spikes [73–76]. Thus the envelopment of the vRNP is closely linked to the HBc 
protein that represents a critical factor in virus replication and as a matter of fact, a 
target in the search for antiviral molecules [77, 78].
6. The CTD of HBV core protein has nucleic acid chaperone activity
The nucleic acid chaperone activity of the CTD was first suggested by the group 
of Loeb [66] and of Zlotnick [79]. In the first case, they followed the strand transfer 
of the initial (−) DNA from the 5′ ε bulge to the 3′ DR1 sequence and (−) DNA 
elongation. This suggests that the core protein has a nucleic chaperone activity simi-
lar to retroviral NC [30, 32, 34, 80, 81]. In the second case, using core constructs 
mimicking the unphosphorylated or phosphorylated core, they found a correlation 
between the number of positive charge in the core protein and the RNA density 
suggesting that the core protein induced RNA structural modification.
The RNA/DNA chaperoning activity of HBc was confirmed using DNA-DNA 
hybridization and hammerhead ribozyme cleavage in vitro [56]. In the first assay, 
authors followed the annealing of the DNA version of HIV TAR. This sequence is 
located in the 5′ end of HIV genome. In addition to its role in the RNA  
transcription with TAT protein [82, 83], this sequence is essential for the (−) single-
stranded transfer along the RT-dependent synthesis of HIV DNA [30, 32, 34, 81]. 
Interestingly they compared assembled and disassembled HBc particles and found 
that dissembled HBc was more efficient in DNA duplex formation. Using a series of 
peptides, they found that this chaperoning activity maps at the CTD and required 
the four stretches of basic residues (Table 1). When a peptide is containing phos-
phorylated serine residues at the positions 155, 162, and 170, considered as the three 
major serine phosphorylation sites, the DNA annealing activity was progressively 
reduced as a function of the number of phosphorylation sites. Similar results were 
obtained with the hammerhead ribozyme cleavage assays [27] (Figure 6).
The role of HBc nucleic acid annealing and matchmaker activities was assessed 
using viral particles. Therefore, a plasmid expressing HBV genome with a stop 
codon in the HBc ORF was cotransfected with a plasmid expressing core in agree-
ment with the fact that HBV competent for the replication can be obtained by 
trans-complementation assays [84, 85]. Mutations shown to decrease HBc in vitro 
activity gave rise to an important decrease of HBV DNA synthesis and a loss of viral 
replication. These results support the notion that HBc has nucleic acid chaperone 
activity essential for minus-stranded and plus-stranded DNA synthesis along the 
replication cycle. Nevertheless, the defect observed in viral DNA synthesis could 
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originate from a defect of HBc assembly [86, 87], RNA encapsidation [88, 89], HBc 
trafficking [46, 68, 90], or HBc maturation/single-stranded blocking model  
[65, 69–71] since all these steps require the arginine residues of the C-terminus.
7. Concluding remarks and questions
As for retroviruses that are widespread in living organisms and can rapidly 
and efficiently circulate and spread in animals, even crossing species barriers, the 
small basic protein called NC has multiple functions in virus structure, replication, 
and dissemination. Indeed, NC protein is a helper factor for the RT enzyme and 
its associated RNAse H activity and also for the integrase enzyme. NC is indeed 
a chaperoning factor required from the start to the end of viral DNA synthesis as 
well as for the recruitment of cofactors required for transport (Figure 7). Also they 
are considered as membrane-less organelles that play key roles in cells such as fine 
tuning of gene expression, translation, and immune controls via noncoding RNAs. 
Furthermore, NC is a key factor for driving the recombination reactions fuelling the 
genetic diversity of the newly made viral particles.
The HBV C-terminal domain (C-ter) appears to play multiple roles in virus rep-
lication in a manner similar to the retroviral NC protein, by chaperoning genome 
replication ensuring the fidelity of the viral DNA synthesis and its stability once it is 
complete.
There are many questions on how do such viral nucleoprotein complexes 
function.
One concerns the process of reverse transcription, i.e., how does the RT 
enzyme copy the RNA molecule coated by hundreds of such highly basic protein 
molecules? Another one deals with the permeability of these viral nucleoprotein 
ensembles [91], i.e., the accessibility of cofactors that can be helper or restriction 
factors such as cytidine and adenosine deaminases, apolipoprotein B-editing cata-
lytic subunit (APOBEC) [92], or adenosine deaminase acting on RNA-1 (ADAR1) 
that was recently shown to inhibit HBV replication by enhancing microRNA-122 
processing [93]. Furthermore, the recruitment of restriction factors is not an 
on-off process since a limited accessibility appears to take place for both HIV and 
HBV, impacting on the genetic diversity of the virus that is a major issue in antivi-
ral treatments [94, 95].
Figure 6. 
Annealing activity of HBc and HBc (147–183). (A) TAR(+)/TAR(−) annealing activity of HBc particles 
(left) and HBc protein (right) as a function of time. TAR(+) was 32P labelled using T4 polynucleotide kinase, 
purified by PAGE and recovered by ethanol precipitation. TAR(+) and TAR(−) were mixed with HBc in 
NaCl-containing TRIS buffer. At time points 15 s to 5 min HBc was removed by a proteinase K treatment 
and reaction stopped by addition of EDTA. TAR DNAs were resolved by 8% PAGE and gels were dried 
and autoradiographed. (B) TAR(+)/TAR(−) annealing activity of the HBc CTD peptide. This assay was 
performed as described above at various concentrations for 5 min. Panels A and B were extracted from 
Figures 1 and 3 of [56].
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elongation. This suggests that the core protein has a nucleic chaperone activity simi-
lar to retroviral NC [30, 32, 34, 80, 81]. In the second case, using core constructs 
mimicking the unphosphorylated or phosphorylated core, they found a correlation 
between the number of positive charge in the core protein and the RNA density 
suggesting that the core protein induced RNA structural modification.
The RNA/DNA chaperoning activity of HBc was confirmed using DNA-DNA 
hybridization and hammerhead ribozyme cleavage in vitro [56]. In the first assay, 
authors followed the annealing of the DNA version of HIV TAR. This sequence is 
located in the 5′ end of HIV genome. In addition to its role in the RNA  
transcription with TAT protein [82, 83], this sequence is essential for the (−) single-
stranded transfer along the RT-dependent synthesis of HIV DNA [30, 32, 34, 81]. 
Interestingly they compared assembled and disassembled HBc particles and found 
that dissembled HBc was more efficient in DNA duplex formation. Using a series of 
peptides, they found that this chaperoning activity maps at the CTD and required 
the four stretches of basic residues (Table 1). When a peptide is containing phos-
phorylated serine residues at the positions 155, 162, and 170, considered as the three 
major serine phosphorylation sites, the DNA annealing activity was progressively 
reduced as a function of the number of phosphorylation sites. Similar results were 
obtained with the hammerhead ribozyme cleavage assays [27] (Figure 6).
The role of HBc nucleic acid annealing and matchmaker activities was assessed 
using viral particles. Therefore, a plasmid expressing HBV genome with a stop 
codon in the HBc ORF was cotransfected with a plasmid expressing core in agree-
ment with the fact that HBV competent for the replication can be obtained by 
trans-complementation assays [84, 85]. Mutations shown to decrease HBc in vitro 
activity gave rise to an important decrease of HBV DNA synthesis and a loss of viral 
replication. These results support the notion that HBc has nucleic acid chaperone 
activity essential for minus-stranded and plus-stranded DNA synthesis along the 
replication cycle. Nevertheless, the defect observed in viral DNA synthesis could 
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originate from a defect of HBc assembly [86, 87], RNA encapsidation [88, 89], HBc 
trafficking [46, 68, 90], or HBc maturation/single-stranded blocking model  
[65, 69–71] since all these steps require the arginine residues of the C-terminus.
7. Concluding remarks and questions
As for retroviruses that are widespread in living organisms and can rapidly 
and efficiently circulate and spread in animals, even crossing species barriers, the 
small basic protein called NC has multiple functions in virus structure, replication, 
and dissemination. Indeed, NC protein is a helper factor for the RT enzyme and 
its associated RNAse H activity and also for the integrase enzyme. NC is indeed 
a chaperoning factor required from the start to the end of viral DNA synthesis as 
well as for the recruitment of cofactors required for transport (Figure 7). Also they 
are considered as membrane-less organelles that play key roles in cells such as fine 
tuning of gene expression, translation, and immune controls via noncoding RNAs. 
Furthermore, NC is a key factor for driving the recombination reactions fuelling the 
genetic diversity of the newly made viral particles.
The HBV C-terminal domain (C-ter) appears to play multiple roles in virus rep-
lication in a manner similar to the retroviral NC protein, by chaperoning genome 
replication ensuring the fidelity of the viral DNA synthesis and its stability once it is 
complete.
There are many questions on how do such viral nucleoprotein complexes 
function.
One concerns the process of reverse transcription, i.e., how does the RT 
enzyme copy the RNA molecule coated by hundreds of such highly basic protein 
molecules? Another one deals with the permeability of these viral nucleoprotein 
ensembles [91], i.e., the accessibility of cofactors that can be helper or restriction 
factors such as cytidine and adenosine deaminases, apolipoprotein B-editing cata-
lytic subunit (APOBEC) [92], or adenosine deaminase acting on RNA-1 (ADAR1) 
that was recently shown to inhibit HBV replication by enhancing microRNA-122 
processing [93]. Furthermore, the recruitment of restriction factors is not an 
on-off process since a limited accessibility appears to take place for both HIV and 
HBV, impacting on the genetic diversity of the virus that is a major issue in antivi-
ral treatments [94, 95].
Figure 6. 
Annealing activity of HBc and HBc (147–183). (A) TAR(+)/TAR(−) annealing activity of HBc particles 
(left) and HBc protein (right) as a function of time. TAR(+) was 32P labelled using T4 polynucleotide kinase, 
purified by PAGE and recovered by ethanol precipitation. TAR(+) and TAR(−) were mixed with HBc in 
NaCl-containing TRIS buffer. At time points 15 s to 5 min HBc was removed by a proteinase K treatment 
and reaction stopped by addition of EDTA. TAR DNAs were resolved by 8% PAGE and gels were dried 
and autoradiographed. (B) TAR(+)/TAR(−) annealing activity of the HBc CTD peptide. This assay was 
performed as described above at various concentrations for 5 min. Panels A and B were extracted from 
Figures 1 and 3 of [56].
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On a more general basis, vRBP’s with chaperoning activities are widespread in 
the virus world, since they are, for example, encoded for by other virus families 
such as flaviviruses, notably the core proteins of HCV and dengue viruses, the N 
protein of coronaviruses and hantaviruses, and the delta antigen of the HDV viroid 
[96–103]. In addition, unpublished data show that the N protein of influenza virus 
has also chaperone activity.
Similar RNA chaperone proteins are found in bacteriophages of the Leviviridae 
family where they regulate vRNA translation and assembly [104]. Also a closer look 
at the replication of the Q-beta genomic RNA by the viral replicase reveals the chap-
eroning contribution of the host factors EF-Tu and Ts. These data favor the notion 
that RNA chaperones may also influence protein conformation and enzymatic activ-
ity, raising the possibility that such proteins are Janus chaperones [28, 105, 106].
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Abstract
The importance of studying the human papillomavirus (HPV) is because it is a 
disease that relies on 14 HPV types classified as carcinogenic high risk and that con-
tributes to cervical cancers affecting approximately 527,600 women yearly and caus-
ing 265,387 deaths yearly, being the second mortality cause for women globally. In 
Mexico, 13.9% of demises are due to cervical uterine cancer (CUCA). The challenges 
for a vaccine that may prevent HPV occurrence are an active field for scientists with 
significant advances but still undergoing for a full cure to this disease. In this work, 
latest research trends to treat HPV are analyzed, and by means of molecular cou-
pling analysis, a modeling and simulation process to predict interactions of leader 
molecules with the target for synthetic elaboration of a possible therapeutic treat-
ment is developed. One of the main topics discussed in this chapter relates to new 
drug design for HPV treatment, which is related to the inhibitors of protein-protein 
interactions and in the protein drugs. Regarding HPV therapy development, a group 
of small molecules has been identified using high-performance sieving capable of 
interrupting HPV16 E1-E2 interaction, which helps avoid viral replication. Some of 
these compounds displayed nanomolar affinities and high specificity.
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1. Introduction
Human papillomavirus (HPV) belongs to the Papillomaviridae family, according 
to the eighth report developed by the International Committee for Viral Taxonomy. 
To date, over 100 different HPV types have been cataloged and around 30 infected 
anogenital mucosae. HPV types are classified as virus from low to high risk accord-
ing to their capability to cause benign or carcinogenic injuries, respectively [1].
Infection provoked by HPV is one of the more common causes among sexually 
transmitted diseases with prevalence levels varying between the population and 
geographic location.
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Abstract
The importance of studying the human papillomavirus (HPV) is because it is a 
disease that relies on 14 HPV types classified as carcinogenic high risk and that con-
tributes to cervical cancers affecting approximately 527,600 women yearly and caus-
ing 265,387 deaths yearly, being the second mortality cause for women globally. In 
Mexico, 13.9% of demises are due to cervical uterine cancer (CUCA). The challenges 
for a vaccine that may prevent HPV occurrence are an active field for scientists with 
significant advances but still undergoing for a full cure to this disease. In this work, 
latest research trends to treat HPV are analyzed, and by means of molecular cou-
pling analysis, a modeling and simulation process to predict interactions of leader 
molecules with the target for synthetic elaboration of a possible therapeutic treat-
ment is developed. One of the main topics discussed in this chapter relates to new 
drug design for HPV treatment, which is related to the inhibitors of protein-protein 
interactions and in the protein drugs. Regarding HPV therapy development, a group 
of small molecules has been identified using high-performance sieving capable of 
interrupting HPV16 E1-E2 interaction, which helps avoid viral replication. Some of 
these compounds displayed nanomolar affinities and high specificity.
Keywords: viral proteins, human papillomavirus, HPV, E1-E2 proteins, TDDFT
1. Introduction
Human papillomavirus (HPV) belongs to the Papillomaviridae family, according 
to the eighth report developed by the International Committee for Viral Taxonomy. 
To date, over 100 different HPV types have been cataloged and around 30 infected 
anogenital mucosae. HPV types are classified as virus from low to high risk accord-
ing to their capability to cause benign or carcinogenic injuries, respectively [1].
Infection provoked by HPV is one of the more common causes among sexually 
transmitted diseases with prevalence levels varying between the population and 
geographic location.
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At least 14 types of them are classified as carcinogenic high risk (hr-HPV); 
among them HPV16 and HPV18 are responsible for around 70% of all cervical 
cancers affecting approximately 527,600 women yearly and causing 265,387 deaths 
yearly, being the second mortality cause for women globally [2]. Over 85% of new 
cases and deaths referred occur in developing countries [3] such as Mexico, where 
13.9% of demises are due to cervical uterine cancer (CUCA) [4].
The challenges for a vaccine that may prevent HPV occurrence is an active field 
for scientists with significant advances but still undergoing for a full solution that 
can eliminate this disease.
In this work latest research trends to treat HPV are analyzed, and by means of 
molecular coupling analysis, a modeling and simulation process to predict interac-
tions of leader molecules with the target for synthetic elaboration of a possible 
therapeutic treatment is developed.
This chapter is a review of the latest advances on new drug design for HPV 
treatment which are related to the inhibitors of protein-protein interactions and in 
the protein drugs. Regarding HPV therapy development, a group of small molecules 
has been identified using high -performance sieving capable of interrupting HPV16 
E1-E2 interaction which helps avoid viral replication. Some of these compounds 
displayed nanomolar affinities and high specificity.
2. HPV genome, treatment, and prevention
2.1 HPV infection, treatment, and prevention
Currently, an antiviral treatment is unavailable that can help eliminate the infec-
tion or avoid progression of injuries caused by CUCA. Current therapies for cervical 
dysplasia and cancer implicate destruction or elimination of infected tissue by cyto-
toxic agents or surgery [5]. On the other hand, FDA has approved three vaccines 
for HPV infection prevention: Gardasil, Gardasil 9, and Cervarix. All three prevent 
HPV infection types 16 and 18 [6, 7]. Gardasil also protects HPV infection types 6 
and 11, which cause 90% of genital warts [8]. Gardasil 9 protects from infection 
of the same four HPV types and other five HPV types (31/33/45/52/58) that cause 
cancer [9]. These vaccines are based in empty particles similar to the “ghost” virus, 
formed by L1 protein capsid from each viral type [8, 10]. It has been demonstrated 
that these vaccines are highly protective against the lesions of transformed cells at 
an early stage that represent cervical cancer precursors. Since HPV 16 and HPV 18 
currently represent the two HR-HPV more common in most geographical locations, 
universal adoption of the vaccines may protect more than two-thirds of HPV-
induced cancers [10].
However, vaccination programs are not implemented worldwide, and coverage is 
still very low especially in low-income countries [10, 11].
It has been estimated that the addition of HPV 31/33/45/52/58 to the nine-valent vac-
cine could prevent almost 90% of cases of invasive cervical cancer worldwide [12, 13].
HPV vaccines currently available are useful tools in the fight against HPV 
infections and cancers but provide an incomplete answer for long-term HPV 
disease eradication. By their very nature of being capable of inducing a strong and 
protective humural—but no cellular—host immune response, they are also of little 
therapeutic value to already infected patients [10].
Scientists are working in new HPV therapeutic vaccines which may help avoid 
cancer formation in women previously infected with HPV [14]. These vaccines 
work by stimulating the immune system to attack and destroy infected cells. 
Clinical studies under development are evaluating safety and efficiency of a DNA 
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therapeutic vaccine to treat injuries by HPV in the cervix and vulva. An ideal 
strategy would be to combine a preventive and a therapeutic vaccine. Another 
prevention strategy under testing is using external microbicidal. It has been found 
that carrageenan, a compound that can be extracted from seaweeds and extensively 
used in foods and other products, inhibits HPV infection in laboratory studies. A 
clinical study is under development to demonstrate if a gel containing carrageenan 
is capable to prevent genital infection by HPV in healthy individuals [15–17].
2.2 HPV genome
HPV genome (Figure 1) consists of a circular double-chain DNA molecule of 
approximately 8 Kb in size. The genome is organized in three regions. The region 
early contains the genes E1–E8 that code predominately for regulatory proteins 
essential for viral transcription and replication, as well as cell cycle control; the late 
region encodes for the two viral structural proteins, L1 and L2, needed for capsid 
formation and the noncoding region also known are long control region (LCR) or 
upstream regulatory region (URR). The LCR region varies in size between 800 and 
1000 pb for the different HPV types, does no encodes any protein but, contains Cis-
elements required for regulation of genes expression and genome replication [18].
2.3 HPV life cycle
HPV life cycle is coupled to the differentiation cell program experienced by epi-
thelium keratinocytes. PVs are highly specific from the species they infect and present 
a tropism defined by epithelial scaly cells infecting undifferentiated basal cells.
Figure 1. 
Representation of HPV genome organization in a circular chain displaying the DNA molecule. LCR is the 
region noncoding the open reading frames (ORFs) encode the early (E) and late (L) viral proteins [18].
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prevention strategy under testing is using external microbicidal. It has been found 
that carrageenan, a compound that can be extracted from seaweeds and extensively 
used in foods and other products, inhibits HPV infection in laboratory studies. A 
clinical study is under development to demonstrate if a gel containing carrageenan 
is capable to prevent genital infection by HPV in healthy individuals [15–17].
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1000 pb for the different HPV types, does no encodes any protein but, contains Cis-
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Representation of HPV genome organization in a circular chain displaying the DNA molecule. LCR is the 
region noncoding the open reading frames (ORFs) encode the early (E) and late (L) viral proteins [18].
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During epithelium mucosa infection, firs of all, virions need to reach the undif-
ferentiated basal cells. Once in contact with blank cells, virion is associated with 
putative receptors such as alpha integrins, heparins, and laminins probably through 
wounds or microabrasions that give access to basal zones at the epithelium [19].
Heparin sulfate proteoglycans (HSPGs) from the cellular surface seem to be the 
primary receptor for initial binding [20]. The joint together is mediated by the last 
15 amino acids from the extreme carboxyl-terminal of L1 protein [21]. Virions enter 
the cell by endocytosis by using the clathrin-dependent route. Decapsidation of the 
particle occurs at the endosome, releasing the capsid genome and proteins in the 
endocytic vesicles [22].
After HPV infects basal cells, viral genome is established as a multiple copies 
episome at the cells’ nuclei through several viral DNA replication cycles.
Conservation of the viral episome at 50–100 copies at these undifferentiated 
cells is obtained then through low DNA replication levels, and it is essential for 
the infection persistence; by itself it is a risk factor for carcinogenesis induced by 
the virus; the first proteins to express themselves are the viral replication proteins 
E1 and E2. E2 protein presents a characteristic regulating function affecting the 
transcription, the replication, and the episome conservation [20, 23].
During the productive infection, viral protein detection at the basal layers 
barely exists, even though E7 protein may be detected by cervical neoplasia, where 
the expression levels cannot be controlled properly [23]. Proliferative basal cells 
would migrate to parabasal and intermediate layers, starting the differentiation 
program and with it the transcription of the different early viral genes, regulated 
through the LCR region. During this period DNA will replicate hundreds of copies 
by cell, thanks to E6 and E7 proteins which will block the exit of cells from the 
cellular cycle [24].
During productive infection, HPV proteins cannot easily be detected in the basal 
cell layer, although the E7 protein can be seen in cervical neoplasia where expression 
levels are not properly controlled.
As HPV-infected cells divide and differentiate, the late HPV promoter is acti-
vated mediated by transcription factors dependent on the differentiation, this has 
as consequence the amplification of the viral DNA, and an increase in the levels of 
viral proteins needed for replication, including E1, E4 and E5, being E4 the more 
abundant.
It has been suggested that E7 continuous expression in a cell containing abun-
dant E4 which favors the conservation of the cell in phase S, this allows the viral 
genome accumulation.
When basal cells enter the differentiation process that will convert them into 
keratinocytes, at the same time they migrate to superior layers in the epithelium 
that will cause an explosion in the viral DNA replication, known as vegetative 
replication.
Finally, both proteins and the capsid (L1 and L2) are expressed only in cells that 
have passed through the vegetative viral amplification. At the end of the productive 
cycle, genomes will encapsidate, generating virions that will be let out with release 
of superior layer cells from the mucous epithelium [23].
HPV DNA replication initiates with the cooperative join of E1 and E2 with 
specific DNA sequences inside the viral origin [15–17]. Formation of this ternary 
compound E1-E2-ori depends on the interaction between both proteins with DNA, 
but also there is a critical interaction between the E2 transactivation domain of 
N-terminal (TAD) and the E1 enzymatic domain of E1 C-terminal [25]. Assembly 
of this initial complex E1-E2-ori is the starting point for additional E1 molecule 
recruitment [26, 27] and its assembly in hexamers and double hexamers that 
display activity in ATPase and helicase [28, 29]. Any of the protein–protein and 
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protein-DNA interactions produced in the origin could be directed toward the 
development of small antiviral molecules to treat infections by HPV.
It has been demonstrated clearly that expression E1 and E2 proteins from dif-
ferent HPV genomes can induce replication of the genomic integrated HPV origin 
[30], and this is a particular danger in the presence of DNA damage [31]. Then, 
anti-HPV agents unblocking viral DNA synthesis could, in time, benefit cancer 
development increasing HPV genome integration. Due to E1 and E2 capability to 
induce HPV DNA integration, HPV DNA replication through E1 interactions with 
cellular replication proteins probably may represent one of the best approaches 
to develop an HPV antiviral that also prevents HPV integration at the host cell 
chromosomes.
2.4 E1 and E2 proteins as therapeutic targets
E1 is the most conserved protein among the papillomavirus and the only with 
enzymatic activity [32, 33]. This situation adds up to the fact that viral DNA replica-
tion is absolutely dependent on E1, and it has contributed to do an attractive target 
out of this protein so antiviral agents may be developed.
E1 gene is the bigger and one of the more conserved PVs with approximately 2 
Kb, and it codifies E1 multimeric protein [28].
E1 protein has three functional domains. C-terminal domain has helicase/
ATPase, and it participates in viral DNA replication and includes sequences 
involved in the protein oligomerization [34, 35].
Variable length central region contains the DNA-binding domain (DBD), which 
recognizes specific sites at the ori but with low affinity [36–38], and an N-terminal 
regulator region which is essential for live optimal replication [39, 40].
The last one codifies several functional elements, such as a nuclear localiza-
tion sequence (NLS), a nuclear export sequence (NES), a joint cyclin motif, and 
Cdk2 phosphorylation sites. E1 N-terminal regulator region for HPV anogenital 
type also interact with cellular p80 protein known alternatively as UAF1 or 
WDR48 [41].
Terminal carboxyl domain and spacer region have been widely studied. 
However, N-terminal domain functions have not been well defined other than those 
related to the nuclear location [35].
DBD of E1 protein consists in a sequence of 60 pb approximately. This sequence 
contains three elements, a sequence rich in A and T, a palindrome sequence found at 
LCR, forming hexamers and double hexamer, and a 12 pb sequence that constitutes 
a joining site for E2 protein [42, 43].
DBD has been widely characterized in vitro and it was the first E1 domain to be 
crystallized [43–45]. And this reveals an unusual joint mode to DNA by an extended 
bond and an α helix forming a continuous surface as DNA join.
Even though DBD more important function is to recognize and mark the ori, 
it has other functions as well. DBD performs an important role in the fusion of 
bicatenary DNA and the formation of hexameric replicative helicase [43].
The E1 N-terminal region is formed by 200 amino acids approximately; it is the 
less preserved segment of this protein. This region contains a number of motifs 
from short sequence amino acids preserved as variable among different PVs, includ-
ing a nuclear localization signal (NLS), a nuclear export signal of dependent-Crm1 
(NES), and a joining motif to the cyclin (CBM) that interacts with cyclin A/E in 
complex with kinase dependent of cyclin 2 (Cdk2) and Cdk2 phosphorylation sites 
and other kinases [40, 46, 47].
The E2 gene has approximately 1100 bp codifies a nuclear protein of 45 kDa 
[18, 48], E2 protein is composed of three functional domains. The first, at 
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During epithelium mucosa infection, firs of all, virions need to reach the undif-
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the virus; the first proteins to express themselves are the viral replication proteins 
E1 and E2. E2 protein presents a characteristic regulating function affecting the 
transcription, the replication, and the episome conservation [20, 23].
During the productive infection, viral protein detection at the basal layers 
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HPV DNA replication initiates with the cooperative join of E1 and E2 with 
specific DNA sequences inside the viral origin [15–17]. Formation of this ternary 
compound E1-E2-ori depends on the interaction between both proteins with DNA, 
but also there is a critical interaction between the E2 transactivation domain of 
N-terminal (TAD) and the E1 enzymatic domain of E1 C-terminal [25]. Assembly 
of this initial complex E1-E2-ori is the starting point for additional E1 molecule 
recruitment [26, 27] and its assembly in hexamers and double hexamers that 
display activity in ATPase and helicase [28, 29]. Any of the protein–protein and 
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enzymatic activity [32, 33]. This situation adds up to the fact that viral DNA replica-
tion is absolutely dependent on E1, and it has contributed to do an attractive target 
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E1 gene is the bigger and one of the more conserved PVs with approximately 2 
Kb, and it codifies E1 multimeric protein [28].
E1 protein has three functional domains. C-terminal domain has helicase/
ATPase, and it participates in viral DNA replication and includes sequences 
involved in the protein oligomerization [34, 35].
Variable length central region contains the DNA-binding domain (DBD), which 
recognizes specific sites at the ori but with low affinity [36–38], and an N-terminal 
regulator region which is essential for live optimal replication [39, 40].
The last one codifies several functional elements, such as a nuclear localiza-
tion sequence (NLS), a nuclear export sequence (NES), a joint cyclin motif, and 
Cdk2 phosphorylation sites. E1 N-terminal regulator region for HPV anogenital 
type also interact with cellular p80 protein known alternatively as UAF1 or 
WDR48 [41].
Terminal carboxyl domain and spacer region have been widely studied. 
However, N-terminal domain functions have not been well defined other than those 
related to the nuclear location [35].
DBD of E1 protein consists in a sequence of 60 pb approximately. This sequence 
contains three elements, a sequence rich in A and T, a palindrome sequence found at 
LCR, forming hexamers and double hexamer, and a 12 pb sequence that constitutes 
a joining site for E2 protein [42, 43].
DBD has been widely characterized in vitro and it was the first E1 domain to be 
crystallized [43–45]. And this reveals an unusual joint mode to DNA by an extended 
bond and an α helix forming a continuous surface as DNA join.
Even though DBD more important function is to recognize and mark the ori, 
it has other functions as well. DBD performs an important role in the fusion of 
bicatenary DNA and the formation of hexameric replicative helicase [43].
The E1 N-terminal region is formed by 200 amino acids approximately; it is the 
less preserved segment of this protein. This region contains a number of motifs 
from short sequence amino acids preserved as variable among different PVs, includ-
ing a nuclear localization signal (NLS), a nuclear export signal of dependent-Crm1 
(NES), and a joining motif to the cyclin (CBM) that interacts with cyclin A/E in 
complex with kinase dependent of cyclin 2 (Cdk2) and Cdk2 phosphorylation sites 
and other kinases [40, 46, 47].
The E2 gene has approximately 1100 bp codifies a nuclear protein of 45 kDa 
[18, 48], E2 protein is composed of three functional domains. The first, at 
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the extreme amino terminal, is the activation domain (E2TAD), responsible 
of regulating the transcription and replication of the viral genome [18, 48]. 
The second domain is a hinge or central domain, with more variable length 
and sequence among the HPVs. The third domain at the carboxyl-terminal is 
for dimerization and binding with the DNA, and it is formed by 100 amino 
acids approximately [18, 48, 49]. Crystal structure E2 protein from all viral 
strains have in common the fact of joining a palindromic DNA sequence 
(ACCgNNNNcGGT, lower case letters indicate preferred nucleotides; NNNN 
region is called spacing region), referred as the E2 union site. Nevertheless, 
there are specific differences in viral strains in regard to E2 protein ability to 
discriminate union sites [48] (Figure 2).
HPV protein E2 displays independent complex functions regarding the tran-
scription and may be able to modulate host cells with respect to the viral replication 
cycle [48–50].
3. Computational modeling of E1 and E2 inhibitors
Several pharmaceutical companies have invested resources in the identification 
of E1 ATPase/helicase inhibitors. Even though small molecules have been identified 
as capable to inhibit this enzyme activity, unfortunately, none of these projects 
has resulted in a viable therapy. In late years, antiviral research has begun to deal 
with the vital interactions modulation between proteins and proteins as a feasible 
therapeutic way.
Figure 2. 
Initiation of HPV DNA replication. (A) Schematic representation of the viral proteins E1 and E2 required for 
replication of the HPV genome. E1 and E2 are approximately 650 and 370 amino acids in length, respectively. 
Locations of the different functional domains in each protein are indicated. OBD, origin binding domain 
helicase/ATPase N-terminal; TAD, transactivation domain; H, hinge region; DBD, DNA-binding domain. (B) 
Schematic diagram of the initiation of HPV DNA replication. (I) Replication is initiated by the recruitment of 
E1 (purple) and by E2 (green), to the viral origin [10].
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An interaction protein–protein essential in the HPV DNA replication is the 
interaction between HPV E1 and E2 proteins. There are diverse reported works with 
advances in identification of leader compounds that may interrupt protein–protein 
E1-E2 interactions. Some of these compounds showed nanomolar affinities and 
high specificity.
Yoakim and coworker [51] discovered a group of small molecules known as 
indanones, and this molecules showed the capability to inhibit specifically E1-E2 
protein interaction, which also have been identified as the first inhibitors for small 
molecules capable to antagonize the assembly of E1-E2 complex and the viral ori 
HPV11. It was identified a compound that inhibited E1-E2 protein interaction 
by means of high-performance sieving from the collection of over Boehringer 
Ingelheim 100,000 compounds, using a scintillation proximity assay (SPA). Also, 
more active analogues were synthesized that were capable to inhibit the E1-E2 
complex assembly with the HPV11 viral ori with low nanomolar power in vitro 
and with activity in cell culture. Structurally, this group of inhibitors presents an 
indandione system spirofused onto a substituted tetrahydrofuran ring which were 
denominated as indandione inhibitors. It was determined that these inhibitors 
act by joining to E2 TAD domain, the same protein region that interacts with E1 
[51, 52]. Crystalline structures, HPV11 E2 TAD by itself or as a complex with an 
indandione inhibitor, both provide a detailed comprehension of the mechanism in 
which indandione inhibitors join E2 to interrupt the interaction E1-E2. A compari-
son between both structures revealed that the union between the inhibitors caused 
insignificant alterations on the protein backbone, but it did induce a significant 
movement of several lateral amino acid chains at the union site. These changes in 
the lateral chain conformation, particularly from Tyr-19, His-32, Leu-94 y, and 
Glu-100 residues, resulted in the formation of a deep hydrophobic bag that is joined 
firmly to the inhibitor indandione fraction. The structure also revealed that the 
inhibitor carboxylate fraction, known by its importance for power, forms hydrogen 
bonds with amides from the protein backbone. Studies regarding the structure-
activity relationship (SAR) revealed that the carboxylate fraction is important in 
potency of the inhibitor. Mechanistic studies, including the use of isothermal titling 
calorimetry, showed that the indandione inhibitors join reversibly to E2 TAD with 
1:1 stoichiometry. Even though indandione inhibitors displayed a powerful activity 
against E2 proteins of low-risk viruses HPV6 and HPV11, these did not show any 
activity against high-risk types HPV16, HPV18, and HPV31. Cellular culture studies 
showed that indandione inhibitors are capable of antagonizing E1-E2 interaction of 
HPV6 and HPV11 [49].
3.1 Other labs’ approach
White and coworker addressed these issues in a series of detailed studies to iden-
tify inhibitors of the cooperative assembly of HPV E1 and E2 on the ori, focusing 
on HPV 6 and 11. They identified two series of inhibitors that bound to overlapping 
sites at the E1 binding interface on the E2 TAD. Results obtained from modeling 
works suggest that inhibitors derived from repaglinide form weak interactions with 
protein E2 TAD but occupy a bigger portion from the inhibitor union bag than the 
indandione series.
Both series of compounds were optimized for binding by medicinal chemistry 
approaches, and in both series the best compounds in each series had low nanomo-
lar activity against the HPV 11 E1-E2 interaction.
The fact that the potent repaglinide derivatives, with values IC50 at nanomolar 
range against HPV6 and HPV11 E2, and EC50 values in cellular DNA replication 
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the extreme amino terminal, is the activation domain (E2TAD), responsible 
of regulating the transcription and replication of the viral genome [18, 48]. 
The second domain is a hinge or central domain, with more variable length 
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(ACCgNNNNcGGT, lower case letters indicate preferred nucleotides; NNNN 
region is called spacing region), referred as the E2 union site. Nevertheless, 
there are specific differences in viral strains in regard to E2 protein ability to 
discriminate union sites [48] (Figure 2).
HPV protein E2 displays independent complex functions regarding the tran-
scription and may be able to modulate host cells with respect to the viral replication 
cycle [48–50].
3. Computational modeling of E1 and E2 inhibitors
Several pharmaceutical companies have invested resources in the identification 
of E1 ATPase/helicase inhibitors. Even though small molecules have been identified 
as capable to inhibit this enzyme activity, unfortunately, none of these projects 
has resulted in a viable therapy. In late years, antiviral research has begun to deal 
with the vital interactions modulation between proteins and proteins as a feasible 
therapeutic way.
Figure 2. 
Initiation of HPV DNA replication. (A) Schematic representation of the viral proteins E1 and E2 required for 
replication of the HPV genome. E1 and E2 are approximately 650 and 370 amino acids in length, respectively. 
Locations of the different functional domains in each protein are indicated. OBD, origin binding domain 
helicase/ATPase N-terminal; TAD, transactivation domain; H, hinge region; DBD, DNA-binding domain. (B) 
Schematic diagram of the initiation of HPV DNA replication. (I) Replication is initiated by the recruitment of 
E1 (purple) and by E2 (green), to the viral origin [10].
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advances in identification of leader compounds that may interrupt protein–protein 
E1-E2 interactions. Some of these compounds showed nanomolar affinities and 
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protein interaction, which also have been identified as the first inhibitors for small 
molecules capable to antagonize the assembly of E1-E2 complex and the viral ori 
HPV11. It was identified a compound that inhibited E1-E2 protein interaction 
by means of high-performance sieving from the collection of over Boehringer 
Ingelheim 100,000 compounds, using a scintillation proximity assay (SPA). Also, 
more active analogues were synthesized that were capable to inhibit the E1-E2 
complex assembly with the HPV11 viral ori with low nanomolar power in vitro 
and with activity in cell culture. Structurally, this group of inhibitors presents an 
indandione system spirofused onto a substituted tetrahydrofuran ring which were 
denominated as indandione inhibitors. It was determined that these inhibitors 
act by joining to E2 TAD domain, the same protein region that interacts with E1 
[51, 52]. Crystalline structures, HPV11 E2 TAD by itself or as a complex with an 
indandione inhibitor, both provide a detailed comprehension of the mechanism in 
which indandione inhibitors join E2 to interrupt the interaction E1-E2. A compari-
son between both structures revealed that the union between the inhibitors caused 
insignificant alterations on the protein backbone, but it did induce a significant 
movement of several lateral amino acid chains at the union site. These changes in 
the lateral chain conformation, particularly from Tyr-19, His-32, Leu-94 y, and 
Glu-100 residues, resulted in the formation of a deep hydrophobic bag that is joined 
firmly to the inhibitor indandione fraction. The structure also revealed that the 
inhibitor carboxylate fraction, known by its importance for power, forms hydrogen 
bonds with amides from the protein backbone. Studies regarding the structure-
activity relationship (SAR) revealed that the carboxylate fraction is important in 
potency of the inhibitor. Mechanistic studies, including the use of isothermal titling 
calorimetry, showed that the indandione inhibitors join reversibly to E2 TAD with 
1:1 stoichiometry. Even though indandione inhibitors displayed a powerful activity 
against E2 proteins of low-risk viruses HPV6 and HPV11, these did not show any 
activity against high-risk types HPV16, HPV18, and HPV31. Cellular culture studies 
showed that indandione inhibitors are capable of antagonizing E1-E2 interaction of 
HPV6 and HPV11 [49].
3.1 Other labs’ approach
White and coworker addressed these issues in a series of detailed studies to iden-
tify inhibitors of the cooperative assembly of HPV E1 and E2 on the ori, focusing 
on HPV 6 and 11. They identified two series of inhibitors that bound to overlapping 
sites at the E1 binding interface on the E2 TAD. Results obtained from modeling 
works suggest that inhibitors derived from repaglinide form weak interactions with 
protein E2 TAD but occupy a bigger portion from the inhibitor union bag than the 
indandione series.
Both series of compounds were optimized for binding by medicinal chemistry 
approaches, and in both series the best compounds in each series had low nanomo-
lar activity against the HPV 11 E1-E2 interaction.
The fact that the potent repaglinide derivatives, with values IC50 at nanomolar 
range against HPV6 and HPV11 E2, and EC50 values in cellular DNA replication 
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assays of approximately 1 mM, make this series a promising route for development 
of small molecular inhibitors for E1-E2 interaction [53].
Capabilities of indandione compounds to inhibit HPV genome in vivo replica-
tion, especially low-risk HPV types, demonstrate for the first time the therapeutic 
potential of protein E2 as target for the development of small molecule inhibitors 
at HPV protein interaction, particularly in the case for treatment of anogenital 
warts caused by HPV6 and HPV11. Furthermore, location and characterization of 
the union bag for E2 TAD inhibitors provide a new potential therapeutic option 
for treatment of HPV infections. These studies have set the basis for the use of 
approaches based in structures for rational design or for virtual selection of inhibi-
tor compounds capable of joining to all or part of the identified inhibitor union bag.
Kantang and coworker worked in the prediction of the interactions of the 
helicase domain of the E1 protein of HPV16 and the TAD domain of HPV16; for 
this purpose, E1 protein domain was modeled (residue 421–622) from HPV16 
with I-TASSER server. The model with the best C-score was selected to coupling to 
structure E2 from HPV16 and HPV18 using ClusPro. Superposition of E1 HPV16 
and the crystalline structure of E1 HPV18 showed an RMSD of 1.39 Å, indicating 
structural similitude. A complex structure for HPV16 E1-E2 is also predicted as 
similar to crystalline structure of HPV18 E1-E2, with an RMSD value of 1.11 Å. An 
analysis of HPV16 E1-E2 interactions revealed there are three sites for interaction 
of complex HPV16 E1 and E2. The residues Glu118, and Tyr178 at the structural 
domain of folded β-sheet for HPV16 E2 form hydrogen bonds with Tyr578, Arg575, 
Ser574, Asp573 of HPV16 E1, respectively.
HPV16 E2 helicoidal N-terminal domain is the main union site for HPV16 E1 
protein where Asp13, Thr17, Tyr19, Asp22, Tyr32, Glu39, and Val58 from HPV16 E2 
interact with Arg615 (for Asp13 and Thr17 E2), Arg447, Arg619, Glu452, Arg447, 
and Tyr602 from HPV16 E1, respectively. Shows Gln95 and Glu100; at the linking 
segment between N-terminal and C-terminal HPV16 E2, there are interactions 
with Arg462 and Ser455 from HPV16 E1, respectively. Besides, structures of nine 
peptides reported [54] were built by I-TASSER server. Using ClusPro web server, 
it was able to predict binding, conformations, and interactions of peptides with 
HPV16 E2 protein; bind conformations and interactions between small peptides 
and HPV16 E2 protein were predicted and analyzed. These results were used 
ahead for the design of more powerful peptides that may potentially inhibit E1-E2 
complex formation. Binding affinities obtained for designed peptides and protein 
E2 of HPV16 recombinant were in good agreement with experimental results. Four 
peptides were the more efficient inhibitors of E1-E2 complex, and they could be 
used for suppression of HPV replication [55].
4. Conclusions
Currently a cure or treatment for HPV is unavailable. In many men and women, 
HPV disappears by itself without causing further problems. There are treatments 
for affections caused by the virus. Among these affections are genital warts, pre-
carcinogenic cells, and cancer.
Even though there are vaccines against the main HPV types, there are therapeu-
tic treatments needed for those that have been already exposed to the virus which 
represent most of the population affected by this disease. In this regard, a diversity 
of research work related to antiviral design exists, including those work using com-
putational methods. These studies have laid the foundation for the use of structure-
based approaches to rationally design or virtually screen inhibitory compounds that 
are capable of preventing HPV replication.
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By means of molecular coupling analysis, it is possible to predict interactions 
of leader molecules with the target with enough detail to be useful for synthetic 
elaboration of those molecules.
It has been considered that protein-protein interactions are difficult to inhibit 
because they often involve big surfaces, depriving small molecules to bind with 
the pocket; however, they are receiving great attention to work as targets for the 
rational design of drugs. The interest in the protein-protein interaction inhibitors 
and in the protein drugs has been in constant growth.
Regarding HPV therapy development, a group of small molecules has been 
identified using high-performance sieving capable of interrupting HPV16 E1-E2 
interaction which helps avoid viral replication.
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Even though there are vaccines against the main HPV types, there are therapeu-
tic treatments needed for those that have been already exposed to the virus which 
represent most of the population affected by this disease. In this regard, a diversity 
of research work related to antiviral design exists, including those work using com-
putational methods. These studies have laid the foundation for the use of structure-
based approaches to rationally design or virtually screen inhibitory compounds that 
are capable of preventing HPV replication.
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By means of molecular coupling analysis, it is possible to predict interactions 
of leader molecules with the target with enough detail to be useful for synthetic 
elaboration of those molecules.
It has been considered that protein-protein interactions are difficult to inhibit 
because they often involve big surfaces, depriving small molecules to bind with 
the pocket; however, they are receiving great attention to work as targets for the 
rational design of drugs. The interest in the protein-protein interaction inhibitors 
and in the protein drugs has been in constant growth.
Regarding HPV therapy development, a group of small molecules has been 
identified using high-performance sieving capable of interrupting HPV16 E1-E2 
interaction which helps avoid viral replication.
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Abstract
Tumor viruses cause cancer; thus, extensive studies are being conducted on 
them. In this article, we will review the basic medical research on the current clini-
cal genetic tests for tumor viruses such as human papilloma virus, hepatitis B virus, 
and T-cell leukemia virus. Recently, clinical genetic tests have been developed for 
quick diagnosis of the tumor virus infection. Additionally, we will review the muta-
genesis of murine leukemia retrovirus. In particular, we will focus on the insertional 
mutagenesis. This will help in deciding the direction of future virus research by 
combining clinical and basic research.
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1. Introduction
1.1 History of tumor virus research
Tumor virus research is an important subject to understand the molecular 
biology of tumor viruses and carcinogenesis. Dr. Katsusaburo Yamagiwa, a Japanese 
pathologist, is famous for the experiment in which coal tar was applied to rabbit 
ears to induce carcinogenesis in 1915. He was also a candidate for the Nobel Prize 
in Medicine. The following year, his student Dr. Akira Fujinami was appointed to 
study carcinogenesis in Germany for 4 years. After returning to Japan, in 1900, 
he became the first professor at the Department of Pathology, Kyoto Imperial 
University Medical College. In 1905, he started studying chicken tumors, and as 
early as 1910, he established a chicken breast tumor transplant system. He had 
suggested the possibility of carcinogenesis by filterable pathogens, which were later 
called Fujinami sarcoma virus (FSV). He is also well known for the discovery of 
Japan schistosomiasis.
Interestingly, in the same year, Peyton Rous, who was studying at the Rockefeller 
laboratory in the United States, also established the avian sarcoma transplant 
system. In 1966, Rous received the Nobel Prize in Physiology and Medicine for the 
discovery of carcinogenic viruses. Hanafusa et al. elucidated the FSV gene structure 
and identified the similarity with the Rous sarcoma virus gene structure [1]. Both 
FSV and Rous sarcoma virus belong to the same alpha-retrovirus. FSV has the onco-
gene v-fps in its genome [2]. It also has long terminal repeats (LTRs) at the ends of 
the genome that stabilizes as parts of the host cell genome when inserted into host 
mesenchymal cells after reverse transcription. In addition to the host cell division, 
the viral genome also replicates during the DNA replication cycle. Tyrosine-protein 
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Japan schistosomiasis.
Interestingly, in the same year, Peyton Rous, who was studying at the Rockefeller 
laboratory in the United States, also established the avian sarcoma transplant 
system. In 1966, Rous received the Nobel Prize in Physiology and Medicine for the 
discovery of carcinogenic viruses. Hanafusa et al. elucidated the FSV gene structure 
and identified the similarity with the Rous sarcoma virus gene structure [1]. Both 
FSV and Rous sarcoma virus belong to the same alpha-retrovirus. FSV has the onco-
gene v-fps in its genome [2]. It also has long terminal repeats (LTRs) at the ends of 
the genome that stabilizes as parts of the host cell genome when inserted into host 
mesenchymal cells after reverse transcription. In addition to the host cell division, 
the viral genome also replicates during the DNA replication cycle. Tyrosine-protein 
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kinase transforming protein Fps encoded by v-fps has the ability to induce trans-
formation by promoting tyrosine phosphorylation of the PDGFbeta receptor [3, 4]. 
Thus, the Japanese scientists have greatly contributed to the field during the early 
days of oncology research.
1.2 Viral genome integration
Retroviral integration is a type of insertional mutagenesis. Integration pro-
cesses are widely studied from biochemistry, and their molecular mechanisms are 
elucidated. Retrovirus-induced tumorigenesis is divided into two types. First, the 
retroviral genome carries the oncogene such as v-onc, and the inserted viral element 
may induce malignant tumors. Second, the inserted retroviral element has the 
promoter or enhancer activity of the host proto-oncogene. The genome of human 
papilloma virus (HPV), hepatitis B virus (HBV), human T-cell adult leukemia 
virus (HTLV) [5], avian sarcoma virus (ASV) [6], feline leukemia virus (FeLV) [7], 
murine leukemia virus (MLV) [8–13], and mouse mammary tumor virus (MMTV) 
can be integrated in the host genome. As a survival strategy, the inserted retroviral 
genome (provirus) is thereafter replicated during host cell division.
The retroviral promoter and enhancer elements in LTRs originally promote the 
expression of retroviral genes such as gag, env, and pol [14] (Figure 1). However, 
once integrated in the host genome, LTR elements can promote host gene expres-
sion in place of the host genome promoters and enhancers. After infection, the 
retroviral RNA genome is reverse-transcribed into DNA, which forms a pre-inser-
tion complex (PIC) with the oligomeric integrase enzyme [15], which catalyzes 
the insertion reaction. The PIC crosses the nuclear envelope through the nuclear 
pore complex to access host cell DNA. The retroviral DNA ends then attack and 
nick the host DNA with target nucleotides. These ends are ligated to the truncated 
host DNA to complete the insertion process involving replication of the target 
nucleotides.
To date, extensive research has been conducted on target motifs for retroviral 
insertion to better understand tumorigenesis, neuronal damage, aging, and immu-
nodeficiency including acquired immunodeficiency syndrome (AIDS). Retroviral-
host DNA interactions support specific host DNA structures [16–21] but are less 
likely to be inserted into particular base sequences. Previous studies on human 
immunodeficiency virus (HIV)-1 insertion have shown that the insertion sites are 
distributed in 10-bp cycles on the nucleosome surface of the outward DNA major 
groove of chromatin [16, 22].
Figure 1. 
A common structure of the retroviral genome. Plus strand RNA is shown. R, terminal redundant sequence; U5, 
unique 5′ sequence; PBS, tRNA primer-binding site; gag, group-specific antigen encoding capsid protein MA 
(matrix), CA, capsid protein; NC, nucleocapsid; pro, protease; pol, polymerase including reverse transcriptase 
(RT) and integrase (IN) catalyzing integration; env, envelope glycoproteins; U3, unique 3′ sequence. U3, R, 
and U5 are duplicated at both ends of the DNA provirus genome in the host genome sequence to form the long 
terminal repeat (LTR). LTR is essential for the initiation of viral DNA syntheses by reverse transcription as 
well as the integration of proviral DNA and the regulation of viral gene expression.
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2. HPV
HPV is one of the most common viruses that infect more than half women 
once in life through sexual intercourse. It is a small DNA virus with approximately 
8000 bp circular double-stranded DNA in its genome. The viral particle has icosa-
hedral capsid structure as its outer shell. The virus has been known to be involved in 
the development of cervical, anal, and vaginal cancer and condyloma acuminatum. 
Many types of HPV are known, and high-risk HPV based on this cancer risk is 
concentrated in specific subgroups epidemiologically. In particular, types 16 and 18 
have high carcinogenic risks of cervical intraepithelial neoplasia (CIN) and cancer. 
Type 16 has been detected in the Japanese 5-year-old girls [23]. High-risk group 
(types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) causes bladder cancer and 
pharyngeal cancer in addition to vulvar and cervical cancer. Low-risk group (HPV2, 
27, and 57) causes verruca vulgaris that develops in the hands and feet [24].
HPV genome has early genes (E1, E2, E4, E5, E6, and E7) and late genes encod-
ing viral capsid proteins (L1 and L2). E6 and E7 are considered to be involved in 
carcinogenesis. E6 binds to a tumor-suppressor gene product p53 and degrades 
p53 through promoting the ubiquitination. It also contributes to carcinogenesis by 
reactivating telomerase reverse transcriptase (hTERT) and degrading proteins with 
PDZ domain [shared by—post-synaptic density protein (PSD95), Drosophila disc 
large tumor suppressor (Dlg1), and Zonula occludens-1 protein (zo-1)]. E7 binds to 
the tumor suppressor gene pRb and contributes to carcinogenesis by releasing and 
activating the transcription factor E2F bound to pRb. It is also involved in carcino-
genesis by interacting with cyclin-dependent kinase (Cdk) inhibitors p21 and p27 
to evade cell cycle checkpoint mechanisms and apoptosis. However, in many cases, 
immortalization does not occur only by the actions of human cervix mucosal cells 
E6 and E7. In the well-known HeLa cell line, telomerase is activated, preventing the 
gradual shortening of telomeres in cell death.
High-risk HPV can be detected in more than 90% patients suffering from 
cervical cancer and dysplasia, which is a precancerous lesion, and in the vulva of 
5% normal women. Although HPV is also integrated into the genome of host cells, 
its integration pattern has unique features. The E6 and E7 genes are retained in the 
provirus with frequent deletion mutations in E2 gene. Thus, the viral genome is also 
found to be truncated in the complex reaction of integration, but its carcinogenicity 
is rather enhanced. Low-grade dysplasia of the cervix and cervical intraepithelial 
neoplasia (CIN) is well known. These pathological changes are reversible and are 
known to spontaneously disappear within about 3 years. However, about 10% 
infected patients sustain the infection for more than 3 years, and cervical cancer 
occurs after several months to several decades in some of them. HPV genome is 
integrated into the host cell genome during the progression of CIN, and the pro-
gression becomes irreversible.
2.1 Clinical test for HPV detection
HPV-DNA typing tests have been conducted using real-time PCR, loop-
mediated isothermal amplification (LAMP) [25, 26], invader, and hybridization 
methods. In recent years, the Clinichip method [27] combining LAMP is broadly 
available in advanced countries including Japan due to the ability to amplify genes 
at a constant temperature. The LAMP method is very specific because it uses four 
primers to recognize the six regions of the HPV genome. Nonspecific amplification 
does not occur because the amplification reaction depends on the order of the six 
regions of the HPV gene. In addition, since the amplification product constitutes 
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formation by promoting tyrosine phosphorylation of the PDGFbeta receptor [3, 4]. 
Thus, the Japanese scientists have greatly contributed to the field during the early 
days of oncology research.
1.2 Viral genome integration
Retroviral integration is a type of insertional mutagenesis. Integration pro-
cesses are widely studied from biochemistry, and their molecular mechanisms are 
elucidated. Retrovirus-induced tumorigenesis is divided into two types. First, the 
retroviral genome carries the oncogene such as v-onc, and the inserted viral element 
may induce malignant tumors. Second, the inserted retroviral element has the 
promoter or enhancer activity of the host proto-oncogene. The genome of human 
papilloma virus (HPV), hepatitis B virus (HBV), human T-cell adult leukemia 
virus (HTLV) [5], avian sarcoma virus (ASV) [6], feline leukemia virus (FeLV) [7], 
murine leukemia virus (MLV) [8–13], and mouse mammary tumor virus (MMTV) 
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does not occur because the amplification reaction depends on the order of the six 
regions of the HPV gene. In addition, since the amplification product constitutes 
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the target gene sequence, the target gene can be detected immediately by the pres-
ence or absence of amplification.
In an environment where electricity availability is limited, easy-to-use and dura-
ble reagents and equipment are desirable. In recent years, attempts have been made 
to spread virus testing as point-of-care tests (POCT) [28]. For some pathogens such 
as malarial parasite (Plasmodium), HIV, Ebola virus, and Zika virus, development of 
the testing system by fluid device is in progress; however, HPV detection methods 
have not been put to practical use as POCT yet.
3. HBV
HBV has been identified as the pathogen that causes acute and chronic hepatitis 
B [29, 30]. HBV is a DNA hepatitis virus and has a double structure of an envelope 
and a core. In persistent infections, the HBV genome is often inserted into the 
hepatocyte genome and is not eliminated by the host’s immune system. Several 
studies on many common insertion sites have identified common integration sites 
in the HBV genome by full genome sequence of hepatocellular carcinoma [31]. The 
envelope protein of HBV covers the HBs antigen, and the core protein is called the 
HBc antigen. HBV DNA encodes HBs antigen, HBc antigen, X protein, and DNA 
polymerase. The HBe antigen is translated from the pre-C gene and the down-
stream HBc antigen. It is released into blood as a soluble protein during HBV virus 
growth and therefore considered a marker for the virus growth. In asymptomatic 
carriers positive for HBe antigen, the host immune system continuously reacts 
with HBV-infected hepatocytes, and biopsy reports show persistent lymphocyte 
infiltration in the portal vascular area of liver tissues. If the damage persists for a 
long time, remodeling of the hepatocytes occurs and progresses to cirrhosis with 
obvious fibrotic crosslinks. After all, when seroconversion occurs in HBV carri-
ers negative for HBe antigen and positive for HBe antibody, the patient becomes 
an inactive carrier. HBV particles remain alive during periods of inactivity. Host 
immune system can attack infected hepatocytes, and hepatocyte regeneration may 
occur with genomic mutations, and the effects of the inserted HBV genome persist. 
Hepatocellular carcinoma can develop with persistent liver dysfunction associated 
with liver cirrhosis.
3.1 Clinical test for HBV detection
For the diagnosis of hepatitis B, HBs antigen/antibody, HBc antibody, HBe 
antigen/antibody, and HBV DNA are detected, and HBV DNA polymerase activity 
is measured. HBs antigen is produced continuously in patients with HBV infec-
tion; thus, positive results for HBe antigen can diagnose current infection with 
HBV. Recently, the HBs antigen measurement system has become very sensitive, 
and infected people have been found to be positive for HBs. In addition to antigen or 
antibody detection method, viral DNA detection system (quantitative PCR, LAMP 
method) has been used for clinical tests. Liver fibrosis is seen as a precancerous 
stage of HBV and hepatitis C virus (HCV) infection. Liver biopsy and qualita-
tive analysis of hyaluronic acid and type IV collagen in blood are well-known 
methods to evaluate liver fibrosis progress. Monitoring of glycolysis of serum 
M2BP (Macingo binding biomarker) is used to evaluate liver fibrotic stage [32]. 
Recent studies have suggested that the most common cause of nonexclusion of 
HBV is covalently closed circular DNA (cccDNA). When HBV infects hepatocytes, 
the incomplete duplex circular DNA genome becomes a complete duplex and is 
retained in the nucleus in the form of cccDNA. This HBV gene is the source of HBV 
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replication. Since cccDNA is an extremely stable biochemical structure, it can be 
used as a monitoring marker after the infection. As the nucleic acid analog drug has 
little effect on reducing HBV cccDNA, a high risk of reactivation remains. If host 
immunity is suppressed, the reactivation occurs from this cccDNA as a starting 
transcriptional point. Therefore, elimination or suppression of reactivation will be 
central to future therapeutic strategies [33].
In the clinical tests for HBV detection, the detection sensitivity of the enzyme-
linked immunosorbent assay (ELISA) method for HBs antigen is higher than those 
of other tests. Each available method depends on the titer of the used antibody, and 
the sensitivity varies. In particular, the mutation in the gene encoding the envelope 
protein HBs antigen may cause false negative results. Many test kits increase sen-
sitivity by using multiple monoclonal antibodies or a polyclonal antibody that has 
an affinity for multiple epitopes. In some cases, antibodies that recognize epitopes 
within the viral particle are used instead of surface proteins with many mutations. 
However, the high sensitivity of many kits may instead cause false positive results. 
Accordingly, actual early diagnosis requires careful evaluation of test results in 
combination with other clinical tests.
4. HTLV type 1 (HTLV-1)
Another important human carcinogenic virus is human T-cell leukemia virus 
type 1 (HTLV-1). This virus has the potential to cause adult T-cell leukemia/lym-
phoma (ATL), HTLV-1-associated myelopathy (HAM), and HTLV-1 uveitis (HU). 
These diseases develop in HTLV-1 carriers after prolonged latent infection. HTLV-1 
carriers are particularly prevalent in southwest Japan, including Kyushu, Shikoku, 
and Okinawa. HTLV-1 was isolated and reported by Gallo R as the first human 
pathogenic retrovirus in 1980. Yorio Hinuma of Kyoto University in Japan precisely 
analyzed the genomic structure and identified the HTLV-1 [34]. HTLV-1 is a weakly 
infective virus particle, and cell-to-cell transmission is the main route of infection.
4.1 Molecular biology of HTLV-1
ATL is a hematologic malignancy in which abnormal lymphocytes appear 
in peripheral blood and infiltrate various organs throughout the body. Kiyoshi 
Takatsuki of Kumamoto University in Japan and Taku Uchiyama of Kyoto 
University collected samples. In 1981, Hinuma identified HTLV-1 to be the causative 
virus of ATL; this was the first report on tumor-induced retrovirus in humans. Most 
infected cells are CD4 + CD25 + T cells. Viral receptors are thought to involve other 
proteins and heparan sulfate. HTLV-1 is an approximately spherical virus particle 
about 100 nm in diameter and has an envelope. It has an RNA genome composed 
of the genes common to retroviruses such as gag, pro, pol, and env, as well as the 
gene encoding pX. It selectively uses the splicing and translation initiation sites in 
a region less than 2 kb called pX located between the env gene and the 3′ LTR [35] 
and uses the plus and minus strands relative to the transcription direction and effi-
ciently. It often encodes several regulatory and accessory genes. As described later, 
this pX is involved in the action of HTLV-1 encoding HTLV-1 bZIP factor (HBZ).
Tax and HBZ may be the carcinogenic potentials of HTLV-1. Tax is a potent 
transactivator essential for the activation of the viral promoter 5′ LTR. After enter-
ing the cell by infection, the virus particle capsid is lost, and the HTLV-1 genomic 
RNA is reverse transcribed to form genomic duplex DNA. Thereafter, the integrase 
encoded by the viral genome and the DNA end forms a complex, which contacts 
the genomic DNA on the cell side, and inserts by catalytic reaction. The 5-base-long 
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replication. Since cccDNA is an extremely stable biochemical structure, it can be 
used as a monitoring marker after the infection. As the nucleic acid analog drug has 
little effect on reducing HBV cccDNA, a high risk of reactivation remains. If host 
immunity is suppressed, the reactivation occurs from this cccDNA as a starting 
transcriptional point. Therefore, elimination or suppression of reactivation will be 
central to future therapeutic strategies [33].
In the clinical tests for HBV detection, the detection sensitivity of the enzyme-
linked immunosorbent assay (ELISA) method for HBs antigen is higher than those 
of other tests. Each available method depends on the titer of the used antibody, and 
the sensitivity varies. In particular, the mutation in the gene encoding the envelope 
protein HBs antigen may cause false negative results. Many test kits increase sen-
sitivity by using multiple monoclonal antibodies or a polyclonal antibody that has 
an affinity for multiple epitopes. In some cases, antibodies that recognize epitopes 
within the viral particle are used instead of surface proteins with many mutations. 
However, the high sensitivity of many kits may instead cause false positive results. 
Accordingly, actual early diagnosis requires careful evaluation of test results in 
combination with other clinical tests.
4. HTLV type 1 (HTLV-1)
Another important human carcinogenic virus is human T-cell leukemia virus 
type 1 (HTLV-1). This virus has the potential to cause adult T-cell leukemia/lym-
phoma (ATL), HTLV-1-associated myelopathy (HAM), and HTLV-1 uveitis (HU). 
These diseases develop in HTLV-1 carriers after prolonged latent infection. HTLV-1 
carriers are particularly prevalent in southwest Japan, including Kyushu, Shikoku, 
and Okinawa. HTLV-1 was isolated and reported by Gallo R as the first human 
pathogenic retrovirus in 1980. Yorio Hinuma of Kyoto University in Japan precisely 
analyzed the genomic structure and identified the HTLV-1 [34]. HTLV-1 is a weakly 
infective virus particle, and cell-to-cell transmission is the main route of infection.
4.1 Molecular biology of HTLV-1
ATL is a hematologic malignancy in which abnormal lymphocytes appear 
in peripheral blood and infiltrate various organs throughout the body. Kiyoshi 
Takatsuki of Kumamoto University in Japan and Taku Uchiyama of Kyoto 
University collected samples. In 1981, Hinuma identified HTLV-1 to be the causative 
virus of ATL; this was the first report on tumor-induced retrovirus in humans. Most 
infected cells are CD4 + CD25 + T cells. Viral receptors are thought to involve other 
proteins and heparan sulfate. HTLV-1 is an approximately spherical virus particle 
about 100 nm in diameter and has an envelope. It has an RNA genome composed 
of the genes common to retroviruses such as gag, pro, pol, and env, as well as the 
gene encoding pX. It selectively uses the splicing and translation initiation sites in 
a region less than 2 kb called pX located between the env gene and the 3′ LTR [35] 
and uses the plus and minus strands relative to the transcription direction and effi-
ciently. It often encodes several regulatory and accessory genes. As described later, 
this pX is involved in the action of HTLV-1 encoding HTLV-1 bZIP factor (HBZ).
Tax and HBZ may be the carcinogenic potentials of HTLV-1. Tax is a potent 
transactivator essential for the activation of the viral promoter 5′ LTR. After enter-
ing the cell by infection, the virus particle capsid is lost, and the HTLV-1 genomic 
RNA is reverse transcribed to form genomic duplex DNA. Thereafter, the integrase 
encoded by the viral genome and the DNA end forms a complex, which contacts 
the genomic DNA on the cell side, and inserts by catalytic reaction. The 5-base-long 
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sequence of the targeted host cell genome is duplicated at both ends of the inserted 
viral genome in the insertion process. Tax, the transcript of TLV-1 regulatory gene 
tax, not only binds to the HTLV-1 promoter to promote viral transcription and 
expression but also interacts with cell-side transcription factors to activate host gene 
transcription activity. Therefore, tax is implicated in the early stages of tumori-
genesis of infected cells. However, in peripheral blood of most ATL patients, Tax is 
suppressed by its promoter 5′ LTR deletion and epigenetic modification. Thus, Tax 
is not essential, at least at the final stage of carcinogenesis. Recently, Matsuoka has 
suggested that Tax is constitutively expressed in a small fraction of leukemia cells, 
and this fraction triggers an anti-apoptotic mechanism to establish sustained infec-
tion and induces oncogenesis [36]. Tax is induced by a variety of cytotoxic stresses 
and also promotes HTLV-1 replication. Thus, it protects infected cells from apopto-
sis and increases the chance of viral infection at the critical phase of disease in the 
carrier. Another HBZ gene is expressed in all ATL patients causing and promoting 
the growth of ATL cells; therefore, it may be the gene responsible for ATL.
4.2 Insertion site of HTLV-1
At present, in addition to the carcinogenesis by the proteins of these viruses 
themselves, attention has been focused on the activation of host genes at the inser-
tion site. The integrated HTLV-1 provirus has the LTR [35] in both directions for 
the transcription. This sequence has many motifs that bind to transcription factors 
on the host and have strong promoter/enhancer activities. Therefore, there may 
be an increase in constitutive expression of the gene at the insertion site. Ogawa 
performed systematic genome analysis of ATL cells in 426 ATL patients and showed 
that genes interacting with Tax, T-cell receptor-NF-κB signal transduction, T-cell 
transport, and other T-cell-related pathways as well as genes related to immune 
surveillance are injured by the integration. Also, the expressions of VAV1, IRF4, 
and FYN related to lymphocyte maturation and signal transduction, chemokine 
receptors CCR4 and CCR7, and gene fusions (CTLA4-CD28 and ICOS-CD28) were 
enhanced in the infected cells [37]. Viral transcripts were mainly derived from 
the antisense strand. Also, the suppression of Tax expression and the constitutive 
expression of HBZ were observed in almost all patients. These insertion sites have 
not been known to be likely to occur in any particular sequence motif.
4.3 Clinical test for HTLV-1 detection
To date, no chromosomal abnormality specific to HTLV-1 has been observed, 
and Southern blot or inverse PCR methods are used for diagnosis; however, in 
recent years, multiplex LAMP (RT-LAMP) using universal probe has been devel-
oped. The method detects both HIV and HTLV-1 RNA from the same sample [39]. 
HAS HTLV-1 analyzing system (HAS)-Flow method has also been proposed to 
evaluate the progression of ATL stage by applying flow cytometric analysis focusing 
on surface markers of infected immune cells [38].
5. Integration model in mice lymphomas
5.1 The specificity of insertion sequence of the retrovirus genome
As experimental models of MLV integration, BXH2 [40], AKXD [41–44], and 
SL/Kh [20, 45–52] are well-known mouse strains into which endogenous provirus 
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genomes have been inserted. The genome of an endogenous MLV, AKV [14], was 
integrated into gltscr 1 [20], which has been characterized as a tumor suppressor 
gene. This locus was identified as emv11 on chr 7. In our previous work, the inserted 
AKV genome was shown to contain the full-length MLV genome and expressed to 
form a retroviral particle, which had the ability to infect lymphocytes according 
to its retroviral tropism. In the consequent tumorigenesis, the phenotype of the 
murine tumor is generally variable in inbred strains. For example, AKR/J mice are 
susceptible to T-cell lymphoma/leukemia [53–55]; however, in BXH2 mice [39, 40], 
tumors resemble myeloid and lymphocytic tumors. Even if the MLV is integrated 
into identical genes, the tumor phenotypes are variable [56]. It is likely that the 
individual genetic backgrounds of the inbred mouse strains determine the pheno-
type in combination with the integration-induced expression of oncogenes. Thus, 
oncogenes are responsible for the tumorigenesis; however, the phenotypes of the 
tumors are determined by other elements, including the genetic background. The 
insertion site of MLV has been studied using model mouse strains. SL/Kh strain is 
known to be a model of acute lymphocytic leukemia/lymphoma by MLV infection, 
and the target sequence of integration has been identified. This phenomenon may 
not always be generalized in human retroviruses as MLV LTR is very long and has 
palindromic motifs unlike HTLV-1 LTR. This sequence motif may contribute to the 
stabilization of the structure as the tetrameric integrase binds to the LTR. Such a 
stabilizing structure is not found in HTLV-1, and the retroviral genome may differ 
in HTLV-1 and MLV in this regard. The existence of a specific sequence motif in the 
genome insertion of the virus has been the subject of much debate and was initially 
resolved negatively in early days. The conclusion was that a virus integration is a 
random event [57] (by Howard Temin, who discovered reverse transcriptase and 
won the Nobel Prize in 1975). The randomness was proved through the genome 
analysis of infecting fibroblasts with integrated MLV in the culture state artificially. 
No common sequence motif for the insertion site was found in this way. However, 
there has been a report that active transcriptional genes can be the target of integra-
tion [21]. Besides, there are reports stating that palindrome sequence is favored by 
integration [16, 58]; however, the target sequence itself is yet to be identified. The 
idea is that viral insertion affects the transcriptional activity of the host cell genome 
by the three-dimensional structure of chromatin. A model may be considered in 
which the integrase complex binds to the site where DNA is locally released during 
transcription.
To study MLV genome insertion in vivo, inbred strains of mice harboring many 
copies of endogenous MLV genomes were developed. SL/Kh is one of the inbred strains 
(Tsukuba, Japan; http://www.riken.jp/engn/index.html) [14, 45]. In this strain, the 
harbored MLV genome is spontaneously and selectively integrated into the genome 
of the B-cell genome DNA. In reference to the data about MLV insertion sites in the 
genome of SL/Kh mice, whether MLV insertion occurred preferentially into the specific 
sequence motifs in the host cell genome was investigated. Stat5a [20, 51, 59, 60] and 
c-myc [47] were the target genes for MLV insertion. More than 95% studied SL/Kh mice 
had such the MLV genome (AKV) insertion in zinc finger protein 521 gene (Zfp521) in 
the genomic DNA of B-cell lineage at 7 weeks of age [61] (Figure 2).
5.2 Integration target sequence
To date, such significantly selective insertion into the specific gene has not been 
known. When insertion further occurs in an oncogene (e.g., Stat5a [51] or c-myc 
[47]) in addition to Zfp521 in the genome of SL/Kh mice, B lymphocytic leukemia 
develops.
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genomes have been inserted. The genome of an endogenous MLV, AKV [14], was 
integrated into gltscr 1 [20], which has been characterized as a tumor suppressor 
gene. This locus was identified as emv11 on chr 7. In our previous work, the inserted 
AKV genome was shown to contain the full-length MLV genome and expressed to 
form a retroviral particle, which had the ability to infect lymphocytes according 
to its retroviral tropism. In the consequent tumorigenesis, the phenotype of the 
murine tumor is generally variable in inbred strains. For example, AKR/J mice are 
susceptible to T-cell lymphoma/leukemia [53–55]; however, in BXH2 mice [39, 40], 
tumors resemble myeloid and lymphocytic tumors. Even if the MLV is integrated 
into identical genes, the tumor phenotypes are variable [56]. It is likely that the 
individual genetic backgrounds of the inbred mouse strains determine the pheno-
type in combination with the integration-induced expression of oncogenes. Thus, 
oncogenes are responsible for the tumorigenesis; however, the phenotypes of the 
tumors are determined by other elements, including the genetic background. The 
insertion site of MLV has been studied using model mouse strains. SL/Kh strain is 
known to be a model of acute lymphocytic leukemia/lymphoma by MLV infection, 
and the target sequence of integration has been identified. This phenomenon may 
not always be generalized in human retroviruses as MLV LTR is very long and has 
palindromic motifs unlike HTLV-1 LTR. This sequence motif may contribute to the 
stabilization of the structure as the tetrameric integrase binds to the LTR. Such a 
stabilizing structure is not found in HTLV-1, and the retroviral genome may differ 
in HTLV-1 and MLV in this regard. The existence of a specific sequence motif in the 
genome insertion of the virus has been the subject of much debate and was initially 
resolved negatively in early days. The conclusion was that a virus integration is a 
random event [57] (by Howard Temin, who discovered reverse transcriptase and 
won the Nobel Prize in 1975). The randomness was proved through the genome 
analysis of infecting fibroblasts with integrated MLV in the culture state artificially. 
No common sequence motif for the insertion site was found in this way. However, 
there has been a report that active transcriptional genes can be the target of integra-
tion [21]. Besides, there are reports stating that palindrome sequence is favored by 
integration [16, 58]; however, the target sequence itself is yet to be identified. The 
idea is that viral insertion affects the transcriptional activity of the host cell genome 
by the three-dimensional structure of chromatin. A model may be considered in 
which the integrase complex binds to the site where DNA is locally released during 
transcription.
To study MLV genome insertion in vivo, inbred strains of mice harboring many 
copies of endogenous MLV genomes were developed. SL/Kh is one of the inbred strains 
(Tsukuba, Japan; http://www.riken.jp/engn/index.html) [14, 45]. In this strain, the 
harbored MLV genome is spontaneously and selectively integrated into the genome 
of the B-cell genome DNA. In reference to the data about MLV insertion sites in the 
genome of SL/Kh mice, whether MLV insertion occurred preferentially into the specific 
sequence motifs in the host cell genome was investigated. Stat5a [20, 51, 59, 60] and 
c-myc [47] were the target genes for MLV insertion. More than 95% studied SL/Kh mice 
had such the MLV genome (AKV) insertion in zinc finger protein 521 gene (Zfp521) in 
the genomic DNA of B-cell lineage at 7 weeks of age [61] (Figure 2).
5.2 Integration target sequence
To date, such significantly selective insertion into the specific gene has not been 
known. When insertion further occurs in an oncogene (e.g., Stat5a [51] or c-myc 
[47]) in addition to Zfp521 in the genome of SL/Kh mice, B lymphocytic leukemia 
develops.
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In AKXD and SL/Kh lymphoma genome, Zfp521 is one of the most frequent 
targets of MLV integration [62]. This gene locus was first reported as a common 
integration site, ecotropic retrovirus integration site 3 (Evi3) [61–64]. In more than 
400 male SL/Kh mice, >90% pre-B-lymphoma genomes acquired the integrated 
proviral genome within a 50-bp segment located in the region of the second to 
third exon of Zfp521. This target gene carries alternating palindrome sequences 
[16], which was frequently targeted by MLV insertion. Zfp521 is one the novel 
identified target genes. It probably contributes to chondrocyte development [65], 
in addition to B-cell development that requires an abnormal chimeric gene [64]. 
Each insertion occurs once or twice during the development of lymphoma within 
a 50-bp segment located in the second intron to the third exon of Zfp521. Most 
commonly, the insertion occurs at the “:” site in the sequence “CTGAATTGAAAC: 
AACTTCAGCTGTTT,” where the pair of underlined sequences and the pair of 
sequences in italics are palindromic sequences [61–63, 66]. The insertion does not 
occur randomly; they frequently occur at approximately 10-bp intervals and are 
symmetrically distributed within the shown 50-bp segment (Figure 3).
SL/Kh mouse has multiple copies of the endogenous virus, which produces viral 
particles and infects immature B-cell lineages suitable for tropism. Several common 
insertion sites such as Stat5a and Stat5b and well-known genes such as c-myc have 
been identified till date. Interestingly, many of these insertions occur upstream of 
the translational initiation site of the protein, so that many intact targeted proteins 
are produced. The fact that many insertions occur in such specific genes suggests 
that DNA structures such as palindromic sequences are targeted. However, insertions 
in a short 50-bp segment cannot have such secondary structure. MLV insertion was 
observed in almost the entire genome of this SL/Kh acute lymphocytic leukemia/lym-
phoma. The integration target segment is located just before the translation initiation 
Figure 2. 
Murine leukemia retrovirus (MLV) integration into oncogenes in SL/Kh lymphoma. In most cases of 
lymphoma, MLV integrations into more than one oncogenes, including Stat5a, c-myc, Fiz1, Hipk2, and others, 
are observed. It is not clear why the tumor cells are restricted to pre-B lymphoma phenotype. To date, genetic 
background dependent on Bomb1 is critical for conferring the phenotype. In addition, Stat5a and Zfp521 genes 
cooperate with IL-7 and pre-B cell receptor signal pathways, respectively. Host cell phenotype at the integration 
may contribute to the phenotypes. Differentiation stage of the host cell at the mutagenesis may be one of the 
critical factors of the phenotype.
43
Basic Research and Clinical Examination of Tumor Virus
DOI: http://dx.doi.org/10.5772/intechopen.89331
origin of the Zfp521 gene, which was first reported as a retrovirus insertion sequence. 
As a result of the insertion, downstream Zfp521 gene is constitutively expressed, and 
the upregulation may be responsible for acute lymphocytic leukemia/lymphoma.
5.3  Interaction partners for MLV integrase and recent developments in the 
biosafety of gene therapy
Recently, several cellular proteins including transcription regulatory factors 
and chromatin and RNA-binding proteins have been discovered as potential 
interaction partners for MLV integrase [67]. The bromodomain and extra-terminal 
domain (BET)-containing family of proteins (BRD2, BRD3, BRD4, and BRDT) act 
as cellular-binding partners of MLV integrase and preferentially bind to open chro-
matin regions that are enriched for transcription start sites, CpG islands, DNase 
I-hypersensitive sites, and proto-oncogenes [68–73]. The BET family of proteins 
plays a critical role in regulating gene transcription through epigenetic interactions 
between dual bromodomains and acetylated lysines on histones H3 and H4 during 
cellular proliferation, cell cycle progression, and differentiation processes [8, 9]. 
In vitro interaction analysis in human cells revealed that the ET domain of BRDs, 
BRD4 in particular, interacts with a motif in the unstructured C-terminal tail of 
MLV integrase, and these interactions are crucial for the recruitment of the MLV 
PIC to host DNA during integration [10, 11]. Through the recognition of open 
chromatin structure, BET proteins have been suggested to contribute to the tether-
ing of the MLV PIC to the host chromatin [10, 12]. Furthermore, it has been shown 
that the cell-permeable small molecule JQ-1, a pan-BET bromodomain inhibitor, 
prevents the BRD4-acetylated lysine interaction by competitively binding to BRD4 
and reduces MLV integration frequencies at transcription start sites [4, 13, 14]. 
These findings suggest that BET proteins navigate the MLV genome and promote 
efficient MLV integration around transcription start sites associated with a chro-
matin structure characteristic of an open, transcriptionally active domain [3].
The dual bromodomain protein of BRD2 promotes B-cell expansion and plays 
a critical role in the regulation of mitogenic response genes, particularly cyclin A, 
in B cells [15]. In addition, it has been shown that the inhibition of BRD4 leads to 
the suppression of germinal center B-cell differentiation and antibody responses 
through the down-regulation of nuclear factor-κBp65 activation and B-cell lym-
phoma 6 expression [16]. Hence, these BET proteins might broadly contribute 
to tumorigenesis in cooperation with MLV integration in spontaneous B-cell 
lymphoma development, and these findings likely provide novel standpoints of 
proto-oncogene function as well as a better understanding of MLV insertional 
mutagenesis [15, 17].
Figure 3. 
Alternate palindrome sequence in Zfp521. The upper and lower sequences represent the native sequence of host 
murine Zfp521 gene and the junction sequence of host murine Zfp521 gene with the integrated MLV genome, 
respectively. Green and red letters represent pairs of alternating palindromes. The sequences in the same colors 
are palindromes. The downward arrows represent the hot spot of the MLV integration.
Viruses and Viral Infections in Developing Countries
42
In AKXD and SL/Kh lymphoma genome, Zfp521 is one of the most frequent 
targets of MLV integration [62]. This gene locus was first reported as a common 
integration site, ecotropic retrovirus integration site 3 (Evi3) [61–64]. In more than 
400 male SL/Kh mice, >90% pre-B-lymphoma genomes acquired the integrated 
proviral genome within a 50-bp segment located in the region of the second to 
third exon of Zfp521. This target gene carries alternating palindrome sequences 
[16], which was frequently targeted by MLV insertion. Zfp521 is one the novel 
identified target genes. It probably contributes to chondrocyte development [65], 
in addition to B-cell development that requires an abnormal chimeric gene [64]. 
Each insertion occurs once or twice during the development of lymphoma within 
a 50-bp segment located in the second intron to the third exon of Zfp521. Most 
commonly, the insertion occurs at the “:” site in the sequence “CTGAATTGAAAC: 
AACTTCAGCTGTTT,” where the pair of underlined sequences and the pair of 
sequences in italics are palindromic sequences [61–63, 66]. The insertion does not 
occur randomly; they frequently occur at approximately 10-bp intervals and are 
symmetrically distributed within the shown 50-bp segment (Figure 3).
SL/Kh mouse has multiple copies of the endogenous virus, which produces viral 
particles and infects immature B-cell lineages suitable for tropism. Several common 
insertion sites such as Stat5a and Stat5b and well-known genes such as c-myc have 
been identified till date. Interestingly, many of these insertions occur upstream of 
the translational initiation site of the protein, so that many intact targeted proteins 
are produced. The fact that many insertions occur in such specific genes suggests 
that DNA structures such as palindromic sequences are targeted. However, insertions 
in a short 50-bp segment cannot have such secondary structure. MLV insertion was 
observed in almost the entire genome of this SL/Kh acute lymphocytic leukemia/lym-
phoma. The integration target segment is located just before the translation initiation 
Figure 2. 
Murine leukemia retrovirus (MLV) integration into oncogenes in SL/Kh lymphoma. In most cases of 
lymphoma, MLV integrations into more than one oncogenes, including Stat5a, c-myc, Fiz1, Hipk2, and others, 
are observed. It is not clear why the tumor cells are restricted to pre-B lymphoma phenotype. To date, genetic 
background dependent on Bomb1 is critical for conferring the phenotype. In addition, Stat5a and Zfp521 genes 
cooperate with IL-7 and pre-B cell receptor signal pathways, respectively. Host cell phenotype at the integration 
may contribute to the phenotypes. Differentiation stage of the host cell at the mutagenesis may be one of the 
critical factors of the phenotype.
43
Basic Research and Clinical Examination of Tumor Virus
DOI: http://dx.doi.org/10.5772/intechopen.89331
origin of the Zfp521 gene, which was first reported as a retrovirus insertion sequence. 
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that the cell-permeable small molecule JQ-1, a pan-BET bromodomain inhibitor, 
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and reduces MLV integration frequencies at transcription start sites [4, 13, 14]. 
These findings suggest that BET proteins navigate the MLV genome and promote 
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The dual bromodomain protein of BRD2 promotes B-cell expansion and plays 
a critical role in the regulation of mitogenic response genes, particularly cyclin A, 
in B cells [15]. In addition, it has been shown that the inhibition of BRD4 leads to 
the suppression of germinal center B-cell differentiation and antibody responses 
through the down-regulation of nuclear factor-κBp65 activation and B-cell lym-
phoma 6 expression [16]. Hence, these BET proteins might broadly contribute 
to tumorigenesis in cooperation with MLV integration in spontaneous B-cell 
lymphoma development, and these findings likely provide novel standpoints of 
proto-oncogene function as well as a better understanding of MLV insertional 
mutagenesis [15, 17].
Figure 3. 
Alternate palindrome sequence in Zfp521. The upper and lower sequences represent the native sequence of host 
murine Zfp521 gene and the junction sequence of host murine Zfp521 gene with the integrated MLV genome, 
respectively. Green and red letters represent pairs of alternating palindromes. The sequences in the same colors 
are palindromes. The downward arrows represent the hot spot of the MLV integration.
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The stable integration of retroviral vectors is suitable to deliver therapeutic 
genes into cells to correct genetic diseases. MLV-based retroviral vectors are one of 
the most frequently used gene delivery vehicles in gene therapy studies for primary 
immunodeficiencies such as adenosine deaminase deficiency-severe combined 
immunodeficiency [10, 18, 19]. However, a subset of patients developed serious 
adverse events including leukemia that could be attributed to the integration 
pattern and vector design [10, 18]. MLV-based retroviral vectors integrate in the 
vicinity of transcription start site through the interaction between the C-terminal 
tail of MLV integrase (amino acids 381–408) and the ET domain of BET family 
of proteins [18, 20]. To resolve side effects such as leukemia, BET-independent 
MLV vectors have been developed by truncation of the C-terminal tail of MLV 
integrase or the single W390A mutation [18, 20]. Most recently, next-generation 
BET-independent MLV vectors have been engineered with the addition of the 
chromodomain of Chromobox protein homolog 1 (CBX1) to MLV integrase_W390A. 
The MLV integrase_W390A-CBX1 efficiently targets integration away from traditional 
markers of MLV integration including gene regulatory elements [10]. These find-
ings open new avenues to improve the biosafety of gammaretroviral vectors for 
gene therapy.
6. Summary
We followed the history of viral carcinogenic research in this review. The topic 
of viral carcinogenesis mentioned here is a case where the viral genome is inserted 
into the host genome. Because the molecular mechanism of viral carcinogenesis 
has been elucidated, significant novel technical methods will be developed in the 
future.
Clinical sequence analyzes gene changes occurring at diseased sites and provides 
information useful for diagnosis and treatment of diseases based on the results of 
gene mutations.
In addition to the various nucleic acid analysis methods such as conventional 
PCR and LAMP, next-generation sequencing and other rapid technological innova-
tion will aid in the measurement and analysis of numerous gene sequences in a 
short period. Furthermore, these technologies are expected to be used in the future 
to analyze infectious diseases such as cancer virus types, HPV high-risk groups, and 
virus insertion sites. Information on cancer virus infection will also be valuable for 
designing personalized drugs for cancer patients in the future.
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1. Introduction
Avian influenza also called as bird flu is an acute, contagious disease caused 
by Influenza A virus. Birds of order Anseriformes and Charadriiformes are reservoir 
hosts of influenza A viruses [1]. These viruses have the ability to infect many mam-
mal species such as horses, pigs, cats, dogs, and humans. Influenza A viruses are 
negative-sense single-stranded RNA viruses with enveloped structure [2]. Influenza 
A viruses have shown high antigenic variability due to antigenic drift and shift 
phenomena. These mutation methods result in the emergence of new variants. 
These new variants can have different host ranges, mortality rates, morbidity rates, 
and patterns of infection [3].
Influenza A viruses are further divided into highly pathogenic avian influenza 
(HPAI) or low pathogenic avian influenza (LPAI). Up till now, only some H5 and 
H7 subtypes have been confirmed as HPAI viruses. However, it is reported that 
some LPAI H5 and H7 subtypes can mutate to HPAI due to antigenic shift and drift 
phenomena [4].
Some influenza A viruses have a zoonotic potential and can cause a pandemic 
hazard to human population. Outbreaks of HPAI in poultry have affected the poul-
try industry worldwide [5]. In 2002, due to HPAI outbreaks, Chile suffered a loss 
of almost $31 million USD. In 2003, the HPAI outbreak resulted in the loss of more 
than $3387 million USD in Indonesia and $55 million USD in Vietnam. Similarly, in 
2012, Mexico suffered an economic loss of approximately $475 million USD due to 
HPAI outbreaks [1].
2. Influenza A virus
Influenza A viruses belong to family Orthomyxoviridae. Influenza A viruses are 
single-stranded negative-sense RNA viruses having genome with 8 segmentation 
that encode for 10 viral proteins: hemagglutinin (HA), neuraminidase (NA), matrix 
proteins (M1 and M2), nucleocapsid protein (NP), nonstructural proteins (NS1 and 
NS2), and polymerase proteins (PB1, PB2, and PA) [6].
Influenza viruses are further classified into subtypes on the basis of their 
hemagglutinin (HA) and neuraminidase (NA) genes [7]. A total of 18 HA and 11 
NA types has been identified up till now. On the basis of phylogenetic analysis 
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single-stranded negative-sense RNA viruses having genome with 8 segmentation 
that encode for 10 viral proteins: hemagglutinin (HA), neuraminidase (NA), matrix 
proteins (M1 and M2), nucleocapsid protein (NP), nonstructural proteins (NS1 and 
NS2), and polymerase proteins (PB1, PB2, and PA) [6].
Influenza viruses are further classified into subtypes on the basis of their 
hemagglutinin (HA) and neuraminidase (NA) genes [7]. A total of 18 HA and 11 
NA types has been identified up till now. On the basis of phylogenetic analysis 
and sequence homology of the HA gene, these viruses are clustered into virus 
clades [4].
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A nomenclature system for influenza viruses has been established by the World 
Health Organization (WHO) and FAO. This system contains the type of influenza, 
the first place of isolation of virus, strain, and year of isolation. For example, A/
Hong Kong/156/97 would be interpreted as influenza type A, isolated in Hong 
Kong, strain 156, and isolated in 1997 [1].
Hemagglutinin mediates binding of the virus to sialic acid receptors at the cell 
surface. Neuraminidase plays its role in the detachment of the virus from the cell 
surface [8]. A specific type of hemagglutinin binds with a specific type of cell surface 
that further clarifies the difference host range for different influenza virus types [9]. 
Mutation of genes coding hemagglutinin and neuraminidase affects the transmission 
of the virus along with the alteration of the host range [10].
3. Avian influenza in birds
Healthy birds can become affected by the avian influenza virus by direct contact 
with an infected bird. Avian influenza virus has the capability to infect more than 
100 species of birds worldwide [11]. Reservoir hosts of the virus include waterfowls 
and shorebirds. Low pathogenic avian influenza infection does not cause any clini-
cal disease. But, the virus survives in the host and sometimes mutates to produce 
highly pathogenic avian influenza virus [12].
Some species of birds are more disease resistant than others. For example, 
domestic poultry is more susceptible to H5N1 HPAIV infection than wild ducks. 
Wild ducks spread the disease to other susceptible hosts [2].
HPAI infection in susceptible birds can cause systemic infection including dam-
age to the nervous and circulatory system that ultimately leads to death. HPAI virus 
inhabits and multiplies in the respiratory and gastrointestinal tracts [13]. Clinical 
signs and symptoms of HPAI infection in birds include loss of appetite, diarrhea, 
nasal discharge, respiration problem, misshapen eggs, ataxia, and incoordination 
[10]. The maximum mortality rate in poultry due to HPAI infection can be up to 
95%. Confirmatory diagnosis of HPAI can be done by performing PCR analysis of 
tracheal or fecal swabs of suspected birds [14].
4. Transmission of disease from birds
Waterfowls and shorebirds are natural reservoirs of the influenza virus, and these 
birds spread the virus to domestic poultry by contaminating the water source, feed, 
and housing of domestic poultry [15]. Influenza virus secreted in feces can survive 
up to 35 days at 4°C. Aerosol transmission of the virus is also possible. Indirect 
contamination via shoes, clothing, and contaminated feathers is also reported [2].
Interspecies transmissions of the avian influenza virus are also possible. In 
Europe and the United States, H1N1 and H3N2 are commonly prevalent in swine 
population, and outbreaks have been reported by the transmission of these viruses 
to susceptible turkeys and chickens [11]. In another case, an outbreak in turkey 
flock has been reported in Canada from a poultry worker having a respiratory 
problem [1].
5. Transmission of disease to humans
In most cases of human infection with the influenza virus, the previous contact 
with alive or dead bird was recorded. People who are involved with poultry at any 
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level are more prone to exposure than other people [16]. Meat workers, poultry 
farmworkers, and bird sellers are under constant threat. Veterinarians are also at 
higher risk due to their contact with different types of birds [17]. Direct human to 
human transmission is also possible at mass gatherings such as airports, concerts, 
and funeral ceremonies [18].
6. Prevention and control
For the control of avian influenza in commercial and rural poultry, risk manage-
ment is the most important point [18]. Implementation of good agricultural prac-
tices such as strict biosecurity measures, training of poultry workers, availability of 
non-contaminated water, disinfection of equipment, and decontamination of farm 
premises before the introduction of the new flock can decrease the chance of an 
outbreak of AI [16].
In case of an outbreak, rapid culling and depopulation are recommended. 
Rapid culling can reduce the spread of the virus and minimize economic loss [19]. 
Poultry and their products infected with HPAI are banned to enter the food chain 
in developed countries [1], whereas in developing countries, HPAI-infected meat 
and products are consumed as feed after cooking at high temperatures. The use of 
effective vaccination can limit the H5N1 HPAI virus spread [18].
7. One health perspective
The first influenza A virus pandemic in humans was recorded almost a century 
ago, in 1918, which resulted in the death of around 20–50 million humans world-
wide [20, 21]. So far, three other pandemics of influenza A virus in humans that 
have caused considerable loss include the 1957 H2N2 pandemic, the 1968 H3N2 
pandemic, and the 2009 H1N1 pandemic [22]. From East Asia to Southeast Asia, 
sporadic human infection of H5N1 viruses was reported in 2003–2004 along with 
outbreaks in the poultry [21].
H5N1 viruses have been reported from domesticated poultry and wild birds in 
Asia, North Africa, Central Africa, and Europe [23]. The transmission of HPAI 
H5N1 viruses from poultry to humans was first documented in 1997 in Hong 
Kong. Some subtypes of avian influenza virus such as H5, H7, H9, and H10 have 
the capability of interspecies transmission [18]. According to the World Health 
Organization, the total confirmed human cases of H5N1 infection to date are 860 
with 454 fatal cases [24]. In 2013, a LPAI H7N9 virus caused an outbreak in China 
with a 36% case fatality [25]. Influenza viruses are a permanent threat for humans 
as well as birds.
Viruses and Viral Infections in Developing Countries
56
A nomenclature system for influenza viruses has been established by the World 
Health Organization (WHO) and FAO. This system contains the type of influenza, 
the first place of isolation of virus, strain, and year of isolation. For example, A/
Hong Kong/156/97 would be interpreted as influenza type A, isolated in Hong 
Kong, strain 156, and isolated in 1997 [1].
Hemagglutinin mediates binding of the virus to sialic acid receptors at the cell 
surface. Neuraminidase plays its role in the detachment of the virus from the cell 
surface [8]. A specific type of hemagglutinin binds with a specific type of cell surface 
that further clarifies the difference host range for different influenza virus types [9]. 
Mutation of genes coding hemagglutinin and neuraminidase affects the transmission 
of the virus along with the alteration of the host range [10].
3. Avian influenza in birds
Healthy birds can become affected by the avian influenza virus by direct contact 
with an infected bird. Avian influenza virus has the capability to infect more than 
100 species of birds worldwide [11]. Reservoir hosts of the virus include waterfowls 
and shorebirds. Low pathogenic avian influenza infection does not cause any clini-
cal disease. But, the virus survives in the host and sometimes mutates to produce 
highly pathogenic avian influenza virus [12].
Some species of birds are more disease resistant than others. For example, 
domestic poultry is more susceptible to H5N1 HPAIV infection than wild ducks. 
Wild ducks spread the disease to other susceptible hosts [2].
HPAI infection in susceptible birds can cause systemic infection including dam-
age to the nervous and circulatory system that ultimately leads to death. HPAI virus 
inhabits and multiplies in the respiratory and gastrointestinal tracts [13]. Clinical 
signs and symptoms of HPAI infection in birds include loss of appetite, diarrhea, 
nasal discharge, respiration problem, misshapen eggs, ataxia, and incoordination 
[10]. The maximum mortality rate in poultry due to HPAI infection can be up to 
95%. Confirmatory diagnosis of HPAI can be done by performing PCR analysis of 
tracheal or fecal swabs of suspected birds [14].
4. Transmission of disease from birds
Waterfowls and shorebirds are natural reservoirs of the influenza virus, and these 
birds spread the virus to domestic poultry by contaminating the water source, feed, 
and housing of domestic poultry [15]. Influenza virus secreted in feces can survive 
up to 35 days at 4°C. Aerosol transmission of the virus is also possible. Indirect 
contamination via shoes, clothing, and contaminated feathers is also reported [2].
Interspecies transmissions of the avian influenza virus are also possible. In 
Europe and the United States, H1N1 and H3N2 are commonly prevalent in swine 
population, and outbreaks have been reported by the transmission of these viruses 
to susceptible turkeys and chickens [11]. In another case, an outbreak in turkey 
flock has been reported in Canada from a poultry worker having a respiratory 
problem [1].
5. Transmission of disease to humans
In most cases of human infection with the influenza virus, the previous contact 
with alive or dead bird was recorded. People who are involved with poultry at any 
57
Prologue: Avian Influenza - An Overview from Endemic to Pandemic
DOI: http://dx.doi.org/10.5772/intechopen.90328
level are more prone to exposure than other people [16]. Meat workers, poultry 
farmworkers, and bird sellers are under constant threat. Veterinarians are also at 
higher risk due to their contact with different types of birds [17]. Direct human to 
human transmission is also possible at mass gatherings such as airports, concerts, 
and funeral ceremonies [18].
6. Prevention and control
For the control of avian influenza in commercial and rural poultry, risk manage-
ment is the most important point [18]. Implementation of good agricultural prac-
tices such as strict biosecurity measures, training of poultry workers, availability of 
non-contaminated water, disinfection of equipment, and decontamination of farm 
premises before the introduction of the new flock can decrease the chance of an 
outbreak of AI [16].
In case of an outbreak, rapid culling and depopulation are recommended. 
Rapid culling can reduce the spread of the virus and minimize economic loss [19]. 
Poultry and their products infected with HPAI are banned to enter the food chain 
in developed countries [1], whereas in developing countries, HPAI-infected meat 
and products are consumed as feed after cooking at high temperatures. The use of 
effective vaccination can limit the H5N1 HPAI virus spread [18].
7. One health perspective
The first influenza A virus pandemic in humans was recorded almost a century 
ago, in 1918, which resulted in the death of around 20–50 million humans world-
wide [20, 21]. So far, three other pandemics of influenza A virus in humans that 
have caused considerable loss include the 1957 H2N2 pandemic, the 1968 H3N2 
pandemic, and the 2009 H1N1 pandemic [22]. From East Asia to Southeast Asia, 
sporadic human infection of H5N1 viruses was reported in 2003–2004 along with 
outbreaks in the poultry [21].
H5N1 viruses have been reported from domesticated poultry and wild birds in 
Asia, North Africa, Central Africa, and Europe [23]. The transmission of HPAI 
H5N1 viruses from poultry to humans was first documented in 1997 in Hong 
Kong. Some subtypes of avian influenza virus such as H5, H7, H9, and H10 have 
the capability of interspecies transmission [18]. According to the World Health 
Organization, the total confirmed human cases of H5N1 infection to date are 860 
with 454 fatal cases [24]. In 2013, a LPAI H7N9 virus caused an outbreak in China 
with a 36% case fatality [25]. Influenza viruses are a permanent threat for humans 
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Abstract
H5 and H7 subtypes are associated with the highly pathogenic form of AI 
(HPAI), which are extremely virulent, causing up to 100% mortality in domestic 
poultry. This virulence and ability to cause systemic infection have been attributed 
to the multibasic cleavage motif in their hemagglutinin molecule, which are rec-
ognized by subtilisin-like endoproteases that are virtually present in every tissue, 
making them capable of replicating in multiple tissue; hence, lesions are multi-
systemic (i.e., nervous, circulatory, respiratory, integumentary, musculoskeletal, 
hemopoietic, gastrointestinal, reproductive systems). The myriads of lesion that 
accompanied outbreaks of HPAI in domestic poultry as seen in Nigeria from 2006 to 
2016 are as a result of the above findings. A critical look at the Nigerian HPAI situa-
tion not only revealed the general clinic-pathologic features in domestic poultry and 
factors that support the persistence of the virus in the environment but also gave 
insight to the flow of the virus in the country. A situation whereby poultry are kept 
in free-range, multispecies, multiage holdings with low biosecurity supports the 
spread of HPAI. Also, the live bird markets (LBMs) that have been fed by this unor-
ganized poultry structure have consistently been the nidus for HPAI detection, be 
it in 2008 after the virus was thought to have been eradicated or in 2015, when the 
virus resurfaced in Lagos. It is proposed that all factors enhancing the propensity of 
the virus to remain in poultry should be giving the attention required. Therefore, 
it is important that the strict biosecurity measures that ensure prevention of HPAI 
incursion into poultry premises after 2008 are revamped while improving on the 
organization of the poultry and product supply chain in the country.
Keywords: avian influenza, multisystemic, domestic poultry, pathology, Nigeria
1. Introduction
Intensive poultry production units are an ideal viral breeding ground due to 
genetic homogeneity which decreases the number and variability of resistance 
genes resulting in little variation between individuals and therefore high infection 
potential for viruses [1]. Also, in the aforementioned environment, these birds do 
not undergo any form of reproduction; therefore, there is no coevolution with the 
pathogen, and this presents the conditions for the maintenance of a highly lethal 
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Abstract
H5 and H7 subtypes are associated with the highly pathogenic form of AI 
(HPAI), which are extremely virulent, causing up to 100% mortality in domestic 
poultry. This virulence and ability to cause systemic infection have been attributed 
to the multibasic cleavage motif in their hemagglutinin molecule, which are rec-
ognized by subtilisin-like endoproteases that are virtually present in every tissue, 
making them capable of replicating in multiple tissue; hence, lesions are multi-
systemic (i.e., nervous, circulatory, respiratory, integumentary, musculoskeletal, 
hemopoietic, gastrointestinal, reproductive systems). The myriads of lesion that 
accompanied outbreaks of HPAI in domestic poultry as seen in Nigeria from 2006 to 
2016 are as a result of the above findings. A critical look at the Nigerian HPAI situa-
tion not only revealed the general clinic-pathologic features in domestic poultry and 
factors that support the persistence of the virus in the environment but also gave 
insight to the flow of the virus in the country. A situation whereby poultry are kept 
in free-range, multispecies, multiage holdings with low biosecurity supports the 
spread of HPAI. Also, the live bird markets (LBMs) that have been fed by this unor-
ganized poultry structure have consistently been the nidus for HPAI detection, be 
it in 2008 after the virus was thought to have been eradicated or in 2015, when the 
virus resurfaced in Lagos. It is proposed that all factors enhancing the propensity of 
the virus to remain in poultry should be giving the attention required. Therefore, 
it is important that the strict biosecurity measures that ensure prevention of HPAI 
incursion into poultry premises after 2008 are revamped while improving on the 
organization of the poultry and product supply chain in the country.
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1. Introduction
Intensive poultry production units are an ideal viral breeding ground due to 
genetic homogeneity which decreases the number and variability of resistance 
genes resulting in little variation between individuals and therefore high infection 
potential for viruses [1]. Also, in the aforementioned environment, these birds do 
not undergo any form of reproduction; therefore, there is no coevolution with the 
pathogen, and this presents the conditions for the maintenance of a highly lethal 
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strain [1]. The artificial increased density of individual host pathogens increases 
spread to other hosts, and the short life cycles of the virus prevent the host from 
developing immunity against the organism [2]. With high density and short life 
span, contagiousness is not under selective pressure, and a selection criteria on 
strains allow strains to be selected mainly on virulence, i.e., harm to the host [2]. 
In addition, inadequate disinfection measures between batches allow the virus 
to survive in the environment [2]. Three potential clinical outcomes have been 
observed with AI infection in birds; these are (a) no clinical signs, (b) mild disease, 
and (c) severe disease with death [3]. The H5 and H7 subtypes of avian influenza 
(AI) virus associated with HPAI, which is extremely virulent, cause up to 100% 
mortality in domestic poultry. The virulence and ability to cause systemic infection 
have been attributed to the multibasic cleavage motif (minimal consensus sequence 
of -R-X-K/RR-) in their hemagglutinin molecule, which are recognized by subtil-
isin-like endoproteases that are virtually present in every tissue of their host and 
preferentially expressed at the surface of respiratory and gastrointestinal epithelia 
[4], making them capable of replicating in multiple tissue [5, 6]; hence, lesions are 
multisystemic (i.e., nervous, circulatory, respiratory, integumentary, musculoskel-
etal, hemopoietic, gastrointestinal, reproductive systems [7]). This chapter consid-
ers avian influenza virus infection with a special X-ray on the Nigerian outbreak 
scenario, general clinicopathologic features in domestic poultry and factors that 
support the persistence of the virus in the environment, and, when not adequately 
controlled, how these can lead to an endemic and/or a pandemic state.
2. Avian influenza transmission
2.1 The virus
Influenza viruses are segmented negative-sense single-stranded RNA, belonging to 
the family Orthomyxoviridae [8]. This family is classified into influenza viruses’ types 
A, B, and C, Thogotovirus, and Isavirus [9]. Only influenza type A viruses infect poultry 
[8], and avian influenza viruses are known to be a diverse group of viruses in the 
Orthomyxoviridae family, genus Influenza A virus, and have been categorized into sub-
types based on the two surface glycoproteins, the hemagglutinin (H) and neuramini-
dase (N) [10]. There are now 18 H and 11 N surface glycoproteins [11]. Previously, 
HA1-16 and NA1-9 have been identified to occur naturally in avian host, mostly 
waterfowls where they exist in benign form (low pathogenic) [12]. Subtypes HA 17 
and 18 and NA 10 and 11 were identified in bats [13] recently. Avian influenza viruses 
have also been further classified into two different pathotypes (low pathogenicity [LP] 
and high pathogenicity [HP]), based on the ability to produce disease and death in the 
major domestic poultry species, the chicken (Gallus gallus domesticus) [14]. HPAI has 
been shown to be caused in susceptible host species by only the avian influenza viruses 
of H5 and H7 subtypes, which contain multiple basic amino acids at the cleavage site of 
the hemagglutinin molecule, [15]. However, not all H5 and H7 avian influenza viruses 
are highly pathogenic. It has been shown that HPAI viruses emerge in domestic poultry 
from LPAI progenitors of the H5 and H7 subtypes [16–18].
2.2 Transmission
A typical flow of avian influenza virus in poultry mostly begins with the intro-
duction of the virus to a region or country where the virus has not been known 
to be present. This introduction has been known to occur by way of contact of 
resident water fowls and/or backyard poultry with an infected migratory wild bird 
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[19–21] which may carry any of the subtype combinations of hemagglutinin (H) 
and neuraminidase (N) glycoproteins. This subtype in the case of an infection with 
HPAI will definitely have H5 or H7 combination. This contact may occur at wetland 
[22, 23] areas or agroecological regions [24].
In addition, there could be direct introduction of infected bird into poultry. 
Figure 1 illustrates the possibilities of the virus flow in poultry which may begin 
with local ducks or mixed species flock having contact (direct) with the virus by 
way of resident water fowls and or migratory wild birds. The virus can move by 
human vectors (indirect) especially when poultry attendants take care of the mixed 
species flock, after which a contact of free-ranging ducks and/or chickens with 
semi-intensive or backyard poultry may take place. At this point, the virus enters 
into intensive poultry directly or indirectly causing deaths.
Experience with farmers/poultry owners and attendants at the Central 
Diagnostic Laboratory of the National Veterinary Research Institute in Vom, 
Nigeria, revealed that poultry owners hurriedly sell off supposedly infected 
chickens to live bird and wet bird markets, from where unsuspecting public and 
local peasant poultry keepers buy these infected poultry for introduction into local 
flocks. The circle of infection can continue unabated for a very long time.
3. The Nigerian scenario
3.1 Index outbreak
Nigeria experienced an outbreak of HPAI H5N1 virus in both commercial and 
local poultry populations during January 2006 as an extension of the global out-
breaks [7]. The index HPAI-H5N1 was confirmed in Nigeria at a commercial poultry 
farm in Kaduna State, and by the end of the initial outbreak, over 46,000 poultry 
Figure 1. 
A flow chart of the typical origin and transmission of avian influenza in poultry.
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strain [1]. The artificial increased density of individual host pathogens increases 
spread to other hosts, and the short life cycles of the virus prevent the host from 
developing immunity against the organism [2]. With high density and short life 
span, contagiousness is not under selective pressure, and a selection criteria on 
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In addition, inadequate disinfection measures between batches allow the virus 
to survive in the environment [2]. Three potential clinical outcomes have been 
observed with AI infection in birds; these are (a) no clinical signs, (b) mild disease, 
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controlled, how these can lead to an endemic and/or a pandemic state.
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Influenza viruses are segmented negative-sense single-stranded RNA, belonging to 
the family Orthomyxoviridae [8]. This family is classified into influenza viruses’ types 
A, B, and C, Thogotovirus, and Isavirus [9]. Only influenza type A viruses infect poultry 
[8], and avian influenza viruses are known to be a diverse group of viruses in the 
Orthomyxoviridae family, genus Influenza A virus, and have been categorized into sub-
types based on the two surface glycoproteins, the hemagglutinin (H) and neuramini-
dase (N) [10]. There are now 18 H and 11 N surface glycoproteins [11]. Previously, 
HA1-16 and NA1-9 have been identified to occur naturally in avian host, mostly 
waterfowls where they exist in benign form (low pathogenic) [12]. Subtypes HA 17 
and 18 and NA 10 and 11 were identified in bats [13] recently. Avian influenza viruses 
have also been further classified into two different pathotypes (low pathogenicity [LP] 
and high pathogenicity [HP]), based on the ability to produce disease and death in the 
major domestic poultry species, the chicken (Gallus gallus domesticus) [14]. HPAI has 
been shown to be caused in susceptible host species by only the avian influenza viruses 
of H5 and H7 subtypes, which contain multiple basic amino acids at the cleavage site of 
the hemagglutinin molecule, [15]. However, not all H5 and H7 avian influenza viruses 
are highly pathogenic. It has been shown that HPAI viruses emerge in domestic poultry 
from LPAI progenitors of the H5 and H7 subtypes [16–18].
2.2 Transmission
A typical flow of avian influenza virus in poultry mostly begins with the intro-
duction of the virus to a region or country where the virus has not been known 
to be present. This introduction has been known to occur by way of contact of 
resident water fowls and/or backyard poultry with an infected migratory wild bird 
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[19–21] which may carry any of the subtype combinations of hemagglutinin (H) 
and neuraminidase (N) glycoproteins. This subtype in the case of an infection with 
HPAI will definitely have H5 or H7 combination. This contact may occur at wetland 
[22, 23] areas or agroecological regions [24].
In addition, there could be direct introduction of infected bird into poultry. 
Figure 1 illustrates the possibilities of the virus flow in poultry which may begin 
with local ducks or mixed species flock having contact (direct) with the virus by 
way of resident water fowls and or migratory wild birds. The virus can move by 
human vectors (indirect) especially when poultry attendants take care of the mixed 
species flock, after which a contact of free-ranging ducks and/or chickens with 
semi-intensive or backyard poultry may take place. At this point, the virus enters 
into intensive poultry directly or indirectly causing deaths.
Experience with farmers/poultry owners and attendants at the Central 
Diagnostic Laboratory of the National Veterinary Research Institute in Vom, 
Nigeria, revealed that poultry owners hurriedly sell off supposedly infected 
chickens to live bird and wet bird markets, from where unsuspecting public and 
local peasant poultry keepers buy these infected poultry for introduction into local 
flocks. The circle of infection can continue unabated for a very long time.
3. The Nigerian scenario
3.1 Index outbreak
Nigeria experienced an outbreak of HPAI H5N1 virus in both commercial and 
local poultry populations during January 2006 as an extension of the global out-
breaks [7]. The index HPAI-H5N1 was confirmed in Nigeria at a commercial poultry 
farm in Kaduna State, and by the end of the initial outbreak, over 46,000 poultry 
Figure 1. 
A flow chart of the typical origin and transmission of avian influenza in poultry.
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[25, 26] had been destroyed. This outbreak brought the Asian strain of highly 
pathogenic avian influenza (HPAI) H5N1 into Africa for the first time in the begin-
ning of January 2006 [7, 27–29] in Nigeria. During this first incursion of the virus 
into Nigeria, the country lost excess of 1 million birds of various species [30, 31]. 
Since its emergence in Africa in 2006, avian influenza viruses of the H5N1 subtype 
have spread rapidly to poultry farms in several African countries.
This acute, generalized, fatal disease [32] affected free-ranged domestic poultry, 
backyard poultry, and commercial poultry comprising of chickens, ducks, geese, 
turkeys, guinea fowls, other gallinaceous birds, and ostriches in the poultry indus-
try of the country. Although elsewhere in the world quails, ratites, passerine bird, 
flamingos, herons, raptors [32], and mammals have also been found to be susceptible 
to HPAI, this was not so in Nigeria. HPAI which is known to be caused by avian influ-
enza viruses (AIVs) that are extremely virulent, resulting in up to 100% mortality in 
domestic chickens [33], was isolated in several outbreaks that occurred in Nigeria.
3.2 Source of the virus
Several sources have been found to be responsible for the introduction and 
reintroduction of the virus; these include wild bird sources, trade in poultry [29], 
and direct source introduction. Following the waves of outbreaks during the 
2006–2007 periods, phylogeographic analysis [22] identified the north-central 
(Katsina, Jigawa, Yobe, Kano, Kaduna, Bauchi, and Gombe) and southwest (Lagos, 
Ogun, Oyo, Ekiti, and Kwara) regions as the two major sources for the HPAIV in 
Nigeria [22]. This supports the hypothesis that the introduction of the virus into 
Nigeria may be by wild birds and trade in poultry [29] and its products. Wild birds 
are strongly believed to be a major source of the virus to the northeastern states 
of Jigawa and Yobe, which are home to the Hadejia-Nguru wetlands and are said 
to be characterized by permanent and seasonal lakes and numerous population of 
migratory and residential waterfowl [22]. It is also known that this area sustains a 
large backyard poultry population and the highest concentration of domestic ducks, 
reared under free-range conditions, providing opportunities for contact between 
wild birds and backyard poultry [24].
3.3 The poultry structure
The poultry structure in Nigeria is comprised of two major systems, rural 
poultry production and commercial poultry production [34], as classified by the 
Food and Agricultural Organization (FAO) of the United Nation (UN). In the 
rural poultry production, it is a common practice to keep poultry in free-range, 
multispecies, multiage holdings with low biosecurity levels, thus exposing them 
to many at-risk contacts, and they could act as the epidemiologic link between the 
wild reservoir of AI viruses [22, 35] and industrial poultry. The commercial poultry 
production can be fully intensive or semi-intensive, depending on the level of 
automation and husbandry. Figure 2A–D, gives an insight to the poultry structure 
practiced in Nigeria.
3.4 Surveillance and outbreaks investigation
As far back as early February 2004, the veterinarians have been saddled with the 
responsibility of gearing efforts toward managing HPAIV outbreaks [37] if Nigeria 
was at risk or eventually experience an outbreak. Prevention strategy document 
for the emergency preparedness and response plan (EPP) [37] was ready as early as 
2005. This included a risk analysis of the 24 wetlands in Nigeria and the two major 
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migratory routes of wild birds, evaluation and upgrading of veterinary services, 
ban on importation of poultry and poultry products, and increased surveillance 
for the virus [37]. Surveillance and disease reporting included passive and active 
surveillance and regular disease reporting. The active surveillance component 
involved epidemiological surveillance of network of 170 points within the country 
and targeted surveillance of wetlands and farms [37]. Surveillance was carried 
out between September and November 2005 at the Nguru-Hadejia wetlands [37]. 
Similarly, active surveillance was carried out in the same period in the high-risk 
agroecological farming areas and among live bird (poultry) markets, but all these 
surveillance activities failed to detect H5 or H7 avian influenza virus [37]. Several 
investigations have been carried out and are available to the public about the HPAI 
H5N1 outbreaks in Nigeria, including the virological identification and confirma-
tion [26, 28, 37, 38], epidemiology and pathology of early [7] and resurgent out-
breaks [39], and molecular characterization [29], including regional mortality and 
morbidity characteristics [40].
3.5 Reintroduction of the virus into domestic poultry
Reintroduction of the virus to Nigeria was first detected in January 2015, when 
the National Veterinary Research Institute (NVRI), Vom, Nigeria, received some 
chicken carcasses from the Kano State Ministry of Agriculture [39]. The carcasses 
were gotten from a backyard-commercial poultry farm and also from a live bird 
market (LBM) in Kauna and Sabon Gari, Kano State, northwestern Nigeria, respec-
tively. The farm husbandry was mixed poultry species system where different types 
of chickens of various ages and stages were kept and were experiencing high mor-
tality of 350 birds daily with eventual 100% mortality observed in the older birds 
(54 weeks) [39]. Also, in a concurrent incidence, unusual high mortality of birds 
brought from the northern part of Nigeria to two LBMs in Onipanu and Mushin, 
Lagos State, Southwestern Nigeria, was reported [39]. The specimens were analyzed 
by RT-PCR and virus isolation in embryonating chicken eggs, and all samples 
were found to be positive for HPAI (H5N1) subtype [39]. This ended the 9-year 
silence of the activity of the virus in Nigerian poultry [39]. Again, a strong genetic 
link between viruses isolated in Nigerian poultry and wild bird from Europe has 
been established [21, 22, 41, 42], thereby suggesting that wild birds are the major 
Figure 2. 
(A) Intensive poultry production system in the tropics [36]. (B) A semi-intensive poultry production system 
in the tropics [36]. (C) A mixed species backyard poultry production system comprising of ostriches, geese, 
Muscovy, mallard, and Pekin ducks before the introduction of HPAI [36]. (D) An extensively (free-ranging) 
reared Muscovy/mallard duck flock [36].
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to HPAI, this was not so in Nigeria. HPAI which is known to be caused by avian influ-
enza viruses (AIVs) that are extremely virulent, resulting in up to 100% mortality in 
domestic chickens [33], was isolated in several outbreaks that occurred in Nigeria.
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reintroduction of the virus; these include wild bird sources, trade in poultry [29], 
and direct source introduction. Following the waves of outbreaks during the 
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Nigeria [22]. This supports the hypothesis that the introduction of the virus into 
Nigeria may be by wild birds and trade in poultry [29] and its products. Wild birds 
are strongly believed to be a major source of the virus to the northeastern states 
of Jigawa and Yobe, which are home to the Hadejia-Nguru wetlands and are said 
to be characterized by permanent and seasonal lakes and numerous population of 
migratory and residential waterfowl [22]. It is also known that this area sustains a 
large backyard poultry population and the highest concentration of domestic ducks, 
reared under free-range conditions, providing opportunities for contact between 
wild birds and backyard poultry [24].
3.3 The poultry structure
The poultry structure in Nigeria is comprised of two major systems, rural 
poultry production and commercial poultry production [34], as classified by the 
Food and Agricultural Organization (FAO) of the United Nation (UN). In the 
rural poultry production, it is a common practice to keep poultry in free-range, 
multispecies, multiage holdings with low biosecurity levels, thus exposing them 
to many at-risk contacts, and they could act as the epidemiologic link between the 
wild reservoir of AI viruses [22, 35] and industrial poultry. The commercial poultry 
production can be fully intensive or semi-intensive, depending on the level of 
automation and husbandry. Figure 2A–D, gives an insight to the poultry structure 
practiced in Nigeria.
3.4 Surveillance and outbreaks investigation
As far back as early February 2004, the veterinarians have been saddled with the 
responsibility of gearing efforts toward managing HPAIV outbreaks [37] if Nigeria 
was at risk or eventually experience an outbreak. Prevention strategy document 
for the emergency preparedness and response plan (EPP) [37] was ready as early as 
2005. This included a risk analysis of the 24 wetlands in Nigeria and the two major 
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migratory routes of wild birds, evaluation and upgrading of veterinary services, 
ban on importation of poultry and poultry products, and increased surveillance 
for the virus [37]. Surveillance and disease reporting included passive and active 
surveillance and regular disease reporting. The active surveillance component 
involved epidemiological surveillance of network of 170 points within the country 
and targeted surveillance of wetlands and farms [37]. Surveillance was carried 
out between September and November 2005 at the Nguru-Hadejia wetlands [37]. 
Similarly, active surveillance was carried out in the same period in the high-risk 
agroecological farming areas and among live bird (poultry) markets, but all these 
surveillance activities failed to detect H5 or H7 avian influenza virus [37]. Several 
investigations have been carried out and are available to the public about the HPAI 
H5N1 outbreaks in Nigeria, including the virological identification and confirma-
tion [26, 28, 37, 38], epidemiology and pathology of early [7] and resurgent out-
breaks [39], and molecular characterization [29], including regional mortality and 
morbidity characteristics [40].
3.5 Reintroduction of the virus into domestic poultry
Reintroduction of the virus to Nigeria was first detected in January 2015, when 
the National Veterinary Research Institute (NVRI), Vom, Nigeria, received some 
chicken carcasses from the Kano State Ministry of Agriculture [39]. The carcasses 
were gotten from a backyard-commercial poultry farm and also from a live bird 
market (LBM) in Kauna and Sabon Gari, Kano State, northwestern Nigeria, respec-
tively. The farm husbandry was mixed poultry species system where different types 
of chickens of various ages and stages were kept and were experiencing high mor-
tality of 350 birds daily with eventual 100% mortality observed in the older birds 
(54 weeks) [39]. Also, in a concurrent incidence, unusual high mortality of birds 
brought from the northern part of Nigeria to two LBMs in Onipanu and Mushin, 
Lagos State, Southwestern Nigeria, was reported [39]. The specimens were analyzed 
by RT-PCR and virus isolation in embryonating chicken eggs, and all samples 
were found to be positive for HPAI (H5N1) subtype [39]. This ended the 9-year 
silence of the activity of the virus in Nigerian poultry [39]. Again, a strong genetic 
link between viruses isolated in Nigerian poultry and wild bird from Europe has 
been established [21, 22, 41, 42], thereby suggesting that wild birds are the major 
Figure 2. 
(A) Intensive poultry production system in the tropics [36]. (B) A semi-intensive poultry production system 
in the tropics [36]. (C) A mixed species backyard poultry production system comprising of ostriches, geese, 
Muscovy, mallard, and Pekin ducks before the introduction of HPAI [36]. (D) An extensively (free-ranging) 
reared Muscovy/mallard duck flock [36].
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possible source of introduction and reintroduction of HPAI viruses into Nigeria’s 
poultry. On the other hand, rural poultry mainly kept in free-range, multispecies, 
multiage holdings with low biosecurity levels are exposed to many at-risk contacts 
and therefore act as the epidemiologic link between the wild reservoir of AI viruses 
and industrial poultry [22, 35]. The predominant species in the rural poultry sector 
of Africa is the scavenging indigenous domestic fowl (Gallus gallus domesticus) 
[43], which in most African countries has no regular health control program, may 
or may not have shelter, and scavenges for most of their nutritional needs [43]. In 
fact, village chickens have been reported to act as potential reservoirs and carriers 
of infections to themselves and to the more susceptible exotic breeds in commercial 
poultry farms [44].
3.6 Factors supporting occurrence of outbreaks
Following initial introduction of the virus from a possible migratory wild bird 
[22] or water fowl [20] through direct means into commercial poultry or by resident 
water fowls and ducks that form bridges of virus transmission from migratory wild 
birds [35], the virus is further spread by inadequate farm biosecurity, trade in poul-
try, human and vehicular exchanges between farms, and uncontrolled farm visits 
by poultry and poultry product vendors. Live bird markets have also been shown 
to harbor [39] and transmit the virus among birds and finally to household poultry 
upon introduction of poultry bought from live bird markets [20]. Mixed-species 
poultry farming has been shown to have higher odds of HPAI virus infection [39] 
and could harbor apparently healthy but infected duck species which may transmit 
the virus to susceptible chickens and turkeys. In a study conducted during the 
first introduction of HPAI into Nigeria, it was shown that mortality rate was much 
higher in mixed species flocks (P < 0.0001) and ranged from 4.92 to 73.15% with 
the chicken-duck-turkey mixed flock farms having the highest rate (73.15%) [39]. 
Also, it was established that higher risk of HPAI disease occurred in multiple, mixed 
species poultry than in single species poultry production [39]. Figure 3 depicts a 
typical live bird scenario.
3.7 Control measures
Enforcement of movement control, surveillance (active and passive), and 
prompt payment of the revised compensation to the affected farmers, includ-
ing reorganization of the LBMs which led to the successes recorded during the 
Figure 3. 
A typical live bird market where poultry from different origins are sold. ©Prof. T. U Obi, University of Ilorin.
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2006–2007 epizootics [45], is necessary to control HPAI in Nigeria. In these current 
HPAI epizootics, it has been observed that coordination and other instituted control 
measures, including biosecurity and compensation of affected farmers, seem to be 
less rigorous, and this may explain the rapid spread from the index cases to 25 states 
of the federation as of March 2016 [42].
4.  Clinicopathologic features of avian influenza infection in domestic 
commercial and rural poultry: chickens and ducks
4.1 General outcome of disease
Three possible clinical outcomes have been shown to occur with AI infection 
in birds: there may be no clinical signs, it may result in a mild disease, and severe 
disease with death may occur [3]. Virus replication within the cell, tissue, organ, or 
a combination results in pathobiological changes which are abnormal physiological 
and anatomic changes. Therefore, in general, as virus replication titers increase, 
so do the severity of pathobiological changes such as gross and microscopic lesions 
with the most pathogenic virus strains causing major cell damage and death if it is 
sufficiently severe to affect critical organs [3] Figure 4.
4.2 Clinical signs
In gallinaceous domestic poultry, infection with HPAI viruses produces severe 
depression, severe decrease in feed and water consumption, high morbidity and 
mortality rates, sudden death, and occasionally nervous signs if they survive the 
peracute syndrome. However, the frequency of clinical signs and gross lesions var-
ies with virus and species of bird and is not consistent in all birds [3] (Figure 5).
4.2.1 Chickens
Individual birds are listless and exhibit edema; cyanosis of the comb, wattles, 
and legs; and diarrhea. Sudden deaths without any symptoms may also occur. 
Signs observed and reported are sudden death, high mortality, weakness, and 
Figure 4. 
(A) An open-sided layer chicken pen infected with highly pathogenic avian influenza virus. (B) The flock 
in A when the pen was already depopulated. (C) The poultry birds been placed in an open dug pit after 
depopulation. (D) The flock in A been burnt after depopulation. A and B courtesy of Dr. Luka Pam; C and D 
received anonymously.
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possible source of introduction and reintroduction of HPAI viruses into Nigeria’s 
poultry. On the other hand, rural poultry mainly kept in free-range, multispecies, 
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Figure 3. 
A typical live bird market where poultry from different origins are sold. ©Prof. T. U Obi, University of Ilorin.
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2006–2007 epizootics [45], is necessary to control HPAI in Nigeria. In these current 
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of the federation as of March 2016 [42].
4.  Clinicopathologic features of avian influenza infection in domestic 
commercial and rural poultry: chickens and ducks
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with the most pathogenic virus strains causing major cell damage and death if it is 
sufficiently severe to affect critical organs [3] Figure 4.
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ies with virus and species of bird and is not consistent in all birds [3] (Figure 5).
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Signs observed and reported are sudden death, high mortality, weakness, and 
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recumbency. Others ranged from nasal discharges, dyspnea, coughing, sneezing, 
shank hyperemia and hemorrhage, inability to stand, ataxia, and torticollis. In lay-
ers, egg structural abnormalities such as shell-less egg, white-colored eggs, and soft 
eggs were reported.
4.2.2 Backyard poultry
In backyard poultry, sudden death is most common especially in turkeys, ducks, 
guinea fowls, and local chickens [31]. Signs were rarely observed and reported in 
these poultry species, as they were seen to die suddenly without premonitory signs 
although paralysis, ataxia and torticollis, dyspnea, coughing, sneezing, and diar-
rhea were occasionally seen and reported [31].
4.2.3 Ducks
Less vulnerable poultry species such as ducks, geese, ratites, and pigeons typi-
cally exhibit nervous symptoms including ataxia, torticollis, and seizures [46, 47].
4.3 Pathologic lesions
The frequency of gross lesions is also dependent on virus and species of bird and 
is not consistent in all birds [3].
4.3.1 Chickens
The main clinical and pathologic findings of HPAI are usually observed in the 
nervous, circulatory, respiratory, integumentary, musculoskeletal, gastrointestinal, 
and reproductive systems, and occasionally lesions are multisystemic. Chickens 
being the most frequently infected species with HPAI viruses exhibit common 
lesions including edema to necrosis of comb and wattle, edema of the head and legs, 
subcutaneous hemorrhage of legs, lungs that fill with fluid and blood, and small 
hemorrhages on internal organs such as the coronary fat. All of these lesions point 
to alternations in the cardiovascular system, which principally affects vascular 
endothelium and the resulting viremia. HPAI infections in gallinaceous birds have 
been shown to result in mortalities of up to 100% within 48 hours [48, 49]. Lesions 
observed in the circulatory system included congestion and cyanosis of comb and 
wattle, comb and wattle edema, and facial and subcutaneous edema. Within the 
respiratory system, there were airsacculitis and pneumonia. There was petechiation 
to ecchymoses of the proventricular and intestinal mucosa with resultant enteritis 
in the gastrointestinal system [31]. Integumentary system lesions are mainly 
cyanosis, edema, and ecchymotic hemorrhages, while there were inflammatory, 
Figure 5. 
(A) Testing for influenza virus using oropharyngeal swab stick. (B) Examining suspected outbreak of influenza 
virus infection in poultry.
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degenerative, and necrotic lesions in the musculoskeletal system. In adult birds, 
mainly layers reproductive lesions were observed, and they were mainly ovarian 
follicular ecchymotic hemorrhages [31]. Figure 6A–C depicts the lesions in chickens 
naturally infected by HPAI virus.
4.3.2 Backyard poultry
The main pathologic findings were observed in the nervous, circulatory, respira-
tory, musculoskeletal, and intestinal systems, and occasionally lesions are multi-
systemic. Lesions observed in the circulatory system included cyanosis of comb 
and wattle, comb and wattle edema, and facial and subcutaneous edema. Within 
the respiratory system, there were nasal discharges, airsacculitis, and pneumonia 
[31]. Petechiation to ecchymoses of the proventricular and intestinal mucosal with 
resultant enteritis in the intestinal system were observed [31]. There were inflam-
matory, degenerative, and necrotic lesions in the musculoskeletal system [31].
4.3.3 Ducks
Ducks oftentime show one or more lesions of the circulatory system and showed 
nervous lesions of neuronal and Purkinje cell necrosis of the cerebrum and cerebel-
lum [31]. There was nasal exudation, airsacculitis, and pneumonia in some ducks 
[31]. Enteric petechiation and ecchymoses were also observed [31] (Figure 7).
Figure 6. 
(A) A layer chicken showing clinical signs of weakness and sitting on hock; the comb and wattles are congested, 
and the wattles are swollen. (B) The feet and shank are severely hemorrhagic. (C) The abdominal fat depot 
shows petechiae to ecchymotic hemorrhages which are sometimes diffuse; the liver is necrotic and friable, i.e., 
color is bleached and has fatty appearance.
Figure 7. 
(A) The Pekin duck is showing signs of nervous involvement which include loss of balance and inability to 
stand upright and ataxia. (B) The pancreas between the intestinal loops of the duodenum of this chicken is 
necrotic, i.e., shows chalky appearance otherwise known as bleaching.
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follicular ecchymotic hemorrhages [31]. Figure 6A–C depicts the lesions in chickens 
naturally infected by HPAI virus.
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systemic. Lesions observed in the circulatory system included cyanosis of comb 
and wattle, comb and wattle edema, and facial and subcutaneous edema. Within 
the respiratory system, there were nasal discharges, airsacculitis, and pneumonia 
[31]. Petechiation to ecchymoses of the proventricular and intestinal mucosal with 
resultant enteritis in the intestinal system were observed [31]. There were inflam-
matory, degenerative, and necrotic lesions in the musculoskeletal system [31].
4.3.3 Ducks
Ducks oftentime show one or more lesions of the circulatory system and showed 
nervous lesions of neuronal and Purkinje cell necrosis of the cerebrum and cerebel-
lum [31]. There was nasal exudation, airsacculitis, and pneumonia in some ducks 
[31]. Enteric petechiation and ecchymoses were also observed [31] (Figure 7).
Figure 6. 
(A) A layer chicken showing clinical signs of weakness and sitting on hock; the comb and wattles are congested, 
and the wattles are swollen. (B) The feet and shank are severely hemorrhagic. (C) The abdominal fat depot 
shows petechiae to ecchymotic hemorrhages which are sometimes diffuse; the liver is necrotic and friable, i.e., 
color is bleached and has fatty appearance.
Figure 7. 
(A) The Pekin duck is showing signs of nervous involvement which include loss of balance and inability to 
stand upright and ataxia. (B) The pancreas between the intestinal loops of the duodenum of this chicken is 
necrotic, i.e., shows chalky appearance otherwise known as bleaching.
Viruses and Viral Infections in Developing Countries
70
5. Persistence of avian influenza viruses in poultry population
Many countries and regions have successfully controlled the virus after its 
occurrence, whereas some other countries face occasional reoccurrences despite 
intensive control efforts [50]. By the last quarter of 2007, outbreaks of HPAIV in 
Nigeria appeared to have been successfully controlled by measures such as “stamp-
ing out with compensation,” restrictions on movement of poultry, and enhanced 
surveillance [19]. But the detection of new cases of HPAIV in farms from Kano 
and Katsina States and in apparently healthy ducks in live bird markets in Gombe 
and Kebbi States [19, 22, 51] proved otherwise. The viruses in sublineage H which 
were isolated from vultures, pigeon, guinea fowl, free-range chicken, and other 
birds from a wildlife park were observed to be geographically and chronologically 
dispersed in Nigeria following infection of the LBMs. Thus, the importance of the 
live bird markets in the spread of the virus in West Africa is particularly evident 
[52]. Also, a resurgent outbreak was recorded in January 2015, after almost 8 years 
following the end of the last epizootics, [39, 41]. Thus far, the outbreak has spread 
to several other African countries including Burkina Faso, Cote d’Ivore, Niger, 
Ghana, Cameroon, and Togo [42].
Influenza A viruses are known to circulate in their natural hosts and wild aquatic 
birds predominantly of the orders Anseriformes (ducks, geese and swans) and 
Charadriiformes (gulls, waders, and terns). These wild ducks are natural reser-
voirs of avian influenza (AI) viruses [10, 53, 54], and epidemiologic evidence and 
experimental infections show that domestic ducks are also susceptible to AI viruses 
[55, 56].
The circulation and reemergence of highly pathogenic avian influenza viruses 
of H5N1 subtype (HPAIV-H5N1) raise major concerns in public health and poultry 
industries [57]. Tens of millions of birds have died of HPAIV-H5N1 in the global 
poultry industry, and hundreds of millions of poultry have been slaughtered to 
control the spread of the virus [58]. Urgent revised control measures are required 
to stem waves of outbreaks and to prevent the virus from becoming enzootic in 
poultry if the ongoing trend of recent outbreaks in Nigeria persists, [42]. If not, this 
may result in severe public health consequences, as observed in countries where 
the virus has become enzootic in poultry [59]. In a little over a year of the reported 
resurgent into Nigeria, several waves of outbreaks were reported in 25 states includ-
ing the Federal Capital Territory (Abuja) [42].
6. Endemic situation
Following the detection and reporting of highly pathogenic avian influenza 
(HPAI) H5N1 virus (clade 2.2) in Nigeria in 2006 [28] and subsequently in other 
parts of Africa, 11 countries in the region had reported outbreaks in poultry within 
a few months of its detection and eventually became enzootic in Egypt’s poultry 
[60] causing human deaths. By July 2016, the human cases as a result of infection 
with HPAI H5N1 in Djibouti, Nigeria, and Egypt stand at 1, 1, and 354 people, 
respectively, with Egypt having the second highest number of human deaths among 
countries with H5N1 infections in the world [61]. The exposure of humans at the 
human-animal interface enzootic circulation of highly pathogenic avian influenza 
virus (HPAIV) in agricultural scenarios poses one of the greatest public health 
concerns [41]. The only human case in Nigeria, which was officially reported by the 
World Health Organization on February 3, 2007, was diagnosed following a thor-
ough investigation of a fever complicated by respiratory distress which finally led to 
death of an average aged woman [38].
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Some of the factors identified to aid the spread of the virus and enzootic situa-
tion include indiscriminate disposal of infected poultry carcasses, poor biosecurity 
measures and disregard for perimeter fencing, uncoordinated movement of poultry 
and poultry products, porous borders which aid poultry smuggling, uncontrolled 
and unregulated live bird market structures and activities, and indiscriminate 
importation of poultry and its products. These are some of the factors responsible 
for the transmission and spread of the 2015 H5N1 outbreak [39].
In Nigeria, the continuous interfaces of wild migratory birds with backyard 
flocks and subsequent movement of live birds from one state to another are strongly 
suspected to be the source of the virus reintroduction for the second time.
Therefore, to effectively control HPAI in Nigeria and to prevent future out-
breaks and rapid spread of the virus, the continuous interfaces of wild migratory 
birds with backyard flocks must be taking into cognizance. Also, cluster farming 
and live bird market chain needs to be organized, as well as preventing in between 
farm transmission. In addition, it has been suggested that minimizing contacts 
between commercial/free-range chickens and wild birds in the northern part of 
Nigeria may help to avert future outbreaks [19]. Also, previous study has shown 
that there is a higher risk of HPAI disease occurrence in mixed poultry farming. A 
more prognostic approach and pragmatic plan is required for the prevention and 
control of HPAI in Nigeria with this resurgence, in order to elude a likely endemic-
ity of the disease [62].
7. Conclusions
The H5 and H7 subtypes associated with the highly pathogenic form of AI 
(HPAI), an extremely virulent virus which causes up to 100% mortality in domestic 
poultry, need special efforts to ensure eradication. Bearing in mind that the inten-
sive poultry production units are an ideal viral breeding ground for these forms of 
AI, all factors that enhance this propensity should be giving the attention required. 
A critical look at the Nigerian HPAI situation not only revealed the general clini-
copathologic features in domestic poultry and factors that support the persistence 
of the virus in the environment but also gave insight to the flow of the virus in the 
country. A situation whereby poultry are kept in free-range, multispecies, multiage 
holdings with low biosecurity supports the spread of HPAI. Also, the LBMs that 
have been fed by this unorganized poultry structure have consistently been the 
nidus for HPAI detection, be it in 2008 after the virus was thought to have been 
eradicated or in 2015, when the virus resurfaced in Kano and Lagos. It is therefore 
important that the strict biosecurity measures that ensure prevention of HPAI 
incursion into poultry premises after 2008 are revamped while improving on the 
organization of the poultry and product supply chain in the country.
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The Thrift of Avian Influenza in 
Indonesia
Khrisdiana Putri, Sitarina Widyarini, Sugiyono  
and Widya Asmara
Abstract
The circulating H5N1 Highly Pathogenic Avian Influenza in chicken has created 
devastating problems in Indonesia since 2003. Although human cases of Avian 
Influenza could be exceptionally reduced, however, it remains unsettled in poultry. 
Phylogenetic analysis of H5N1 virus (2003–2011) revealed the introduction of 
a single ancestral of 2.1 HA clade before 2003. The enzootic clade subsequently 
evolved into fourth order with predominantly 2.1.3.2. Pathological lesions showed 
cyanotic wattle, torticollis and haemorrhage in chicken feet and multi-internal 
organs. However, the introduction of vaccination and stringent biosecurity resulted 
in milder manifestations compared to classical lesions. In 2012, unusual high 
mortality in duck farms revealed the introduction of exotic clade 2.3.2.1. Despite the 
inefficient transmission of avian virus to humans and experimental receptor bind-
ing of 2.3.2.1 virus that showed avian preference, substitution of N158D and E190D 
in HA gene indicates possible threat to humans. In the same year, the Government 
of Indonesia announced the introduction of H9N2. Furthermore, a recent publica-
tion (2018) has reported new reassortant between HPAIV H5N1 and LPAIV H3N8 
with resulting virulence attenuation in chicken.
Keywords: chicken, Indonesia, antigenic thrift, pathological lesion
1. Introduction
Avian Influenza (AI) is influenza A virus of avian origin, which may cause 
disease in domestic and wild birds and in some cases can infect mammalian spe-
cies, including humans. The highly pathogenic variant (HPAI) has spread to more 
than 60 countries in Africa, Asia, Australia, Europe and North and South America 
only within decades. The disease has continuously involved in detrimental impact 
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Abstract
The circulating H5N1 Highly Pathogenic Avian Influenza in chicken has created 
devastating problems in Indonesia since 2003. Although human cases of Avian 
Influenza could be exceptionally reduced, however, it remains unsettled in poultry. 
Phylogenetic analysis of H5N1 virus (2003–2011) revealed the introduction of 
a single ancestral of 2.1 HA clade before 2003. The enzootic clade subsequently 
evolved into fourth order with predominantly 2.1.3.2. Pathological lesions showed 
cyanotic wattle, torticollis and haemorrhage in chicken feet and multi-internal 
organs. However, the introduction of vaccination and stringent biosecurity resulted 
in milder manifestations compared to classical lesions. In 2012, unusual high 
mortality in duck farms revealed the introduction of exotic clade 2.3.2.1. Despite the 
inefficient transmission of avian virus to humans and experimental receptor bind-
ing of 2.3.2.1 virus that showed avian preference, substitution of N158D and E190D 
in HA gene indicates possible threat to humans. In the same year, the Government 
of Indonesia announced the introduction of H9N2. Furthermore, a recent publica-
tion (2018) has reported new reassortant between HPAIV H5N1 and LPAIV H3N8 
with resulting virulence attenuation in chicken.
Keywords: chicken, Indonesia, antigenic thrift, pathological lesion
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disease in domestic and wild birds and in some cases can infect mammalian spe-
cies, including humans. The highly pathogenic variant (HPAI) has spread to more 
than 60 countries in Africa, Asia, Australia, Europe and North and South America 
only within decades. The disease has continuously involved in detrimental impact 
to poultry farms despite global efforts towards control and eradication. The 
Indonesian lineage has attracted human health community for its zoonotic attribute 
by demonstrating the capacity for causing three family cluster cases (West Java, 
Banten and North Sumatera) with one of them being the largest case in human AI 
history [1–3]. However, surveillance of H5N1 antibody in poultry farmers from 
human H5N1 outbreak areas was reported and not detected [4].
Molecular identification on samples obtained during surveillance for H5N1 virus 
in municipal of Muntilan, Center Java, conducted by Regional Influenza Working 
Group, after suspected human H5N1 infection announced in 2005, were able to 
identify H5N1 virus in pet animals and fish pond in the housing areas. However, virus 
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sequences are not available. The number of human deaths in Indonesia were out-
growing to 150 by 2011 (Figure 1) [2, 5–7] with 46% reported to have direct contact 
with infected poultry [7]. Although, to date the virus demonstrated inefficient 
person-to-person transmission, ongoing outbreaks in poultry pose warning to possi-
bly establish human reassortant Avian Influenza virus [8]. New outbreaks of H5N1 in 
2014 in Cambodia, China, India, Korea, Lybia, Russia and Vietnam have shown high 
adaptability in a heterogeneous ecosystem, requiring urgent need for reliable surveil-
lance tool to improved strategies to control and eradicate this enzootic disease.
2. Host specificity of Asian lineage virus
Part of the HA protein that binds to the host receptor [called the receptor bind-
ing site (RBS)] has a unique amino acid arrangement which contributes to viral 
specificity to the host [9].
Infection occurs when the viral ligand binds to a glycoprotein or glycolipid 
receptors on the cell surface possessing sialylgalactose terminal group [Neu5Ac 
(α2-3) Gal] or [Neu5Ac (α2-6) Gal]. Influenza virus of 226Gln and 228Gly avian 
origin prefers to bind to [Neu5Ac (α2-3) Gal], while influenza virus of 226Leu and 
228Ser human origin binds specifically to [Neu5Ac (α2-6) Gal] [9, 10]. The fact the 
epithelial cells of human respiratory tract mainly contain [Neu5Ac (α2-6) Gal], 
while the majority in chicken is [Neu5Ac (α2-3) Gal], has provided an explanation 
the avian origin virus cannot readily infect humans. The shift in host specificity 
is possible due to the changes in amino acids in RBS through genetic mutations. 
Experimentally substituting an amino acid of Ser228Gly in addition to Leu226Gln 
of human origin virus has supported viral replication in duck intestines [11]. 
Although, solely mutation event of single amino acid in RBS was adequately altering 
binding specificity to the receptor [12, 13]. Amino acid substitution Ser227Asn in 
highly pathogenic avian influenza virus (HPAIV) H5N1 of Asia strain decreases its 
affinity for the receptor [Neu5Ac (α2-3) Gal] and gives the virus ability to bind to 
[Neu5Ac (α2-6) Gal] moderately. This indicates that mutations in RBS are capable 
to induce cross-species transmission without genetic reassortment [14].
Figure 1. 
Number of human Avian Influenza A (H5N1) cases by reporting country and month of onset (Taken from the World 
Health Organisation. Influenza at human-animal interface. Summary and assessment as of 1 May 2015 https://www.
who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_1_May_2015.pdf).
79
The Thrift of Avian Influenza in Indonesia
DOI: http://dx.doi.org/10.5772/intechopen.85105
A genetic rearrangement between influenza viruses of avian origin and influ-
enza viruses from mammals has the potential to emerge new pandemic influenza 
virus strains in humans. Classical genetic reassortment model has settled pigs as 
mixing vessel to both viruses. The basis of the model is the specificity of the influ-
enza virus strain to the host cell surface receptors [15, 16].
The emergence of four influenza pandemics, 1918 (H1N1), 1957 (H2N2), 1968 
(H3N2), and 1977 (H1N1) was not due to genetic reassortment in pigs. The speci-
ficities of the receptors in haemagglutinin gene of 1918 virus vary between strains. 
Isolates A/South Caroline/1/18 tend to bind to [Neu5Ac (α2-6) Gal] receptors, 
while isolates A/New York/1/18 have the ability to bind both [Neu5Ac (α2-6) Gal] 
and [Neu5Ac (α2-3) Gal] receptors. Compared to the H1 virus from avian origin 
in general, isolates A/New York/1/18 differ only in amino acid 190. The viral HA 
mutation in this position from Asp to Glu decreases the ability of the virus to bind 
to the [Neu5Ac (α2-6) Gal] receptor and increases preference to the [Neu5Ac (α2-3) 
Gal] (avian receptor) [13]. The avian influenza virus that caused the outbreak in 
Asia in 2003–2004 did not show such characteristics. Some viruses isolated from 
Vietnam, Thailand, Hong Kong and Indonesia, both from human and avian, show 
similarities in amino acid sequences in the RBS area and have a preference for bind-
ing to [Neu5Ac (α2-3) Gal] (avian receptors) [12, 17–19].
3. Indonesia situation
Highly Pathogenic Avian Influenza (HPAI) has been a major problem for 
 poultry industry in Indonesia till today. Since first announced in 2003–2004 
(Figure 2), H5N1 outbreak was rapidly spread to most provinces, before abated 
by the end of 2007, after causing death to more than 16 million poultry [2, 5, 7]. In 
April 2011, a new outbreak was reported from Gorontalo, leaving only one prov-
ince free of disease [20].
Phylogenetic analysis of Indonesian 2.1. clade virus indicated direct precursor-
descendant link to viruses of genotype Z, isolated from Hunan province, China in 
2002, presumably as single introduction. However, the spread and transmission 
from Hunan to Indonesia remained unclear [21, 22].
Up to the year 2008, all Indonesian H5N1 viruses have been classified into clade 
2.1, with three virus sublineages: 2.1.1, 2.1.2 and 2.1.3. The viruses within clade 2.1.1 
were mainly isolated from HPAI-infected poultry during the outbreaks between 
Figure 2. 
H5N1 Avian Influenza poultry epidemic in Indonesia. (Map by Free Vector Maps. https://freevectormaps.com/
indonesia/ID-EPS-01-0003).
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affinity for the receptor [Neu5Ac (α2-3) Gal] and gives the virus ability to bind to 
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2003 and 2005. The clade 2.1.2 viruses were isolated from avian- and human-derived 
predominantly from Sumatra between 2004 and 2007, while clade 2.1.3 viruses dis-
covered in 2004, were isolated either from birds or from humans. Interestingly, when 
clade 2.1.3 viruses have begun to predominate, the numbers of clade 2.1.1 and 2.1.2 
isolates were subsequently declined. Although 2.1.3 viruses have spread and become 
endemic in many provinces in Indonesia, a new sublineage virus has emerged since 
2004. In September 2012, several duck farms from Central Java have reported high 
mortality of AIV H5 subtype. Interestingly, the HA genes of the duck isolates were not 
related to long-established Indonesian clade 2.1 isolates but closely resembled clade 
2.3.2.1 viruses, which recently were found in Vietnam, China and Hong Kong [23].
Bali Island has reported only one human death because of Avian Influenza until 
2017, although Bali is speculated as an ideal environment for influenza re-assort-
ment: world-renowned tourism destination, suckling pigs, and fighting cocks tradi-
tion. Circulating A(H5N1) viruses obtained during surveillance of A(H5N1) viruses 
in Bali between 2009 and 2011 concluded clade 2.1 [24, 25]. Although incident of 
human death has occurred in Bali, the HA gene analysis at 226Q and 228G of chicken 
isolates yet showed binding preference to avian host. However, a single mutation 
finding at S137A has shown the potential of recognizing human receptor. Although 
evolution analysis of obtained isolates from Bali (A/Ck/Klungkung/T/2009 and 
A/Ck/Bali/Y/2009) is unable to determine due to lack of HA gene sequences of 
Indonesian isolate available in GenBank, phylogenetic analysis has clustered these 
isolates with the only Indonesian domestic cat virus (Figure 3). Consistent with the 
outbreak in Thailand, the HA gene of pigeon, chicken, tiger, and human isolates 
were closely related [26]. The potency of pigs as a mixing vessel for avian virus to 
adapt in human host is also unable to analyze due to the lack of available sequences 
in GenBank. However, the phylogenetic analysis of swine virus from Bali showed a 
close relation to other pig and chicken viruses within the corresponding year [27].
Surveillance of A(H5N1) viruses in live bird markets (LBM) during 2012-2013 
indicated that most viruses were HPAIV (H5N1), which were related to other clade 
2.1.3.2a viruses. The surveillance also detected LPAIV A (H3N8) A/environment/
West Java/KRW54/2012, which forms outlier with other LPAI H3 of Eurasian 
lineage. The A (H3N8) also demonstrated 90% nucleotide identical to A/Duck/
Siberia/100/2001. Importantly, genetic reassortment among AIV isolates is occurred 
by contribution of internal and NA gene segments of LPAIV virus into HPAIV 
(H5N1) clade 2.1.3.2a virus. Three reassortant viruses (A/Muscovy Duck/East Java/
SB29/2012, A/Muscovy Duck/East Java/LM47/ 2012 and A/Ck/East Java/BP21/2012) 
possessed PB2, PB1 and NS genes of LPAI virus, while the surface glycoproteins 
(HA and NA) and other internal genes (PA, NP and M) were contribution of HPAI 
A(H5N1) virus lineage. The experimental data of the reassortant HPAI A(H5N1) 
viruses showed slight attenuation possibly due to acquisition of LPAI internal genes 
to HPAI virus [8]. In 2017, the government of Indonesia has officially announced the 
introduction of enzootic H9N2 subtype; however, it is still poorly documented. The 
introduction of LPAIV A(H9N2) may possess new hidden endemic zoonotic threat. 
Chinese Centre for Diseases Control and Prevention has highlighted the role of 
H9N2 as “incubators” to facilitate new zoonotic human avian strain [28].
Since 2004, the Indonesian Government have been applying vaccination in poul-
try to control AIV H5N1 and simultaneously intensify biosecurity in poultry farm, 
conducting active diseases surveillance, application of stamping-out policy limited to 
endemic area and extensive to newly infected area, and improving public awareness 
of the disease [29, 30]. Although vaccine can be used as a prevention tool, it does not 
provide full protection or “sterilising immunity” [31]. Vaccine application for Avian 
Influenza in the field is recommended to allow to serologically differentiate vaccinated 
birds from infected (DIVA) [32–34]. Proposed strategy for DIVA by the use of sentinel 
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chickens has been conducted in West Java [30, 35]. However, as possible, new infections 
in the flock may originate from these sentinel naive birds, which may acquire infection 
prior to being placed; this DIVA strategy has not received widespread acceptance in 
Indonesia. Several alternative strategies using viral protein for marker in chickens have 
been developed, that is, NS1 [36, 37], M2e [38, 39] and HA2 [40, 41].
4. Pathological features
The pathological features of Avian Influenza infection in poultry since the first 
outbreak in Indonesia have undergone slight changes over time. The pathological 
changes are currently showing milder description compared to classical discovery 
in the middle of 2003. Avian Influenza viruses in poultry were reported to produce 
asymptomatic to mild upper respiratory infections, egg production loss to rapid 
fatal systemic disease [42].
Pathogenicity attributes of AI virus were categorised as low pathogenic avian influ-
enza virus (LPAIV) and highly pathogenic avian influenza viruses (HPAIV) [43, 44]. 
Figure 3. 
Phylogenetic tree analysis of A/Ck/Klungkung/T/2009 and A/Ck/Bali/Y/2009 A (H5N1) compared to other 
sequences of poultry, human, swine and human Indonesia available in GenBank. A/Goose/Guangdong/1997 
was served as outgroup in rooted neighbour-joining calculation. The scale indicated 0.02 nt substitution per site. 
The analysis was performed using Geneious R.10 (Biomatters, Ltd).
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Bali Island has reported only one human death because of Avian Influenza until 
2017, although Bali is speculated as an ideal environment for influenza re-assort-
ment: world-renowned tourism destination, suckling pigs, and fighting cocks tradi-
tion. Circulating A(H5N1) viruses obtained during surveillance of A(H5N1) viruses 
in Bali between 2009 and 2011 concluded clade 2.1 [24, 25]. Although incident of 
human death has occurred in Bali, the HA gene analysis at 226Q and 228G of chicken 
isolates yet showed binding preference to avian host. However, a single mutation 
finding at S137A has shown the potential of recognizing human receptor. Although 
evolution analysis of obtained isolates from Bali (A/Ck/Klungkung/T/2009 and 
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close relation to other pig and chicken viruses within the corresponding year [27].
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viruses showed slight attenuation possibly due to acquisition of LPAI internal genes 
to HPAI virus [8]. In 2017, the government of Indonesia has officially announced the 
introduction of enzootic H9N2 subtype; however, it is still poorly documented. The 
introduction of LPAIV A(H9N2) may possess new hidden endemic zoonotic threat. 
Chinese Centre for Diseases Control and Prevention has highlighted the role of 
H9N2 as “incubators” to facilitate new zoonotic human avian strain [28].
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conducting active diseases surveillance, application of stamping-out policy limited to 
endemic area and extensive to newly infected area, and improving public awareness 
of the disease [29, 30]. Although vaccine can be used as a prevention tool, it does not 
provide full protection or “sterilising immunity” [31]. Vaccine application for Avian 
Influenza in the field is recommended to allow to serologically differentiate vaccinated 
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in the flock may originate from these sentinel naive birds, which may acquire infection 
prior to being placed; this DIVA strategy has not received widespread acceptance in 
Indonesia. Several alternative strategies using viral protein for marker in chickens have 
been developed, that is, NS1 [36, 37], M2e [38, 39] and HA2 [40, 41].
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The pathological features of Avian Influenza infection in poultry since the first 
outbreak in Indonesia have undergone slight changes over time. The pathological 
changes are currently showing milder description compared to classical discovery 
in the middle of 2003. Avian Influenza viruses in poultry were reported to produce 
asymptomatic to mild upper respiratory infections, egg production loss to rapid 
fatal systemic disease [42].
Pathogenicity attributes of AI virus were categorised as low pathogenic avian influ-
enza virus (LPAIV) and highly pathogenic avian influenza viruses (HPAIV) [43, 44]. 
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The analysis was performed using Geneious R.10 (Biomatters, Ltd).
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Figure 4. 
Latest cases of Avian Influenza: Cyanotic wattles (Courtesy: Dr. Sitarina Widyarini).
The low pathogenic variant (LPAI) in poultry describes signs of respiratory diseases 
[43, 45], while high pathogenic variant (HPAI) demonstrates severe systemic signs 
with necrotic and inflammatory lesions of skin, viscera and brain [46–48], although 
mortality may occur in the absence of clinical signs [42]. The degree of clinical mani-
festations and recovery rate of the birds are notably age-related. Older birds generally 
recover within a week, since the onset of clinical signs. Conversely, younger birds are 
suffering from severe respiratory symptoms as of reflecting in high mortality rates 
(40–97%). Furthermore, co-infection of other secondary pathogens also contribute to 
high mortality [45]. Low-pathogenic infection is typically demonstrating low mortal-
ity (<5%) accompanied by high morbidity (>50%) [44, 45], contrarily, infection by 
HPAI virus results in 100% mortality of susceptible poultry species [43, 48].
Low pathogenic variant AI demonstrates clinically mild to severe respiratory 
signs, i.e., coughing, sneezing, swollen infraorbital, excessive ocular and nasal 
discharge [43, 44]. Infected birds, in general show lethargy, mild weight loss, 
neurological signs, occasional diarrhoea and sudden drop in eggs production from 
30 to 80% during acute phase [43–45, 49]. In humans, a high viral load in pharynx 
resulted in fatality [50].
Presented clinical signs of infected birds depend on the species and age of the 
host, virus strain and also the pathophysiological changes in the respiratory, diges-
tive, urinary, nervous and reproductive systems [44, 51, 52]. Hence, avian influenza 
virus pathobiology varies among strains and the host species. Therefore, pathobiol-
ogy characters of new avian influenza virus are important to control the outbreaks 
and understand the epidemiology of this disease [53].
Clinical signs and pathological features of H5N1 in layer chickens from East Java, 
Central Java, West Java and Yogyakarta during 2003–2005 outbreaks have demon-
strated depression, loss of appetite, neurologic disorder, respiratory disorder, egg 
production drop and diarrhoea [54]. These clinical signs were similar to previously 
described infections naturally or experimentally with highly pathogenic avian 
influenza virus in domestic poultry [44, 45, 51, 55, 56].
On post-mortem examination of infected chicken showed severe subcutaneous 
haemorrhages, oedema in the wattles, head, neck, and the leg shanks appeared 
haemorrhages [55]. However, Mutinelli et al. [45] and Elbers et al. [57] also 
described peritonitis; haemorrhage, enlarged and hardened of pancreas; enlarged 
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with whitish and dark brown haemorrhage of liver areas. In a few cases, proven-
triculus and ventriculus showed petechial haemorrhages [45, 55, 57], haemor-
rhages of comb and wattles, ecchymose haemorrhages in the skin of the breast and 
abdomen [47]. Similar lesions such as cyanotic wattles, swollen head and comb, 
haemorrhages in the skeletal muscles, abdominal fat, proventriculus and feet were 
also observed in chicken during 2003–2005 Avian Influenza outbreaks in Indonesia 
[54]. Furthermore, in layer chickens, haemorrhagic ovary and atrophy oviduct were 
also found [54, 56, 58]. Similar findings in mute and whooper swans infected by 
HPAI, was showing coalescent haemorrhages with necrosis in the pancreas [59, 60], 
kidney enlargement yet elastic without deposits of uric acid [45].
Recent case in layer chicken of 40 weeks from East Java (August, 2018) with 
cyanotic wattles (Figure 4), brain congestion (Figure 5), haemorrhages in the 
feet (Figure 6) and proventriculus (Figure 7), haemorrhages and adhesion 
Figure 5. 
Latest cases of Avian Influenza: Brain congestion (Courtesy: Dr. Sitarina Widyarini).
Figure 6. 
Latest case of Avian Influenza: Haemorrhages feet (Courtesy: Dr. Sitarina Widyarini).
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between ovarian follicles (Figure 8), haemorrhage of abdominal fat (Figure 9), 
haemorrhage of pectoral muscles (Figure 10), swollen and oedematous kidney 
(Figure 11). The farm experienced 20% mortality rates within 3 weeks and the 
egg production dropped by 18% suddenly in 5 days. Vaccination for avian influ-
enza H5 was done at 14 weeks of chick age. Molecular identification was confirm-
ing H5 subtype. In a few cases, virus can be isolated from properly vaccinated 
flock [61].
Histopathological findings of HPAIV-infected chicken and turkey were domi-
nated by acute haemorrhages (skin, under serous membrane, mucosae and pectoral 
muscles), oedema (skin of head, neck, legs and lungs) and necrosis (skin, pancreas, 
spleen and heart) [42, 46, 49, 55, 62–66]. The comb and wattles showed mark-
edly severe cellulitis associated with congestion, oedema and mild heterophilic 
infiltration in the dermis and subcutis [55]. Lymphocytic meningo-encephalitis 
and meningo-encephalomyelitis with multifocal gliosis, degeneration of neuron, 
necrosis and neuronophagia, as well as mild-to-moderate perivascular cuffs, with 
predominance of macrophages and lymphocytes in both grey and white matter in 
the majority of brain region [60, 67, 68]. Necrosis with focal lymphohistiocytic 
Figure 7. 
Latest case of Avian Influenza: Proventriculus Haemorrhages (Courtesy: Dr. Sitarina Widyarini).
Figure 8. 
Latest case of Avian Influenza: Ovarial Haemorrhages (Courtesy: Dr. Sitarina Widyarini).
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infiltration in the myocardium, focal necrosis in the pancreas and other organs (e.g. 
lungs, lymphatic organs and skeletal muscles) are defined as important histopatho-
logical lesions [58, 60, 68].
Histological lesions associated with the presence of viral antigen were observed 
in the tissue of infected chickens. Several studies have observed intranuclear and 
intracytoplasmic viral antigens distribution at surrounding tissues of parenchymal 
myofibres and capillary endothelium of the heart, hepatocytes and sinusoidal endo-
thelium of the liver, pulmonary endothelium, pancreas, kidney, central nervous 
system, leukocytes of the Peyer’s patches, bursa, epithelium of the adrenal glands, 
renal tubules and pancreatic acini [44, 55, 69, 70].
Figure 9. 
Latest case of Avian Influenza: Abdominal fat haemorrhages (Courtesy: Dr. Sitarina Widyarini).
Figure 10. 
Latest case of Avian Influenza: Pectoral muscles haemorrhages (Courtesy: Dr. Sitarina Widyarini).
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5. Conclusion
Vaccine application and stringent biosecurity practices helped to suppress the 
viral load in the flock. As consequences, the morbidity and mortality rate is sup-
pressed, the presentation of clinical signs is milder although the gross pathology 
features remained consistent. The introduction of H9N2 has initiated the new 
threat. Egg production drop is today mainly observed as an indication of infection 
regardless of the virus subtype, although as the latest published active surveillance 
data (2012–2013) continued blaming H5N1. The masking effect of partial low-level 
herd immunity may be responsible for the phenomenon.
Virus isolated from chicken with both specific and non-specific lesion between 
2003 and 2006 showed high pathogenic avian influenza virus based on molecular 
marker analysis. Although vaccination has been applied, full viral characterisa-
tion continues, evaluation of antibody protective response after vaccination and 
differentiation between vaccinated and infected birds is needed. Cartography 
surveillance of avian virus is importantly required to understand cross-immunity 
of latest strains to use as vaccine seeds. Antigen panel is a must in order to predict 
future outbreak. Enforcement on regulation for live birds market (LBM) is a must, 
considering massive human death in China of novel reassortant virus. In addition, 
wild bird migration from Asia to high densities poultry farms population in Java 
could increase reassortment rate of circulating virus. Furthermore, the finding 
of A(H3N8) may trigger novel reassortant virus strain with zoonotic potential. 
Although, human cluster, Tangerang and Karo, is required for further research 
since the cases occurred only between people with genetic relation.
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Figure 11. 
Latest case of Avian Influenza: Swollen and oedematous kidney (Courtesy: Dr. Sitarina Widyarini).
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Avian influenza viruses are shared among wild birds and sometimes are shed 
from wild birds to domestic poultry and backyard domestic animals. Usually avian 
influenza viruses infect wild birds as asymptomatic or low pathogenesis and are 
stocked in birds, water, and soil. Accumulation of genetic changes of influenza 
viruses in hosts diversities the pathogenesis to hosts described as highly pathogenic 
avian influenza viruses and low pathogenic avian influenza viruses. Highly patho-
genic avian influenza viruses being categorized among influenza A subtype viruses 
(H5, H7, H9) and different from low pathogenic avian influenza viruses cause 
severe illness and sudden increased deaths of wild birds, chicken, or other poultry. 
These infect from avian to humans. The adequate approaches of information and 
action for appearance of HPAI and LPAI viral infections in flock may prohibit the 
outbreak of avian to humans, which are mostly including quarantine of the infected 
area of the flock from surrounding laboratory tests for HPAI and LPAI viruses in 
early illness and antiviral treatments in humans.
Keywords: zoonotic infection, antigenic drift, antigenic shift,  
influenza A virus strain
1. Introduction
There are four types of influenza viruses, types A, B, C, and D, in the world. 
Influenza virus infection is zoonotic and sometimes restricted to specific spe-
cies. Influenza A and B viruses mainly cause disease among humans, swine, and 
avian. Influenza C virus infects humans and swine but does not cause severe 
disease, and its infection to humans is rarely reported [1]. Influenza D viruses 
affect swine and cattle and are not known to cause sickness to humans [1]. 
Influenza B viruses infect humans and avian and cause epidemic in the limiting 
mild disease [2]. Influenza B virus is concerned about seasonal viral infection 
but not endemic or pandemic. Influenza A virus is different from other types of 
influenza viruses about the wide infectious ranges of host and severity of dis-
ease. Influenza A viruses are theoretically classified into thousands of different 
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mild disease [2]. Influenza B virus is concerned about seasonal viral infection 
but not endemic or pandemic. Influenza A virus is different from other types of 
influenza viruses about the wide infectious ranges of host and severity of dis-
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antigenic subtypes by the combinations of the main viral antigens: hemag-
glutinin (HA) and neuraminidase (NA) [3]. Recently 18 different HA subtypes 
and 11 different NA subtypes have been identified [4, 5]. Influenza A viruses are 
classified from H1N1 to H18N11 and are called as avian influenza virus, swine 
influenza virus, or other types of animal influenza viruses depending on original 
infectious host. Humans, swine, and avian are infective host of influenza A 
virus, but infectious influenza A viral subtypes among intraspecies are restricted 
by the binding affinity of the HA protein to sialyloligosaccharides (oligosac-
charides containing terminal silica acids linked to galactose) on host cell surface 
glycoprotein or glycolipids [6]. Influenza A viruses cause normally self-limited 
disease (asymptomatic or mild) and are shared with humans and many dif-
ferent animals. Most subtypes of influenza A viruses are primarily reserved in 
aquatic birds, are distinct from human influenza A viruses, and do not easily 
transmit to human due to host species barriers [7]. Zoonotic infection between 
humans and animals or interspecies of infection of influenza A viruses makes 
viral evolutions which can help to surmount species barriers [8]. Avian influenza 
viruses transmit from aquatic birds to poultry and change virus properties and 
result in change pathogenesis ranging from mild disease to severe disease with 
high death rates in host species. According to these phenomena, avian influenza 
viruses cause severe disease and high death rate in host, which are called as 
highly pathogenic avian influenza (HPAI) viruses, and avian influenza viruses 
result in mild disease or asymptomatic infection to host, which are called as low 
pathogenic avian influenza (LPAI) viruses. A virus is defined as HPAI or LPAI 
by its ability to cause disease and mortality in intravenously inoculated young 
chickens in the laboratory or by its possession of molecular characteristic fea-
tures associated with HPAI viruses. Avian, swine, and other zoonotic influenza 
infections in humans may happen on the condition of the successful transmis-
sion with the sufficient contact between donor and recipient species, successful 
species jumps of influenza viruses, the influenza viral complex adaptations, and 
achieved sustained transmission in a new species [7]. Those may cause several 
ranges of disease in humans depending on viral factors and human factors [9]. 
HPAI virus infections have been monitored from avian to humans and caused 
the endemic disease of high fatality rate [10]. HPAI viruses may cause pandemic 
from endemic on the condition of no effective protection for wide shedding of 
HPAI viruses. Monitoring of disease severity of avian and human influenza A 
virus infection could prevent the severe damage to the society from the emerging 
infectious disease of influenza A viruses [9].
2. Evolution of influenza A viruses
2.1 Antigenic drift
Influenza viruses cause annual recurrent epidemics in humans, which approxi-
mately result in 3–5 million cases of severe illness and 250,000–500,000 deaths 
worldwide [11]. Most of these were occurred by influenza A and B viruses. Especially 
influenza A viruses change viral surface glycoproteins HA and NA by accumulations 
of point mutations in HA and NA genes and escape from human immunity called 
as antigenic drift, which may occur as seasonal influenza epidemic. But antigenic 
drift does not evolve virulence of influenza A viruses which cause severe disease 
in humans [12]. Seasonal influenza viral infections are limiting disease and mild, 
which cause severe disease and death by factors of host immune conditions. This 
does not mean that there is no necessity of treatment of anti-influenza viral therapy 
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for seasonal influenza infections. The adequate diagnosis and treatment for seasonal 
influenza infection diminish severe illness and subsequent death from seasonal 
influenza infections and lead to awareness of emerging infectious disease [13].
2.2 Avian influenza A H5N1 viruses
In 1997 HPAI (H5N1) viruses occurred among wild birds and caused an out-
break in poultry and sporadic human infection in Hong Kong [14]. This was firstly 
identified as the crossover of avian-human species barrier and resulted in 18 infected 
individuals and 6 of 18 patients died [15]. Zoonotic infection of avian influenza 
virus H5N1 has been widely spread from Asia to Europe and Africa, which has been 
endemic in some countries and caused outbreaks resulting in millions of poultry 
infections, several hundreds of human infectious cases, and many human deaths 
since 2003 [16]. Avian influenza virus H5N1 causes a disease which has aggressive 
symptoms different from a mild disease of seasonal influenza virus infection in 
humans [9]. HA is a surface viral protein which binds to and uses sialic acid-contain-
ing molecules as receptors for viral infection to multiple cells. Avian influenza virus 
strains circulated in waterfowl contain HAs with preference for binding to sialic 
acids linked to the rest of the sugar by an α2–3 linkage. In contrast, HAs from human 
influenza virus strains show enhanced binding to α2–6-linked sialic acids [17]. 
Seasonal influenza viruses cause symptoms of upper respiratory infection by cor-
relation with an abundance of α2–6-linked sialic acids in the upper respiratory tract 
of humans [18]. More detailed analysis of H5N1 infection showed an abundance of 
α2–3-linked sialic acids in the lower respiratory tract of humans, and the explanation 
of severe disease of the lung was done, as pneumonia and respiratory failure in H5N1 
infection [19]. In addition to an abundance of avian influenza viral receptor in lower 
respiratory tract in humans, the autopsy reports of H5N1-infected patients revealed 
avian influenza virus infection intra and extra lung concluding the brain, intestine, 
heart, spleen, lymphoid tissue, kidney, and placenta by applying immunohisto-
chemistry (IHC) with monoclonal antibodies to hemagglutinin (HA) and nucleo-
capsid protein (NP) and/or in situ hybridization with sense and antisense probes 
to HA and NP to detect viral antigens and genomic sequences in various organs of 
H5N1 cases and RT-PCR and nucleic acid sequence-based amplification H5 detection 
assays [20–25]. HAs with multiple residues at the cleavage site of precursor HAs that 
can be activated by ubiquitous intracellular proteases may cause systemic infections; 
on the other hand, HAs with a single arginine residue at the cleavage site of precur-
sor HAs that can only be cleaved by extracellular trypsin-like proteases present in the 
upper respiratory and gastrointestinal tracts may give rise to local infections [26]. 
The disease severity in human cases varies from mild to extremely severe; mutations 
of HA may always be related to the ability of receptor binding but not the virulence 
of viruses, which imply that there are other factors responsible for the virulence of 
H5N1 influenza viruses in humans [27]. As the characterization of avian influenza 
A H5N1, the analysis of H5N1 infections showed the deletion of 19 amino acids of 
the stalk region in NA protein that cleaves and separates the HA of progeny virions 
from the sialic acid-containing receptors on the surface of the infected host cells, in 
which they were generated [14, 28]. This deletion may play a role in the transmis-
sion of virus across species [29]. The polymerase complex is composed of three viral 
polymerase proteins  
(PB1, PB2, and PA) involved in viral RNA synthesis. In the polymerase complex 
of avian influenza viruses, glutamic acid to lysine substitution at position 627 of 
PB2 was isolated but not a prerequisite for high virulence in humans [30]. The 1918 
pandemic was called as Spanish flu and proposed that the 1918 virus was not a reas-
sorted virus (like those of the 1957 and 1968 pandemics), but more likely an entirely 
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A H5N1, the analysis of H5N1 infections showed the deletion of 19 amino acids of 
the stalk region in NA protein that cleaves and separates the HA of progeny virions 
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(PB1, PB2, and PA) involved in viral RNA synthesis. In the polymerase complex 
of avian influenza viruses, glutamic acid to lysine substitution at position 627 of 
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sorted virus (like those of the 1957 and 1968 pandemics), but more likely an entirely 
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avian-like virus that has adapted to humans. But the 1918 influenza virus was ana-
lyzed as 10 amino acids change the polymerase complex including the lysine residue 
at position 627 [31]. These mutations require more investigation for the precursors of 
a new influenza pandemic. PB1-F2 is a small mitochondrial protein that is encoded 
on an open reading frame of PB1 [32]. This open reading frame is highly conserved 
in avian influenza isolates [33]. The reconstructed 1918 influenza virus linked to the 
PB1-F2 protein and recombinant virus with a single mutation in the PB1-F2 protein 
[serine (S) instead of asparagine (N) at position 66] of H5N1 (Hk/97) increase 
viral pathogenicity [34, 35]. PB1-F2 may induce apoptosis of immune cells and 
an insufficient adaptive immune response [35]. The NS proteins (NS1 and NS2) 
are viral proteins, and NS1 has multiple functions including splicing and nuclear 
export of cellular mRNA as well as stimulation of translation [36]. The NS1 protein 
is crucial for evading the innate immune response of the host by inhibiting the 
antiviral response mediated by type I interferons [37]. The presence of glutamic acid 
at position 92 of NS1 has been investigated to be a prerequisite for the resistance to 
antiviral cytokines considering the results of severe disease induction by inoculation 
of reassortant influenza virus (H1N1) bearing the NS gene of the H5N1/97 virus to 
pigs and the lack of glutamic acid at position of the NS1 protein in the recent human 
and avian isolates [38–41]. Two PDZ ligand (PL) sequence motifs (a Glu-Pro-Glu-
Val (EPEV), a Glu-Ser-Glu-Val (ESEV)) were detected in viruses isolated during 
1997 but not in viruses after 1997 as a potential codominants of virulence disrupting 
several PDZ-domain protein-mediated pathways for cell signaling [33].
M1 and M2 are matrix proteins, and M2 is a 97-residue single-pass membrane 
protein with its N-terminus directed toward the outside of the virus. It determines 
proton selectivity and unidirectional conductance of the channel by mutagenesis 
studies [42]. A serine to asparagine substitution at residue 31 of M2 protein is 
associated with resistance to adamantanes which were used for therapy of influenza 
A virus infections [43]. On the other hand, M2 protein is suggested to be a candidate 
for the adaptation of the virus to a new host in addition to PB1-F2 from a study of 
Thai and Indonesian isolates [43].
2.3 Avian influenza A H7N9 viruses
Avian influenza viruses sometimes infect poultry as LPAI, and there is no con-
cern to LPAI, but even LPAI suddenly caused the sporadic infection among humans 
which started on February 19, 2013, in Shanghai [44]. There was no epidemic of 
severe disease in poultry infections with H7N9 before human infections with H7N9. 
In April 2013, the number of human cases of H7N9 virus infections increased 
significantly, reaching 125 confirmed cases in China, which was suggested to be 
derived from contacting with poultry and/or contaminated environments in farm-
ers’ markets with live birds [45]. After closure of live birds’ markets, the number 
of new human cases infected with H7N9 declined rapidly. But the second wave of 
human infections with H7N9 virus started again owing to the lower fall tempera-
ture and reopening of poultry markets in the fall of 2013. This wave is characterized 
by the extensive geographic spread from the province of Eastern China to Southern 
China and a large number of human infections with H7N9 (440 human infections 
and 122 associated death of 440 as of May 16, 2014) [46]. For the protection of 
widespread of H7H9, two strategies composed of suspending farmers’ markets with 
live birds and stopping the transport for trading of live birds carrying the virus were 
applied by provincial and Chinese authorities [47, 48]. These measures controlled 
the more spread of H7N9 virus infections in China, but the potential benefits 
of public health measures should be balanced against the potentially significant 
societal and economic costs [49]. The lack of protective antibodies in human against 
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H7N9 virus leads to the result of influenza pandemic in humans, nevertheless of 
zoonotic infection of poultry to humans [50]. During October 1, 2016–August 7, 
2017, the largest fifth epidemic of Asian H7N9 infections since 2013 was reported as 
759 human infections including 281 deaths [51]. The total of human infections has 
reached to 1557 human infections and at least 605 deaths (39%) during March 31, 
2013–August 7, 2017 [51]. Fourteen clusters of two or three persons with H7N9 hap-
pened during the fifth epidemic Asian H7N9 that was explained in association with 
wider geographic spread and higher prevalence of Asian virus among poultry and 
not as a result of any increased incidence of poultry to humans or human-to-human 
spread [51]. In the genesis of H7N9, H7 of H7N9 is derived from H7N3 viruses 
isolated among ducks in Eastern China in 2010–2011, and N9 of H7N9 is derived 
from avian H2N9 and/or H11N9 viruses isolated among wild migratory birds along 
the East Asian flyway [50, 52]. Both of them are Eurasian lineage of avian viruses, 
and reassortment of gene (so-called as antigenic shift) may happen and produce the 
possible precursor of H7N9 virus. Six viral genes except H7 and N9 of H7N9 virus 
likely originated from chicken H9N2 sub-lineages 1 and 2 circulating in Eastern 
China [50, 52]. Antigenic shift is suggested to form H7N9 virus during the genera-
tion and evolution of viruses. In the analysis of H7N9, viral sequences revealed that 
H7N9 virus possesses leucine or isoleucine at position 226 of HA which binds to 
both sialic acid-α2,3-galactose (avian-type receptor) and sialic acid-α2,6-galactose 
(human -type receptor) [53]. This may mean as the avian virus infection to humans 
in addition to expression of sialic acid-α2,6-galactose in the upper respiratory tract 
and sialic acid-α2,3-galactose in the lower respiratory tract in humans [19, 21–25]. 
According to PB2 protein of H7N9, sequence analysis revealed that many isolated 
H7N9 viruses encode lysine at position 627 of PB2 [54]. This substitution of glu-
tamic acid (E) to lysine (K) of position 627 of PB2 (E627K mutation) may enable 
avian viruses to adapt to efficient replication at 33 and 37°C of human temperature 
lower than original avian host temperature (41°C) [55, 56]. Other mutations of 
position 627 of PB2 in these viruses have been reported and investigated [56]. The 
resistant H7N9 variants encoding the R294K mutation in NA that confers resistance 
to oseltamivir have been detected in patients treated with neuraminidase inhibitors 
(NAIs). R294K substitution was revealed as multidrug resistance with extreme osel-
tamivir resistance by the study of using protein- and virus-based assays [57]. On the 
other hand, K294 mutation of H7N9 infections was found. Compared with H7N9 
viruses containing K294 which leads to mild resistance to NAIs, R294K appeared in 
clinical course under the selective pressure of oseltamivir treatment and conferred 
not only multidrug resistance to NAIs but also decreases NA activity and impaired 
virus replication. These phenomena may explain the failure for predominance of 
R294K-mutated strains of H7N9 in this outbreak. But the drug-resistant mutations 
should be monitored vigilantly in order to help the most effective drug administra-
tion and the prevention of unnecessary loss of human lives in clinical course [57]. 
Recently LPAI H7N9 viruses have evolved to HPAI viruses and caused the increased 
morbidity and mortality in poultry, and the same phenomenon has more likely 
occurred in human infections [51].
2.4 Avian influenza A H7N7 viruses
Outbreaks of HPAI virus infections mostly originate from endemic LPAI viral 
strains of H5 and H7 subtypes among wild waterfowl. These LPAI virus strains 
can transmit from waterfowl to poultry and change virulence to HPA virus 
among poultry [58]. In the Netherlands, an epidemic of HPAI virus H7N7 infec-
tion occurred in 2003 that resulted in 255 affected flocks and culling (killing and 
removing of infected poultry flocks) of 30 million birds [59]. Control measures 
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avian-like virus that has adapted to humans. But the 1918 influenza virus was ana-
lyzed as 10 amino acids change the polymerase complex including the lysine residue 
at position 627 [31]. These mutations require more investigation for the precursors of 
a new influenza pandemic. PB1-F2 is a small mitochondrial protein that is encoded 
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PB1-F2 protein and recombinant virus with a single mutation in the PB1-F2 protein 
[serine (S) instead of asparagine (N) at position 66] of H5N1 (Hk/97) increase 
viral pathogenicity [34, 35]. PB1-F2 may induce apoptosis of immune cells and 
an insufficient adaptive immune response [35]. The NS proteins (NS1 and NS2) 
are viral proteins, and NS1 has multiple functions including splicing and nuclear 
export of cellular mRNA as well as stimulation of translation [36]. The NS1 protein 
is crucial for evading the innate immune response of the host by inhibiting the 
antiviral response mediated by type I interferons [37]. The presence of glutamic acid 
at position 92 of NS1 has been investigated to be a prerequisite for the resistance to 
antiviral cytokines considering the results of severe disease induction by inoculation 
of reassortant influenza virus (H1N1) bearing the NS gene of the H5N1/97 virus to 
pigs and the lack of glutamic acid at position of the NS1 protein in the recent human 
and avian isolates [38–41]. Two PDZ ligand (PL) sequence motifs (a Glu-Pro-Glu-
Val (EPEV), a Glu-Ser-Glu-Val (ESEV)) were detected in viruses isolated during 
1997 but not in viruses after 1997 as a potential codominants of virulence disrupting 
several PDZ-domain protein-mediated pathways for cell signaling [33].
M1 and M2 are matrix proteins, and M2 is a 97-residue single-pass membrane 
protein with its N-terminus directed toward the outside of the virus. It determines 
proton selectivity and unidirectional conductance of the channel by mutagenesis 
studies [42]. A serine to asparagine substitution at residue 31 of M2 protein is 
associated with resistance to adamantanes which were used for therapy of influenza 
A virus infections [43]. On the other hand, M2 protein is suggested to be a candidate 
for the adaptation of the virus to a new host in addition to PB1-F2 from a study of 
Thai and Indonesian isolates [43].
2.3 Avian influenza A H7N9 viruses
Avian influenza viruses sometimes infect poultry as LPAI, and there is no con-
cern to LPAI, but even LPAI suddenly caused the sporadic infection among humans 
which started on February 19, 2013, in Shanghai [44]. There was no epidemic of 
severe disease in poultry infections with H7N9 before human infections with H7N9. 
In April 2013, the number of human cases of H7N9 virus infections increased 
significantly, reaching 125 confirmed cases in China, which was suggested to be 
derived from contacting with poultry and/or contaminated environments in farm-
ers’ markets with live birds [45]. After closure of live birds’ markets, the number 
of new human cases infected with H7N9 declined rapidly. But the second wave of 
human infections with H7N9 virus started again owing to the lower fall tempera-
ture and reopening of poultry markets in the fall of 2013. This wave is characterized 
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live birds and stopping the transport for trading of live birds carrying the virus were 
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the more spread of H7N9 virus infections in China, but the potential benefits 
of public health measures should be balanced against the potentially significant 
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H7N9 virus leads to the result of influenza pandemic in humans, nevertheless of 
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avian viruses to adapt to efficient replication at 33 and 37°C of human temperature 
lower than original avian host temperature (41°C) [55, 56]. Other mutations of 
position 627 of PB2 in these viruses have been reported and investigated [56]. The 
resistant H7N9 variants encoding the R294K mutation in NA that confers resistance 
to oseltamivir have been detected in patients treated with neuraminidase inhibitors 
(NAIs). R294K substitution was revealed as multidrug resistance with extreme osel-
tamivir resistance by the study of using protein- and virus-based assays [57]. On the 
other hand, K294 mutation of H7N9 infections was found. Compared with H7N9 
viruses containing K294 which leads to mild resistance to NAIs, R294K appeared in 
clinical course under the selective pressure of oseltamivir treatment and conferred 
not only multidrug resistance to NAIs but also decreases NA activity and impaired 
virus replication. These phenomena may explain the failure for predominance of 
R294K-mutated strains of H7N9 in this outbreak. But the drug-resistant mutations 
should be monitored vigilantly in order to help the most effective drug administra-
tion and the prevention of unnecessary loss of human lives in clinical course [57]. 
Recently LPAI H7N9 viruses have evolved to HPAI viruses and caused the increased 
morbidity and mortality in poultry, and the same phenomenon has more likely 
occurred in human infections [51].
2.4 Avian influenza A H7N7 viruses
Outbreaks of HPAI virus infections mostly originate from endemic LPAI viral 
strains of H5 and H7 subtypes among wild waterfowl. These LPAI virus strains 
can transmit from waterfowl to poultry and change virulence to HPA virus 
among poultry [58]. In the Netherlands, an epidemic of HPAI virus H7N7 infec-
tion occurred in 2003 that resulted in 255 affected flocks and culling (killing and 
removing of infected poultry flocks) of 30 million birds [59]. Control measures 
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were applied to HPAI virus infection in poultry leading to the potential start of 
human influenza pandemic, such as culling and banning the movement of infected 
flocks and tracing and screening of the infection which were implemented, fol-
lowed by preemptive culling of flocks in a 1-km zone around the infected flock. In 
this HPAI viral epidemic in poultry, 86 poultry workers and 3 household contacts 
were identified to be affected with H7N7 by RT-PCR, and the main symptom of 
this infection was conjunctivitis (83/89 persons) and one fatal case happened 
[60, 61]. Since 2006–2011 LPAI virus infection in the Netherlands (2006) and in 
Germany (2011) and HPAI virus infection in England (2008) and in Spain (2009), 
H7N7 viral infections were reported. These show the difficulty in the elimination 
of epidemic avian influenza viral infection from the endemic avian influenza virus 
infection among wild waterfowls. As additional measures, vaccination for poultry 
in outbreaks of H7N7 significantly reduced the excretion of viruses, which may 
reduce virus spread in infected areas and the risk of human exposure to viruses, in 
Italy (2000) [62]. Compared with the H7N1 and H7N3 episodes leading no bird to 
human transmission in Italy, in the genetic analysis of H7N7, HA gene of H7N7 is 
quite similar to HA genes of H7N1 and H7N3. So other mutations in NA or internal 
genes of H7N7 virus including E627K in PB2 except HA may determine the capac-
ity to replicate and cause disease in humans. Although H7N7 virus may replicate 
well in the human cells near the eyes, it may not well replicate in the human upper 
respiratory tract [61].
2.5 Avian influenza A H9N2 viruses
Influenza virus A H9N2 has been firstly known in 1966 as the infection among 
turkeys in Wisconsin. Until 1998–1999, influenza H9N2 viruses are less considered to 
be as zoonotic transmission, although this H9N2 widespread is nearly global includ-
ing several Asian countries among from wild birds to domestic poultry populations 
[63]. H9N2 viruses are characterized as LPAI viruses that have caused mild disease 
which led to decreased egg production and deaths in poultry [64]. In China, natural 
human infections with H9N2 were firstly reported as seropositive cases in Guangdong 
province in 1998 and several cases with mild or asymptomatic illness in the South or 
mainland China and Hong Kong in 1999 [65]. H9N2 LPAI viruses, that were isolated 
from an infected human in Pakistan in 2012–2015 and in Northern China in 2017, have 
an identical amino acid residue leucine at 226 in the receptor binding site of HA, the 
C-terminus of PDZ ligand motif in NS1 (KSEI), NP (E372D), and L55F in the M2 
protein that are mammalian host-specific markers [64, 66]. Avian influenza H9N2 
viral infections have been globally distributed as mild and asymptomatic infection in 
humans, poultry, pet birds, and other domestic animals and may trigger weak immune 
responses and production of low titer of antibody to H9N2 in humans [63, 66]. These 
were inducted as infections from poultry to humans directly or indirectly, but not as 
human-to-human transmission [63, 66]. Low rates of influenza A H9N2 viral infec-
tion in poultry-exposed individuals may cause an epidemic with a longer duration 
or a greater magnitude than if the virus was introduced to a completely unexposed 
population [67]. H9N2 also demonstrates its potential to efficient transmission from 
avian hosts and sharing genetic materials (e.g., internal genes) with other viruses as 
appearance of H7N9 and H10N8 [68, 69].
2.6  Other avian viruses in human infections: H10N8, H5N6, H7N2, H7N3,  
H6N1, and H10N7
In China in 2013, human infection of avian influenza A H10N8 virus was firstly 
reported as severe illness which resulted in death within 9 days of clinical course [69]. 
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This strain is different from others isolated from poultry and wild birds and reas-
sortant of H9N2 containing genetic markers for mammalian adaptation and virulence 
in HA (A135T, S138A), M1 (N30D, T215A), NS1 (P42S), and PB2 (E627K). This virus 
was sensitive to neuraminidase inhibitors (NAIs) [69].
In China in 2014, human infection of avian influenza virus was caused by H5N6 
HPAI virus following the epidemic infections of many birds’ death [70]. Until 2017, 
a total of 16 human cases infected with avian influenza H5N6 and 11 fatal cases 
of 16 cases (an overall CFR of 69%) were reported [71]. Thirteen of 16 cases had 
exposure to live poultry or live poultry markets (LPMs). Avian influenza H5N6 
viruses belonged to HA H5 genetic clade 2.3.4.4 have evolved from H5N1 and H9N2 
viruses [72], and similar H5 clade A (H5N6) viruses have been detected in wild 
birds and poultry in China, Japan, Lao People’s Democratic Republic, Myanmar, 
the Republic of Korea, and Vietnam [73]. Analyses of poultry and environmental 
samples indicate that the different avian influenza A H5N6 virus genotypes may 
vary by geographic regions as HPAI viruses or LPAI viruses [73].
In the United States of America (USA) in 2016, avian influenza A H7N2 infected 
one human after an outbreak of infection among cats in an animal shelter in 
New York City. This person’s infection was associated with close contact with sick 
cats affected with H7N2-isolated virus and no widespread to any other persons [74]. 
Avian influenza H7N2 viral infection to humans has been reported as the result of 
prolonged long contact with infected birds since 2002 in the USA. But the screen-
ing of more than 350 people with exposure to infected cats during this outbreak 
appeared no more human infection except one, and the risk posed by this virus to 
the public was thought to be low. Isolated H7N2 viruses in the USA are characterized 
as LPAI virus but have increased binding to sialic acid-α2,6-galactose receptor and 
reduced binding to sialic acid-α2,3-galactose receptor which has the possibility of 
human-to-human infection [75].
In Canada in 2004, a two-time outbreak of avian influenza A H7N3 viral infec-
tion happened in one farm: the first was characterized as LPAI viral infection which 
resulted in 8–16 deaths/day among 9200 chickens in a barn, and the second was 
detected as HPAI viral infection which resulted in 2000 deaths in 2 days among 
9030 chickens in an adjacent barn [76]. After the outbreaks of LPAI and HPAI virus 
infections, the examination of testing for H7N3 among approximately 2000 poultry 
farm workers and 650 workers assisted with outbreak management and control 
revealed 57 suspected and/or confirmed as avian influenza infections [76]. Only 
two confirmed patients with avian influenza A H7N3 virus had conjunctivitis and 
mild influenza-like illness cases infected with avian influenza A H7N7 virus in the 
Netherlands.
In Taiwan in 2013, a human infection with avian influenza A H6N1 was rec-
ognized as mild pneumonia and quick improvement by treated oseltamivir. A 
20-year-old woman works at a breakfast shop and had not been exposed to poultry 
or birds and no travel to China. Investigation of 36 close contacts with her cleared 
no positive tests for avian influenza A H6N1, and two poultry farms within 1 km 
from the woman’s house were investigated as the results of no H6N1 virus infection 
[77]. Avian influenza A H6N1 virus strain commonly circulates in domestic birds in 
Taiwan, and this infection happened to be found in the alert of a Taiwanese trav-
eler’s infection with epidemic avian influenza H7N9 virus in China in 2013. Genetic 
and structural analysis of isolated H6N1 virus reveals that a single nucleotide 
substitution resulting in a change from Gly to Asp at position 225 of HA (G225D) 
leads to direct interaction of Asp225 with the penultimate of Gal of the human-type 
receptor and the stabilized binding to human receptor [78]. E627K mutation in PB2 
is well known to human adaptation of avian influenza viruses but is not present in 
avian and human isolates.
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were applied to HPAI virus infection in poultry leading to the potential start of 
human influenza pandemic, such as culling and banning the movement of infected 
flocks and tracing and screening of the infection which were implemented, fol-
lowed by preemptive culling of flocks in a 1-km zone around the infected flock. In 
this HPAI viral epidemic in poultry, 86 poultry workers and 3 household contacts 
were identified to be affected with H7N7 by RT-PCR, and the main symptom of 
this infection was conjunctivitis (83/89 persons) and one fatal case happened 
[60, 61]. Since 2006–2011 LPAI virus infection in the Netherlands (2006) and in 
Germany (2011) and HPAI virus infection in England (2008) and in Spain (2009), 
H7N7 viral infections were reported. These show the difficulty in the elimination 
of epidemic avian influenza viral infection from the endemic avian influenza virus 
infection among wild waterfowls. As additional measures, vaccination for poultry 
in outbreaks of H7N7 significantly reduced the excretion of viruses, which may 
reduce virus spread in infected areas and the risk of human exposure to viruses, in 
Italy (2000) [62]. Compared with the H7N1 and H7N3 episodes leading no bird to 
human transmission in Italy, in the genetic analysis of H7N7, HA gene of H7N7 is 
quite similar to HA genes of H7N1 and H7N3. So other mutations in NA or internal 
genes of H7N7 virus including E627K in PB2 except HA may determine the capac-
ity to replicate and cause disease in humans. Although H7N7 virus may replicate 
well in the human cells near the eyes, it may not well replicate in the human upper 
respiratory tract [61].
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Influenza virus A H9N2 has been firstly known in 1966 as the infection among 
turkeys in Wisconsin. Until 1998–1999, influenza H9N2 viruses are less considered to 
be as zoonotic transmission, although this H9N2 widespread is nearly global includ-
ing several Asian countries among from wild birds to domestic poultry populations 
[63]. H9N2 viruses are characterized as LPAI viruses that have caused mild disease 
which led to decreased egg production and deaths in poultry [64]. In China, natural 
human infections with H9N2 were firstly reported as seropositive cases in Guangdong 
province in 1998 and several cases with mild or asymptomatic illness in the South or 
mainland China and Hong Kong in 1999 [65]. H9N2 LPAI viruses, that were isolated 
from an infected human in Pakistan in 2012–2015 and in Northern China in 2017, have 
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viral infections have been globally distributed as mild and asymptomatic infection in 
humans, poultry, pet birds, and other domestic animals and may trigger weak immune 
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were inducted as infections from poultry to humans directly or indirectly, but not as 
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tion in poultry-exposed individuals may cause an epidemic with a longer duration 
or a greater magnitude than if the virus was introduced to a completely unexposed 
population [67]. H9N2 also demonstrates its potential to efficient transmission from 
avian hosts and sharing genetic materials (e.g., internal genes) with other viruses as 
appearance of H7N9 and H10N8 [68, 69].
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This strain is different from others isolated from poultry and wild birds and reas-
sortant of H9N2 containing genetic markers for mammalian adaptation and virulence 
in HA (A135T, S138A), M1 (N30D, T215A), NS1 (P42S), and PB2 (E627K). This virus 
was sensitive to neuraminidase inhibitors (NAIs) [69].
In China in 2014, human infection of avian influenza virus was caused by H5N6 
HPAI virus following the epidemic infections of many birds’ death [70]. Until 2017, 
a total of 16 human cases infected with avian influenza H5N6 and 11 fatal cases 
of 16 cases (an overall CFR of 69%) were reported [71]. Thirteen of 16 cases had 
exposure to live poultry or live poultry markets (LPMs). Avian influenza H5N6 
viruses belonged to HA H5 genetic clade 2.3.4.4 have evolved from H5N1 and H9N2 
viruses [72], and similar H5 clade A (H5N6) viruses have been detected in wild 
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samples indicate that the different avian influenza A H5N6 virus genotypes may 
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one human after an outbreak of infection among cats in an animal shelter in 
New York City. This person’s infection was associated with close contact with sick 
cats affected with H7N2-isolated virus and no widespread to any other persons [74]. 
Avian influenza H7N2 viral infection to humans has been reported as the result of 
prolonged long contact with infected birds since 2002 in the USA. But the screen-
ing of more than 350 people with exposure to infected cats during this outbreak 
appeared no more human infection except one, and the risk posed by this virus to 
the public was thought to be low. Isolated H7N2 viruses in the USA are characterized 
as LPAI virus but have increased binding to sialic acid-α2,6-galactose receptor and 
reduced binding to sialic acid-α2,3-galactose receptor which has the possibility of 
human-to-human infection [75].
In Canada in 2004, a two-time outbreak of avian influenza A H7N3 viral infec-
tion happened in one farm: the first was characterized as LPAI viral infection which 
resulted in 8–16 deaths/day among 9200 chickens in a barn, and the second was 
detected as HPAI viral infection which resulted in 2000 deaths in 2 days among 
9030 chickens in an adjacent barn [76]. After the outbreaks of LPAI and HPAI virus 
infections, the examination of testing for H7N3 among approximately 2000 poultry 
farm workers and 650 workers assisted with outbreak management and control 
revealed 57 suspected and/or confirmed as avian influenza infections [76]. Only 
two confirmed patients with avian influenza A H7N3 virus had conjunctivitis and 
mild influenza-like illness cases infected with avian influenza A H7N7 virus in the 
Netherlands.
In Taiwan in 2013, a human infection with avian influenza A H6N1 was rec-
ognized as mild pneumonia and quick improvement by treated oseltamivir. A 
20-year-old woman works at a breakfast shop and had not been exposed to poultry 
or birds and no travel to China. Investigation of 36 close contacts with her cleared 
no positive tests for avian influenza A H6N1, and two poultry farms within 1 km 
from the woman’s house were investigated as the results of no H6N1 virus infection 
[77]. Avian influenza A H6N1 virus strain commonly circulates in domestic birds in 
Taiwan, and this infection happened to be found in the alert of a Taiwanese trav-
eler’s infection with epidemic avian influenza H7N9 virus in China in 2013. Genetic 
and structural analysis of isolated H6N1 virus reveals that a single nucleotide 
substitution resulting in a change from Gly to Asp at position 225 of HA (G225D) 
leads to direct interaction of Asp225 with the penultimate of Gal of the human-type 
receptor and the stabilized binding to human receptor [78]. E627K mutation in PB2 
is well known to human adaptation of avian influenza viruses but is not present in 
avian and human isolates.
Viruses and Viral Infections in Developing Countries
102
In Australia in 2010, an outbreak of LPAI H10N7 viruses was identified as 10–25 
bird’s deaths for 8–14 days, a 15% decrease of egg production, and no respiratory 
signs in affected flocks. Two of seven abattoirs who had conjunctivitis and minor 
upper respiratory tract symptoms were identified to be infected by H10N7 virus 
[79]. In Australia in 2010, surveillance for H10N7 viruses showed small numbers 
of wild waterfowl on the affected site and no infection of H10 subtypes in poultry 
around 2 km of affected farms.
2.7 Other strains of avian influenza viruses.
In addition to avian influenza strains of poultry to human infections, epidemics 
of avian influenza A strains are reported: H5N2, H5N5, and H5N8 viruses as HPAI 
viruses and H3N8, H6N6, H10N4, H10N5, H11N2, and H7N8 as occasional infection 
to mammals.
3. Transmission of species
3.1 Genes’ transport of wild birds to poultry by antigenic shift
As above, many avian influenza reasssortant viruses have emerged during viral 
transmission from wild birds (donor spices) to poultry (recipient species). LPAI 
viruses from wild birds have been reasserted with other influenza virus strains of 
poultry and changed virulence in poultry. If LPAI viruses could not adapt to new host 
of poultry, they would die out. LPAI viruses have been environmentally sustained by 
close contact to LPAI viruses among wild birds when avian influenza A virus infections 
happened in endemic countries. Host species barriers do not mean simply the biologi-
cal barriers [7]. Biological barriers between wild birds and poultry are almost the same 
in concerning about influenza binding receptor in cell membrane (α2–3-linked sialic 
acids) and replication condition in host temperature [19, 53]. In addition to biological 
barriers, interspecific interactions between wild birds (donor) and poultry (recipient), 
interactions between avian influenza viruses and poultry (recipient), and interactions 
among individuals of poultry (recipient) are considered as environmental barriers [7]. 
In consequence of surmounting these barriers, LPAI viruses have been sustained by the 
successful onward adaptation to new hosts like H7N7 viruses, H9N2 viruses and H7N9 
viruses in the present [47, 59, 64]. If humans have been in close contact to poultry 
affected with LPAI viruses, asymptomatic or mild illness of avian influenza A virus 
infections would appear in humans but rarely leads to fatal disease [45, 46]. LPAI 
viruses suddenly have changed virulence to HPAI viruses and caused severe disease 
and deaths among poultry like the emergence of H5N1 virus being in consequent to 
human epidemic [14]. Increased virulence from LPAI to HPAI following antigenic 
shift could not be predicted before the happening. Avian influenza A viruses need to 
acquire the abilities to transmit to new host species and replicate effectively in new 
host before an epidemic or pandemic [7]. Antigenic shift in avian viruses has trans-
mitted the abilities of transferring from poultry to humans and replicating progeny in 
humans by accumulated mutations in HA, NA, PB2, NS1, etc. but has not transmitted 
the abilities of transferring from human to human [28–38].
3.2  Possibility of intermediate hosts or mixing vessels for the generation for 
pandemic influenza viruses
Avian has α2–3-linked sialic acids, human has α2–6-linked sialic acids, and 
swine has both types of receptor for HA of influenza A viruses [80]. These enable 
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pigs to be susceptible to both human and avian influenza viruses. If a human 
influenza A virus infection and an avian influenza A virus infection happened 
simultaneously in swine, antigenic shift may produce new pandemic viruses which 
can be transmitted easily from person to person among human population with 
little or no immune response to them. In China, avian-like H1N1 and novel reas-
sortant H1N2 influenza viruses from pigs were reported [81]. The swine H1N1 virus 
(A/swine/Zhejiang/1/07) was close to avian-like H1N1 viruses which is seemed to 
be derived from the European swine H1N1 viruses, and the two H1N2 viruses (A/
swine/Shanghai/1/07 and A/swine/Guangxi/13/06) were novel reassortant H1N2 
influenza viruses containing genes from the classical swine (HA, NP, M, and NS), 
human (NA and PB1), and avian (PB2 and PA) lineage, which indicated that the 
reassortment of influenza viruses happened among humans, avian, and swine 
and the generation of new viruses was produced in swine [81]. In the analysis of 
influenza virus H1N1 pdm in 2009, the main persistent pdm/09-origin reassortant 
forms had at least five pdm/09-origin internal genes, and their surface genes were 
primarily of European avian-like (EA) or human H3N2-like swine influenza virus 
[82] (Figure 1). The monitor for a new pandemic virus is necessary to monitor 
and survey the epidemic infection in swine, in addition to monitoring of endemic 
LPAI infections among wild birds and poultry, epidemic LPAI and HPAI infections 
among wilds birds and poultry, and the following human infections by LPAI and 
HPAI viruses.
4.  Systemic monitor and approach for a new information of epidemic 
and pandemic infections
Avian influenza viral infections are wide ranges of mammalians, and it is not 
enough to monitor avian, swine, and humans for covering all types of avian influ-
enza virus infection because of the rare case appearance of the LPAI outbreak in 
cats in the USA [74]. The World Health Organization (WHO) continuously moni-
tors avian and other zoonotic influenza viruses closely through its Global Influenza 
Surveillance and Response System (GISRS) (http://www.who.int/influenza/
gisrslaboratory/en/). From this site, necessary information about occurrence of 
outbreaks, conditions, widespread of infections, etc. can be investigated and 
gathered. But insufficient monitor for zoonotic influenza infections as potential to 
Figure 1. 
Reassortant H1N2 influenza viruses and H1N1 pdm 2009 in swine.
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In Australia in 2010, an outbreak of LPAI H10N7 viruses was identified as 10–25 
bird’s deaths for 8–14 days, a 15% decrease of egg production, and no respiratory 
signs in affected flocks. Two of seven abattoirs who had conjunctivitis and minor 
upper respiratory tract symptoms were identified to be infected by H10N7 virus 
[79]. In Australia in 2010, surveillance for H10N7 viruses showed small numbers 
of wild waterfowl on the affected site and no infection of H10 subtypes in poultry 
around 2 km of affected farms.
2.7 Other strains of avian influenza viruses.
In addition to avian influenza strains of poultry to human infections, epidemics 
of avian influenza A strains are reported: H5N2, H5N5, and H5N8 viruses as HPAI 
viruses and H3N8, H6N6, H10N4, H10N5, H11N2, and H7N8 as occasional infection 
to mammals.
3. Transmission of species
3.1 Genes’ transport of wild birds to poultry by antigenic shift
As above, many avian influenza reasssortant viruses have emerged during viral 
transmission from wild birds (donor spices) to poultry (recipient species). LPAI 
viruses from wild birds have been reasserted with other influenza virus strains of 
poultry and changed virulence in poultry. If LPAI viruses could not adapt to new host 
of poultry, they would die out. LPAI viruses have been environmentally sustained by 
close contact to LPAI viruses among wild birds when avian influenza A virus infections 
happened in endemic countries. Host species barriers do not mean simply the biologi-
cal barriers [7]. Biological barriers between wild birds and poultry are almost the same 
in concerning about influenza binding receptor in cell membrane (α2–3-linked sialic 
acids) and replication condition in host temperature [19, 53]. In addition to biological 
barriers, interspecific interactions between wild birds (donor) and poultry (recipient), 
interactions between avian influenza viruses and poultry (recipient), and interactions 
among individuals of poultry (recipient) are considered as environmental barriers [7]. 
In consequence of surmounting these barriers, LPAI viruses have been sustained by the 
successful onward adaptation to new hosts like H7N7 viruses, H9N2 viruses and H7N9 
viruses in the present [47, 59, 64]. If humans have been in close contact to poultry 
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pigs to be susceptible to both human and avian influenza viruses. If a human 
influenza A virus infection and an avian influenza A virus infection happened 
simultaneously in swine, antigenic shift may produce new pandemic viruses which 
can be transmitted easily from person to person among human population with 
little or no immune response to them. In China, avian-like H1N1 and novel reas-
sortant H1N2 influenza viruses from pigs were reported [81]. The swine H1N1 virus 
(A/swine/Zhejiang/1/07) was close to avian-like H1N1 viruses which is seemed to 
be derived from the European swine H1N1 viruses, and the two H1N2 viruses (A/
swine/Shanghai/1/07 and A/swine/Guangxi/13/06) were novel reassortant H1N2 
influenza viruses containing genes from the classical swine (HA, NP, M, and NS), 
human (NA and PB1), and avian (PB2 and PA) lineage, which indicated that the 
reassortment of influenza viruses happened among humans, avian, and swine 
and the generation of new viruses was produced in swine [81]. In the analysis of 
influenza virus H1N1 pdm in 2009, the main persistent pdm/09-origin reassortant 
forms had at least five pdm/09-origin internal genes, and their surface genes were 
primarily of European avian-like (EA) or human H3N2-like swine influenza virus 
[82] (Figure 1). The monitor for a new pandemic virus is necessary to monitor 
and survey the epidemic infection in swine, in addition to monitoring of endemic 
LPAI infections among wild birds and poultry, epidemic LPAI and HPAI infections 
among wilds birds and poultry, and the following human infections by LPAI and 
HPAI viruses.
4.  Systemic monitor and approach for a new information of epidemic 
and pandemic infections
Avian influenza viral infections are wide ranges of mammalians, and it is not 
enough to monitor avian, swine, and humans for covering all types of avian influ-
enza virus infection because of the rare case appearance of the LPAI outbreak in 
cats in the USA [74]. The World Health Organization (WHO) continuously moni-
tors avian and other zoonotic influenza viruses closely through its Global Influenza 
Surveillance and Response System (GISRS) (http://www.who.int/influenza/
gisrslaboratory/en/). From this site, necessary information about occurrence of 
outbreaks, conditions, widespread of infections, etc. can be investigated and 
gathered. But insufficient monitor for zoonotic influenza infections as potential to 
Figure 1. 
Reassortant H1N2 influenza viruses and H1N1 pdm 2009 in swine.
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the human pandemic is reinforced by the information from the collaboration with 
the World Organization for Animal Health (OIE) (www.oie,int/) and the Food and 
Agriculture Organization (FAO) (www.fao.org/home/en/). In each country, the 
national disease center monitors its own country and internationally collaborates 
with the WHO. Monitoring reinforces the environmental barriers by noticing 
abnormal wild birds’ deaths in a province to the provincial and national authorities 
in an early stage of an endemic. Following this information, provincial authorities 
would start to investigate etiology of birds’ deaths and any other birds’ deaths 
around this area and water pollution by avian influenza viruses in ponds if avian 
influenza viruses caused birds’ deaths. Environmental barriers have three steps 
which are composed of a first step of transmission from waterfowl to poultry, a 
second step of transmission of individuals among poultry, and a third step of 
transmission from poultry to humans (Figure 2). When a first step of environmen-
tal barrier from wild birds to poultry is surmounted by avian influenza viruses, two 
patterns of damage in poultry (asymptomatic/mild disease or severe disease/
deaths) are recognized. It is very difficult to detect early and diagnose asymptom-
atic infections in poultry, but any changes in poultry including coughing and 
decrease numbers of egg production should not be missed. Recently rapid influenza 
diagnostic tests (RIDTs) are available in testing for avian influenza viruses (H5, H7, 
and H9), but other RIDTs for detection of more HA subtypes are desirable to be 
developed in demand [83]. If any doubt for avian influenza infection, RIDTs are 
recommended to be applied immediately within the limits of lower sensitivity than 
RT-PCR and other methods. A combination of RIDTs (infection of avian influenza 
viruses), RT-PCR (viral genes sequence and subtypes), HA inhibition test (viral 
subtype), ELISA (all subtypes of avian influenza viruses and widespread of viral 
infection), and the inoculation of isolated viruses to chicken (identification of  
viral pathogeny) would be adapted without any time consumption for diagnosis. 
These tests may provide an initial measure and further measures for control of an 
endemic, epidemic, and a potential pandemic infection of avian viruses. A second 
step of environmental barrier is reinforced by using the following measures: 
isolation of birds from the others, the use of personal protection equipment (PPEs) 
Figure 2. 
Comparison WHO Pandemic Phase and biological and environmental barriers step ladder.
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by farm workers, and culling the affected birds. But widespread of avian viral 
infections among poultry is not necessary for a long time. So it is desirable to 
diagnose avian viral infection in the shortest time since the first notification of 
disease by these diagnostic tests. Vaccination of poultry has been applied for the 
prevention from economic damage of culling and a potential pandemic, as biologi-
cal barriers [84]. But vaccines of animals for avian viral infections would be desired 
to high efficacy and prevalence use in the areas. Considering the negative effect for 
the difficulty of conducting surveillance for persistence of the virus after vaccina-
tion or insufficient immune response in birds leading to the latent viral infection in 
poultry, vaccination should carefully be adapted as one component of control 
measures [84]. Control strategies and measures including technical guidelines for 
pandemic potential are available from FAO and OIE [84, 85]. It is emphasized that 
the surveillance standards and methodology are necessary for calling rapid response 
for containment or mitigation of emerging infectious disease of avian influenza but 
not a system for rapid detection of emerging novel influenza strains or outbreaks of 
disease [85]. Sentinel surveillance is desired to protect poultry and humans from 
the threat of epidemic and/or pandemic potential in the prevalence of avian viruses 
among wild birds and poultry. Collapse of a third step of environmental barrier is 
recognized as human infection with avian influenza viruses. This condition is called 
as pandemic phase 2 in the WHO pandemic phase descriptions [86] (Figure 2). 
Human infection primarily may appear in direct or indirect exposure to infected 
live or dead poultry or contaminated environments, such as live bird markets. And 
human infection also may appear concerning slaughtering, de-feathering, handling 
carcasses of infected poultry, and preparing poultry for consumption, especially in 
household settings [87]. Surveillance of avian viral infections in these persons will 
be done by applying combinations of diagnostic methods as soon as possible from 
the onset of the first poultry infections. Consumption of prepared poultry and raw 
egg dishes has been reported to be linked with the infection of H5N1 human cases 
[87]. The virus is inactivated at temperatures (at least 70°C the center of the 
product) in conventional cooking, and consumption of properly cooked poultry 
and eggs should be recommended [88]. Although human-to-human transmission 
of avian influenza viruses may occur in the close and/or prolonged contact with the 
patients, there has been no sustained human-to-human transmission of these 
viruses identified [89]. But in North America in 2009, influenza A (H1N1) pdm 009 
virus originated from swine influenza viruses surmounted biological barriers. It 
took only a few months to amount to a total number of 73 affected countries and 
more than 26,000 laboratory-confirmed infected cases from the first case in Mexico 
in February of 2009 which is called as pandemic phase 6 (Figure 2) [90]. These 
suggested how fast infections had been spread in the world and how difficult to 
control the widespread of emerging infectious disease (EID) after the new emerg-
ing avian influenza virus had obtained the capacity of the interhuman transmission. 
In this phase, therapy for patients and adaptation of control measures for pandemic 
were necessary. Antiviral drugs for influenza viral infections except adamantanes 
are effective for avian influenza infections in the early stage of infection for the 
decrease of mortality rate [91]. Administration of neuraminidase inhibitors (NAIs) 
to infected persons within 48 hours of onset would be recommended, and isolation 
of infected people from the public would be important in a limited term. Recently 
baloxavir marboxil that prevents replication by inhibiting the cap-dependent 
endonuclease activity of the viral polymerase and is effective for seasonal influenza 
and avian influenza virus infections is available in Japan [92]. In addition to NAIs, it 
may be one of the powerful tools as antiviral therapy. In the pre-pandemic stage to 
the pandemic stage, network information and control measures from the national 
disease center, the Global Influenza Surveillance Network (GISN), Global Outbreak 
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the human pandemic is reinforced by the information from the collaboration with 
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deaths) are recognized. It is very difficult to detect early and diagnose asymptom-
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decrease numbers of egg production should not be missed. Recently rapid influenza 
diagnostic tests (RIDTs) are available in testing for avian influenza viruses (H5, H7, 
and H9), but other RIDTs for detection of more HA subtypes are desirable to be 
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viral pathogeny) would be adapted without any time consumption for diagnosis. 
These tests may provide an initial measure and further measures for control of an 
endemic, epidemic, and a potential pandemic infection of avian viruses. A second 
step of environmental barrier is reinforced by using the following measures: 
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by farm workers, and culling the affected birds. But widespread of avian viral 
infections among poultry is not necessary for a long time. So it is desirable to 
diagnose avian viral infection in the shortest time since the first notification of 
disease by these diagnostic tests. Vaccination of poultry has been applied for the 
prevention from economic damage of culling and a potential pandemic, as biologi-
cal barriers [84]. But vaccines of animals for avian viral infections would be desired 
to high efficacy and prevalence use in the areas. Considering the negative effect for 
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poultry, vaccination should carefully be adapted as one component of control 
measures [84]. Control strategies and measures including technical guidelines for 
pandemic potential are available from FAO and OIE [84, 85]. It is emphasized that 
the surveillance standards and methodology are necessary for calling rapid response 
for containment or mitigation of emerging infectious disease of avian influenza but 
not a system for rapid detection of emerging novel influenza strains or outbreaks of 
disease [85]. Sentinel surveillance is desired to protect poultry and humans from 
the threat of epidemic and/or pandemic potential in the prevalence of avian viruses 
among wild birds and poultry. Collapse of a third step of environmental barrier is 
recognized as human infection with avian influenza viruses. This condition is called 
as pandemic phase 2 in the WHO pandemic phase descriptions [86] (Figure 2). 
Human infection primarily may appear in direct or indirect exposure to infected 
live or dead poultry or contaminated environments, such as live bird markets. And 
human infection also may appear concerning slaughtering, de-feathering, handling 
carcasses of infected poultry, and preparing poultry for consumption, especially in 
household settings [87]. Surveillance of avian viral infections in these persons will 
be done by applying combinations of diagnostic methods as soon as possible from 
the onset of the first poultry infections. Consumption of prepared poultry and raw 
egg dishes has been reported to be linked with the infection of H5N1 human cases 
[87]. The virus is inactivated at temperatures (at least 70°C the center of the 
product) in conventional cooking, and consumption of properly cooked poultry 
and eggs should be recommended [88]. Although human-to-human transmission 
of avian influenza viruses may occur in the close and/or prolonged contact with the 
patients, there has been no sustained human-to-human transmission of these 
viruses identified [89]. But in North America in 2009, influenza A (H1N1) pdm 009 
virus originated from swine influenza viruses surmounted biological barriers. It 
took only a few months to amount to a total number of 73 affected countries and 
more than 26,000 laboratory-confirmed infected cases from the first case in Mexico 
in February of 2009 which is called as pandemic phase 6 (Figure 2) [90]. These 
suggested how fast infections had been spread in the world and how difficult to 
control the widespread of emerging infectious disease (EID) after the new emerg-
ing avian influenza virus had obtained the capacity of the interhuman transmission. 
In this phase, therapy for patients and adaptation of control measures for pandemic 
were necessary. Antiviral drugs for influenza viral infections except adamantanes 
are effective for avian influenza infections in the early stage of infection for the 
decrease of mortality rate [91]. Administration of neuraminidase inhibitors (NAIs) 
to infected persons within 48 hours of onset would be recommended, and isolation 
of infected people from the public would be important in a limited term. Recently 
baloxavir marboxil that prevents replication by inhibiting the cap-dependent 
endonuclease activity of the viral polymerase and is effective for seasonal influenza 
and avian influenza virus infections is available in Japan [92]. In addition to NAIs, it 
may be one of the powerful tools as antiviral therapy. In the pre-pandemic stage to 
the pandemic stage, network information and control measures from the national 
disease center, the Global Influenza Surveillance Network (GISN), Global Outbreak 
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and Alert Network (GOARN), and the original network for influenza viral infection 
in province. In usual diagnosis and treatment of influenza viral infection, RIDTs are 
a useful step-up strategy for the treatment of influenza viral infections regardless of 
limiting sensitivity. RIDTs for seasonal influenza viral infection can only detect A 
type and/or B type of viral HA but not subtypes of HA strains. But these tests 
recognize human and avian influenza viral strains (H1N1, H2N3, H3N8, H4N6, 
H5N2, H6N2, H7N7, H8N4, H9N2, H10N7, H11N6, H12N6, H13N6, H14N5, H15N8, 
H16N3, H5N1, H5N6, H5N8, H7N1, N7 N7, and H7N9) as influenza type A viral 
infections (Tauns Inc.). By the results of these tests, and then if an antiviral therapy 
for influenza viral infection would be applied to patients. And then if an antiviral 
therapy is judged as not to be effective by the evaluation for the time of alleviation 
of fever in humans with influenza viral infections, further investigation for compli-
cations of viral infections, a new emerging viral infection using RIDTs for HA 
sub-strains, RT-PCR and/or viral cell culture, or mutant viruses resistant to antiviral 
drugs [13, 93]. In the pandemic phases 4–6, there may be many patients with 
influenza viral infection. It is very important to minimize the severe fatal disease 
from HPAI or LPAI infections and to select and send the patients with severe disease 
to the hospitals under the capacities for admission effectively by the triage between 
mild disease and severe disease. So this system may enable an early intervention of 
viral infections within 48 hours from onset and less numbers of patients with severe 
disease. It is not necessary to divide seasonal viral infection treatment from LPAI 
infection treatment except the necessity of special training and area for protection 
of widespread of EID using PPE. Like in the case with LPAI H6N1 virus in Taiwan 
[77], LPAI viral infections may be treated without identification in the circum-
stance of avian viral widespread among domestic birds. As one of the control points 
for pandemic preparedness, the candidate pandemic vaccine is desired and planned 
to be developed for prophylaxis and the most effective one of the control measures. 
The WHO has developed the influenza candidate vaccine viruses (CVVs) which are 
planned to be supplied to national authorities for pilot lot vaccine production, 
clinical trials, and other pandemic preparedness purposes based on their assessment 
of public health risk and need (contact at gisrs-whohq@who.int) [94]. Effective 
pandemic vaccines may be the most powerful measures for pandemic.
5. Conclusion
Pandemic is unpredictable, but sequential efforts to minimize and diminish 
the vulnerability of human public health from pandemic are desired in the world. 
Sentinel monitor and surveillance for endemic, epidemic, and pandemic potential 
is necessary for early detection of pandemic potential and pandemic preparedness 
planning. Sequential diagnosis and treatment from seasonal to avian influenza 
viruses adapted to humans may be beneficial in decreasing the risk of pandemic 
potential derived from zoonotic influenza virus infections. Preparations and devel-
opments of the candidate vaccine for the information following sequential monitor 
are necessary for the control against the phase of pre-pandemic and pandemic by 
avian influenza virus. The diverse of using several types of anti-influenza viral 
drugs with single and/or combinations for the pandemic infections would be desir-
able to be established as possible as a pandemic will be happen.
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Measles in Developing Countries
Anyebe Onoja and Oluwaseyi Ajagbe
Abstract
Measles is a major childhood problem which causes significant illness, death 
and disability. It infects approximately 40 million people resulting in nearly 1 
million deaths annually in developing countries. Measles virus accounts for 44% 
of total deaths among children that are less than 15 years of age. Highest mortal-
ity occurs among children living in poor communities especially in areas that are 
overcrowded, and where there is malnutrition and vaccination coverage is low. Most 
of the measles infections in the world are recorded in developing countries of Africa 
and Asia. Endemic areas are largely confined to the tropics, where transmission 
increases after rainy season. Inability to effectively immunize most children in this 
area has hampered global measles mortality reduction initiatives and reduction 
of under-five child mortality. Although, this was initially scheduled to have been 
met by 2015, recent WHO resolution called for measles elimination in the African 
Region by 2020. It is not certain that this will be met; hence the need for coordi-
nated and strategic mass vaccination efforts to target unimmunized children in 
these regions.
Keywords: measles virus, genotypes, immunization, vaccination, coverage, Africa
1. Introduction
Measles is a serious medical problem in Africa, Latin America, Europe, south-
east Asia and eastern Mediterranean [1]. During the pre-vaccine era, 130 million 
measles cases occurred annually worldwide, and it was the leading cause of 
childhood deaths [2]. In Africa, about 13 million cases and 650,000 deaths occur 
annually, with sub-Saharan Africa having the highest morbidity and mortality [3]. 
In 2018, many developing countries reportedly confirmed measles through labora-
tory testing with high incidence rates. In AFRO region, Liberia confirmed 218 cases 
with 412.24% incidence rate. Similarly, Libya confirmed 286 cases with 98.84% 
incidence rate, Burkina Fasso confirmed 567 cases with 84.2% incidence rate and 
the southern part of the continent was not left out as Uganda confirmed 531 cases 
in the laboratory with incidence rate of 65.83%. In the Western Pacific region, 
Philippines confirmed 1677 cases with incidence rate of 118.5% while Malaysia 
confirmed 1374 cases with incidence rate of 80.35% [4]. In EURO region, Albania 
confirmed 1290 cases with incidence rate of 477.05%, Georgia reported 1091 
laboratory confirmed cases with 374.74% incidence rate and Kyrgyzstan confirmed 
376 cases in the laboratory with 75.22% incidence rate. In EMRO, Afghanistan 
reported 1846 laboratory confirmed cases with 62.64% incidence rate, Saudi 
Arabia reported 833 laboratory confirmed cases with 29.99% and 793 laboratory 
confirmed cases in Yemen with incidence rate of 344.36%. Venezuela in AMRO 
confirmed 5525 cases in the laboratory with an incidence rate of 23.03% [4].
117
Chapter 8
Measles in Developing Countries
Anyebe Onoja and Oluwaseyi Ajagbe
Abstract
Measles is a major childhood problem which causes significant illness, death 
and disability. It infects approximately 40 million people resulting in nearly 1 
million deaths annually in developing countries. Measles virus accounts for 44% 
of total deaths among children that are less than 15 years of age. Highest mortal-
ity occurs among children living in poor communities especially in areas that are 
overcrowded, and where there is malnutrition and vaccination coverage is low. Most 
of the measles infections in the world are recorded in developing countries of Africa 
and Asia. Endemic areas are largely confined to the tropics, where transmission 
increases after rainy season. Inability to effectively immunize most children in this 
area has hampered global measles mortality reduction initiatives and reduction 
of under-five child mortality. Although, this was initially scheduled to have been 
met by 2015, recent WHO resolution called for measles elimination in the African 
Region by 2020. It is not certain that this will be met; hence the need for coordi-
nated and strategic mass vaccination efforts to target unimmunized children in 
these regions.
Keywords: measles virus, genotypes, immunization, vaccination, coverage, Africa
1. Introduction
Measles is a serious medical problem in Africa, Latin America, Europe, south-
east Asia and eastern Mediterranean [1]. During the pre-vaccine era, 130 million 
measles cases occurred annually worldwide, and it was the leading cause of 
childhood deaths [2]. In Africa, about 13 million cases and 650,000 deaths occur 
annually, with sub-Saharan Africa having the highest morbidity and mortality [3]. 
In 2018, many developing countries reportedly confirmed measles through labora-
tory testing with high incidence rates. In AFRO region, Liberia confirmed 218 cases 
with 412.24% incidence rate. Similarly, Libya confirmed 286 cases with 98.84% 
incidence rate, Burkina Fasso confirmed 567 cases with 84.2% incidence rate and 
the southern part of the continent was not left out as Uganda confirmed 531 cases 
in the laboratory with incidence rate of 65.83%. In the Western Pacific region, 
Philippines confirmed 1677 cases with incidence rate of 118.5% while Malaysia 
confirmed 1374 cases with incidence rate of 80.35% [4]. In EURO region, Albania 
confirmed 1290 cases with incidence rate of 477.05%, Georgia reported 1091 
laboratory confirmed cases with 374.74% incidence rate and Kyrgyzstan confirmed 
376 cases in the laboratory with 75.22% incidence rate. In EMRO, Afghanistan 
reported 1846 laboratory confirmed cases with 62.64% incidence rate, Saudi 
Arabia reported 833 laboratory confirmed cases with 29.99% and 793 laboratory 
confirmed cases in Yemen with incidence rate of 344.36%. Venezuela in AMRO 
confirmed 5525 cases in the laboratory with an incidence rate of 23.03% [4].
Viruses and Viral Infections in Developing Countries
118
Despite the comprehensive WHO and United Nations International Children 
Emergency Fund’s (UNICEF’s) measles-reduction strategy, and partnership of 
international organizations for measles mortality reduction, certain countries con-
tinue to face recurrent epidemics [5]. The optimal age for infantile measles vaccina-
tion is an important since maternal antibodies may neutralize the vaccine antigen 
before specific immune response develops. Delaying vaccination on the other hand 
may increase risk of complicated disease [6]. Measles vaccine effectiveness is 84% 
when administered at 9–11 months of age and 93% when given at ≥12 months of 
age [7]. First dose of measles-containing vaccine (MCV1) given at 9 months of age 
was introduced into the Expanded Programme on Immunization (EPI) in 1977 [8]. 
Since >93–95% population immunity is required to prevent measles epidemics, the 
WHO recommends all children receive two doses of measles vaccine [9]. In Nigeria 
just like in many developing countries, children are given monovalent measles vac-
cine at 9 months of age in the EPI [10]. In 2010 and continuing through 2014, DRC 
experienced the largest nationwide measles outbreak in Africa [11–13]. DRC is a 
key country for regional elimination efforts because of its large population, central 
location with nine international borders, and persistent reservoir of circulating 
measles viruses [14]. The Reaching Every District (RED) approach to strengthening 
immunization services has been implemented beginning in some developing coun-
tries like Democratic Republic of Congo (DRC). A second opportunity for measles 
vaccination, nationwide measles supplementary immunization activities (SIAs) 
using a phased approach intended to cover the country every 3 years [15].
2. Epidemiology and immunization
2.1 Measles virus detection strategies and sero-surveillance in Africa
Following a successful polio laboratory platform, The Global Measles and 
Rubella Laboratory Network (GMRLN) was developed. As at 2018, there are 
presently 723 laboratories established in 164 countries. It was proposed that in all 
districts in WHO AFRO surveillance performance should target ≥2 cases of non-
measles febrile rash illness per 100,000 population and ≥1 suspected measles case 
investigated with blood specimens in ≥80% of districts [16]. Case-based surveil-
lance with laboratory confirmation of suspected measles cases is in place in many 
developing countries. Integrated Disease Surveillance and Response (IDSR) was 
established for aggregate reporting of 18 infectious diseases, including measles. 
Through the IDSR, aggregate numbers of suspected measles cases and deaths are 
reported weekly from districts to national level. Through measles case-based sur-
veillance, suspected measles cases were investigated using case investigation form 
and laboratory testing of blood specimen. Specimens are tested using standard 
enzyme-linked immunosorbent assays for measles-specific immunoglobulin M 
(IgM) antibodies. Suspected measles case was defined as an illness with maculopap-
ular rash and fever and one or more symptoms of cough, coryza or conjunctivitis, or 
where clinician suspects measles. Laboratory-confirmed measles case on the other 
hand is defined as suspected measles case with positive laboratory test result for 
measles specific IgM in the absence of measles vaccination within 30 days of speci-
men collection. An epidemiologically-linked case is suspected measles case having 
contact (or living in same district) with laboratory-confirmed measles case whose 
rash onset was within preceding 30 days. Clinically-compatible case is suspected 
measles case without laboratory test result or established epidemiological link. PCR 
detection is carried out in specific laboratories with technology for confirm hemag-
glutinin (H) and nucleoprotein (NP) gene of measles virus.
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2.2 Circulating genotypes and clades in Africa
Measles virus is monotypic; however, genetic variations occur in the H and NP 
genes. Currently, the WHO recognizes 8 clades, A-H which consists of 24 genotypes 
and an additional provisional genotype, D11. Clades B, C, D, G and H each contain 
multiple genotypes (B1-3, C1-2, D1-10, G1-3 and H1-2) while clades A, E and F each 
contain single genotype (A, E and F) respectively [17, 18]. Epidemiological findings 
reveal circulation of several genotypes in Africa. Genotype A has been detected 
in South America, parts of China and South Africa over the last 40 years [19], 
and recently in a 3 year old child in Nigeria West Africa [20]. The most endemic 
genotype circulating in Africa is B3. Studies have shown clade B to be endemic in 
sub-Saharan Africa [21] with B3 genotype reported in Ghana, Gambia, Nigeria, 
Libya and Tunisia [20, 22, 23]. The measles viruses isolated in 1983 from Yaoundé, 
Cameroon, were designated as B1 genotype. However, in 2001 viruses belonging 
to B3 genotype were found in the country. B3 genotype has been reported in the 
Gambia. The B3 genotype (2001) in Cameroon were related to B3.1 subgroup, 
whereas the Gambian (1993) isolates corresponded to B3.2 subgroup. Geographical 
distribution for period 1993–2001 of these two viruses shows that B3.1 is found 
from Sudan to Nigeria and Ghana extending to Cameroon, whereas B3.2 genotype 
is found in West Africa. In Nigeria and Ghana, the viruses co-circulate [3, 14]. 
Nucleotide sequence analysis show strains from Senegal clustered in B3.1 and B3.3 
sub-genotypes. Measles virus detected in Tunisia and Libya from 2002 to 2009 
belonged to genotype B3. Viruses isolated from 2002 to 2007 and 2009 were subtype 
B3.1. Seven of isolates during 2008 and 2009 epidemic were divergent from the B3 
isolates and can represent a new subtype of genotype B3 [21]. B3 strain circulates in 
Addis Ababa, Bahir Dar and possibly elsewhere in Ethiopia [24]. In a 2014 outbreak 
among refugees from Central African Republic in Cameroon, the genotype B3 
found were similar to those circulating in Northern Cameroon in 2010–2011 [25]. 
Clade B viruses is reported to be endemic in central and western parts of sub-Saha-
ran Africa while genotypes D2 and D4 has been continually detected in southern 
and eastern parts of Africa. D10 in Uganda is represented by Clade MVi/Kampala.
UGA/51.00.1 with accession number AY923185.1. Genotype C2 is found to circulate 
widely in northern Africa [17, 26–28].
2.3 MV complications in developing countries
Measles is characterized by fever of 38°C or more; maculopapular rash of 3 days 
or more; with one or combination of coryza, cough, conjunctivitis and Koplik spots 
in the oral mucosa of measles’ victims [29]. Mortality rates can exceed 10% in parts 
of the developing world. Sequela of measles includes giant cell pneumonia, inclu-
sion body encephalitis and sub-acute sclerosing pan encephalitis [SSPE] [30]. A 
study carried out in the largest children’s hospital in Ibadan-Nigeria in West Africa 
observed several complications ranging from bronchopneumonia (60%), heart 
failure (12%), gastroenteritis (11%), protein losing malnutrition (8%), encephalitis 
(5%), croup (2%) and dehydration (2%) [10], whereas bacterial complication is the 
usual cause of death when measles kills malnourished children [31].
2.4 Vaccination and herd immunity
After routine and catch-up vaccinations in 2005 and 2006, as well as follow-up 
vaccination by 2008 in Nigeria, remarkable level of protection was observed in 
children. This is attributed to immunological dynamics which is an after-effect of 
these campaigns [32]. Herd immunity varies between heterogeneous populations in 
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Despite the comprehensive WHO and United Nations International Children 
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detection is carried out in specific laboratories with technology for confirm hemag-
glutinin (H) and nucleoprotein (NP) gene of measles virus.
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developing countries. Nigeria is the most populous country in Africa with a popula-
tion of over 160million. In an assessment of immune status carried out in 2014, herd 
immunity against measles was 66.8% in Kano State and 73.0% in Ibadan, Oyo State. 
These are two largely different populations in the north and southern respectively 
[33]. When history of measles was compared with level of immunity, a significant 
association was observed between those who had measles and who had protective 
immunity. There was strong correlation between malnutrition and immune level, a 
lot of malnourished children who were vaccinated were not protected [33].
2.5 Measles vaccination coverage in Africa
Strategies based on vaccination program have been implemented in order to 
reduce measles mortality. In 2008, countries in the WHO African Region adopted 
measles pre-elimination goal to be achieved by the end of 2012. Target was to 
achieve >98% reduction in estimated regional measles mortality. The goal was to 
have national measles incidence of <5 cases per 1,000,000 population per year, 
achieve >90% national coverage with MCV1 with >80% MCV1 coverage target. For 
SIAs, MCV coverage >95% was targeted in all districts [16]. In the WHO regions, 
highest percentage of reduction was in Eastern Mediterranean (90%) and African 
(89%) regions, accounting for 16 and 63% of global reduction [34, 35]. Relatively 
high measles vaccination in southern Nigeria in West Africa can be attributed to 
high level of literacy and awareness created by free use of mass media to dissemi-
nate information on vaccination activities, without fear of intimidation [33]. The 
Global Vaccine Action Plan (GVAP) set out a target of reaching 80% coverage with 
all vaccines including measles vaccine in all districts by 2020 [36]. Health policy 
decision-making based on spatially heterogeneous vaccination has resulted in shift 
from pursuing coverage targets at national-level to ensuring high coverage levels 
evenly distributed across provinces or districts [37]. While this likely represents a 
more effective strategy over targeting country-level goals, administrative area sum-
maries may still mask important geographical inequities in coverage [38].
2.6 Challenges of measles immunization in resource-limited settings
Vaccination history of children is not documented in hospital’s records because 
many people do not properly keep children’s/wards’ vaccination records. This is 
coupled with high illiteracy level found in many developing countries [32]. Many 
people present as emergencies upon admission, at which point their parents cared 
less about vaccination status because they were overwhelmed by anxiety. There is 
need for enhanced comprehensive national vaccination campaigns with intense com-
munity engagement and diligent health workers including large number of ad-hoc 
staff. Weak government support across all levels is responsible for poor surveillance 
activities hence, their inability to detect new cases. Awareness creation should be 
intensified to inform concerned citizens about the essence and time of vaccination.
Ability to produce vaccines is a major setback for developing countries. Japan 
International Cooperation Agency (JICA) is currently supporting transfer of a 
Measles-Rubella vaccine manufacturing technology to Polyvac® in Vietnam, 
following the precedent set by multiple previous successful projects. Transfer 
of an oral polio vaccine (OPV) technology from Biken Co., Ltd. to Bio Farma 
in Indonesia was pivotal in the global polio eradication efforts. JICA supports 
UNICEF supply of vaccine cold chain equipment to India, Afghanistan, Angola, 
Liberia, Zambia and Zimbabwe which has significantly overcome the problem of 
vaccine failure resulting from inability of most immunization officers to maintain 
cold chain in remote areas.
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Government bodies responsible for ensuring safety and effectiveness of vaccines 
face serious challenges when protecting the public from harm once the products are 
used in uncontrolled, real world context [39–41]. Regulations have been moving 
towards an approach that takes into account the full lifecycle of the vaccine. While 
this shift has been very slow in countries like Canada, there have been further 
calls for changes on how regulators safeguard public health and public healthcare 
resources [42]. This approaches are a far cry from the reality on ground in develop-
ing countries, because they utilize whatever vaccines are supplied by donor agencies 
or vendors who have passed through government’s registration processes.
Most countries grapple with unreliable immunization service funding. But in 
spite of active measles vaccination efforts in several developing countries, re-
emergence of measles continues to occur [33]. An interplay of several factors affect 
immunization. These factors include break in cold-chain of measles vaccine due 
to long distance to vaccination centers, history of measles, intercurrent infections 
and malnutrition. In both developing and industrialized countries, loss of public 
confidence in vaccine due to real or spurious links to adverse events can curtail or 
even halt immunization activities. This is similar to reports about polio vaccine 
laced with sterilizing agents which led to decline in vaccination uptake in northern 
Nigeria. Despite the scientific evidence refuting links between the measles-mumps-
rubella (MMR) vaccine and autism, there has been decline in coverage in some 
countries as a result of this. Measles is making a comeback in several industrialized 
countries, including Austria, Italy and the United Kingdom. This can be attributed 
to presence of migrants and refugees from developing countries especially those 
who are biased against vaccines in light spurious or religious sentiments.
Masking of geographical inequalities in vaccination because of poor administra-
tive summaries is a big problem. Spatial clustering of unvaccinated children sus-
tains disease transmission, even when high overall vaccination coverage is achieved. 
Continued measles virus circulation occurs as a result of missing age cohorts during 
routine vaccination. Access to high quality vaccines is important however, there is 
limited expertise to review technical product information in vaccine regulatory dos-
siers hence the inability to effectively register and supply vaccines in many develop-
ing countries. They lack appropriate expertise and certified personnel to perform 
good manufacturing practice (GMP) inspections leading to lengthy registration/
review process and delays in vaccine registration even in emergency situations. 
Worrisome is the fact that there is limited compliance with good clinical practice 
standards for some clinical trials. Therefore, improving vaccine supply chain in 
developing countries is very important. A review of existing data shows freeze 
exposure occurred in 18–67% of vaccine shipments throughout various stages of 
storage. Also, heat denatures vaccines when cold chain is not maintained. Such may 
reduce vaccine potency, ultimately supplying potentially less-effective vaccines.
2.7 Sourcing of vaccines
The developing countries vaccine manufacturers’ network (DCVMN) is a public 
health driven, international alliance of manufacturers trying to strengthen vac-
cine supply through information and professional training programs, technology 
improvements, innovative vaccine research and development, encouraging transfer 
initiatives, to improve availability of safe, effective and affordable vaccines. Three 
goals were proposed for vaccines. First, to ensure uninterrupted supply of afford-
able and suitable vaccines for GAVI. Second, improve market dynamics information 
and expertise to solve vaccine access challenges. Third, strengthening global health 
and manufacturers’ partnerships to enable better alignment of goals, alignment 
with global strategy and coordination of internal investments [43].
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2.8 Negative impact of population explosion
Civil unrest is common in developing countries and this has led to migration of 
millions of people. There is increased movement by land, air and sea. In Northern 
Nigeria, activities of Boko Haram terrorist have caused several families to abandon 
their homelands and converge on Internally Displaced Peoples camps where health 
care services are poor and even non-existent in some cases. Many children are 
born in these camps, but vaccination activities may not be sustained at the desired 
national vaccination level. Wars and famines or other natural disasters increase 
mortality due to measles. In 2000, measles was responsible for 22% of deaths in 
children less than 5 years of age and 17% of deaths in children aged 5–14 years in 
Ethiopia [44]. Increased air travel by people within some regions in developing 
countries has been reported. For local flights, cabin air flow may not be as reliable a 
barrier to the spread of measles virus. Several measles reports, including index cases 
and apparent secondary cases on flights, have been reported in which transmission 
on board the aircraft appeared likely and which included seating information for 
both index (primary) and secondary case [45].
3. Conclusion
Regulations for safety and effectiveness of vaccines in the uncontrolled, real 
world context should be strengthened in developing countries. Perhaps the set of 
ethical considerations when fully operational in developed countries will be applied 
to them also. The World Health Assembly established 3 milestones towards eradi-
cation of measles. They intend to increase routine coverage with MCV1 by more 
than 90% nationally and more than 80% in every district; reduce and maintain 
annual measles incidence to less than 5 cases per million; and reduce estimated 
measles mortality by more than 95%. Based on current trends of measles vaccina-
tion coverage and incidence, and report of the strategic review, the WHO Strategic 
Advisory Group of Experts on Immunization (SAGE) concluded that the 2015 
global milestones and measles elimination goals were not achieved because immuni-
zation coverage gaps exist. SAGE recommended focus on improving immunization 
and surveillance systems to ensure gains made thus far in measles control can be 
sustained. The situation in developing countries requires serious attention and strict 
compliance by stakeholders to ensure goals are met.
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Guwahati by Ranked Set Sampling
Vivek Verma and Dilip C. Nath
Abstract
In order to study the efficacy of the ranked set sampling (RSS), as an alternative
procedure, for estimation of the proportion of children aged 12–23 immunized against
measles vaccine, a study is conducted in slum and non-slum regions of Guwahati, the
capital of Assam, India. The RSS-based approach in the cases of both perfect and
imperfect rankings is compared with its counterpart simple random sampling (SRS).
The results revealed that estimates based on RSS with set size (4) are very close to
Census report for Assam (2012) and has less variability than the SRS estimator. RSS-
based estimates for different choices of probability of ranking error (ρ) are not only
more accurate but are more precise and efficient than the SRS procedure, and also
suggest that a the procedure of RSS better than the classical SRS.
Keywords: relative precision, relative saving, order statistics,
maximum likelihood estimator
1. Introduction
In public health related studies, the virus of measles is considered as highly
epidemic and responsible for serious diseases. According to the medical dictionary,
measles virus infects the lungs in children, which can cause pneumonia in older
children, can cause inflammation of the brain, called encephalitis, which can cause
seizures and brain damage [1]. As a preventive measure, adequate vaccination is
introduced in early childhood to acquire immunity against measles virus. According
to the Integrated Child Development Services Program (ICDS) in India, a child
should have received the basic vaccines (BCG, polio, DPT and measles) at
12–23 months of age.
In this regard, the World Health Organization (WHO) launched the Expanded
Program on Immunization (EPI) in May 1974 to immunize children around the
world. Since then, it has been widely used to access coverage. India launched the
National Vaccination Program entitled Expanded Programme of Immunization in
1978 with the introduction of the BCG, OPV, DPT and anti-typhoid-paratyphoid
vaccine. The EPI was renamed and launched, with a major change in list of
vaccinations, as the Universal Vaccination Program on 19 November 1985.
The measles vaccine [2] has been added to latest schedule.
To study the vaccination coverage a few among various sampling procedures
and are the most popular viz., lot quality assurance sampling (LQAS) [3, 4],
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In order to study the efficacy of the ranked set sampling (RSS), as an alternative
procedure, for estimation of the proportion of children aged 12–23 immunized against
measles vaccine, a study is conducted in slum and non-slum regions of Guwahati, the
capital of Assam, India. The RSS-based approach in the cases of both perfect and
imperfect rankings is compared with its counterpart simple random sampling (SRS).
The results revealed that estimates based on RSS with set size (4) are very close to
Census report for Assam (2012) and has less variability than the SRS estimator. RSS-
based estimates for different choices of probability of ranking error (ρ) are not only
more accurate but are more precise and efficient than the SRS procedure, and also
suggest that a the procedure of RSS better than the classical SRS.
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1. Introduction
In public health related studies, the virus of measles is considered as highly
epidemic and responsible for serious diseases. According to the medical dictionary,
measles virus infects the lungs in children, which can cause pneumonia in older
children, can cause inflammation of the brain, called encephalitis, which can cause
seizures and brain damage [1]. As a preventive measure, adequate vaccination is
introduced in early childhood to acquire immunity against measles virus. According
to the Integrated Child Development Services Program (ICDS) in India, a child
should have received the basic vaccines (BCG, polio, DPT and measles) at
12–23 months of age.
In this regard, the World Health Organization (WHO) launched the Expanded
Program on Immunization (EPI) in May 1974 to immunize children around the
world. Since then, it has been widely used to access coverage. India launched the
National Vaccination Program entitled Expanded Programme of Immunization in
1978 with the introduction of the BCG, OPV, DPT and anti-typhoid-paratyphoid
vaccine. The EPI was renamed and launched, with a major change in list of
vaccinations, as the Universal Vaccination Program on 19 November 1985.
The measles vaccine [2] has been added to latest schedule.
To study the vaccination coverage a few among various sampling procedures
and are the most popular viz., lot quality assurance sampling (LQAS) [3, 4],
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systematic sampling, cluster sampling [5] and stratified sampling [6], are based on
simple random sampling (SRS) either at one stage or subsequent stage. In most of
the practical situations to obtain actual measurement of an observation is not
relatively easy and economical, but ranking a small subset of auxiliary information
about a sample is relatively easy, economical and reliable. McIntyre in 1952 [7] have
introduced the procedure of ranked set sampling (RSS), as an alternative, which is
highly beneficial and much superior to the standard SRS, for estimating population
parameters. In RSS procedure a set of units is randomly drawn from the population
and the selected units are ranked by using judgment method or by other means
which does not require actual measurement. Only the unit possessing lowest rank is
measured for this set of units. Next, a second set of units of the same size is drawn
as earlier and ranked; then the unit at the second lowest position is measured. This
procedure of ranking and measuring is continued until we get as many observations
as the size of the set. This entire procedure is regarded as a cycle. The process of
cycle formation will be continued until the desired sample size is obtained for
analysis.
Based on real-life primary data, in the present study, the procedure of RSS is
investigated against SRS for estimating the proportion of children aged 12–23 months
of slum and non-slum households of Guwahati, the capital city of state Assam,
India, who are not immunized with the vaccine against measles. The information on
a total of 500 (260 slum and 240 non-slum) households, were obtained after being
ranked using mother’s age 15–49 years (in months), as auxiliary variable is used as
auxiliary variable. The data of the same size is obtained by following the SRS
procedure, for the evaluation of the performance and effectiveness of the RSS
estimator compared to SRS estimator.
2. Sampling design
The study population is a representative cross-sectional sample of children aged
12–23 months to mothers aged 15–49 of Guwahati City, India. Five hundred house-
holds, following both SRS and RSS procedures, having the children of age from
6 months to 5 years were identified for the present study. Following the SRS
technique, from both slum and non-slum regions, a sample 250 households were
obtained. Among the selected 500 households under RSS, 260 were residents of
slum region whereas remaining 240 are of non-slum parts of the Guwahati City.
The variable considered in the study is the proportion of children in Guwahati City,
India who are not immunized with the vaccine against measles. It is assumed that
the case of receiving the vaccination of children usually depends on the awareness
of the child’s mother on immunization. Lower the age of a mother who has children
aged 12–23 months, lower would be the consciousness as expected. Therefore, the
age of the mother (in months) was used as a ranking variable in RSS for classifica-
tion of the sample. Information on children was obtained by a face to face interview
with the mothers. Mothers were selected through RSS conducted in Guwahati City.
The observation were divided into m sets of size four (s ¼ 4) each. The obser-
vations under RSS procedure are obtained through the following steps.
1.A simple random sample of units s2 is selected from the target population and
is distributed randomly in sets s, each with s units.
2. In each set s, the units are ranked according to the age of the mother. Since the
samples in different sets are ranked according to the age of themother (1, 2, 3, 4).
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Obviously, there is a high chance of having ties then in this situation, the
observations are ordered systematically in sequence, as explained by Terpstra
and Nelson (2005).
3.From the first set, the unit corresponds to the mother with the lowest age (in
months) is selected. From the second set, the unit corresponds to the mother
with the second lowest age is selected and so on. Finally, from sth set, the unit
corresponding to the mother with the highest age is selected. The other s(s� 1)
sampled units are discarded from the data set.
4.Steps 1–3, called a cycle, are repeated m times to obtain a ranked set sample of
size ms.
Corresponding to each selected mother, information regarding whether her
child is administrated with measles vaccination or not is collected.
Suppose X is the binary response that takes value “1” if the child is vaccinated
with measles vaccine and “0” otherwise. Let X i½ � j, i ¼ 1, 2,⋯, s, j ¼ 1, 2,⋯,m
� �
rep-
resent a ranked set sample of size ms, where X i½ � j takes the values “1” or “0”
according as the jth child in the ith ranking class is vaccinated or not. By virtue of
ranked set sampling all X i½ � j0s are independently distributed. Here for any i from 1 to
s, X i½ �1,X i½ �2,⋯,X i½ �m are independently and identically (i.i.d.) distributed. Here X i½ �1
can be regarded as the ith order statistic corresponding to a simple random sample
of s observations, say, X1,X2,⋯,Xsð Þ on X. Obviously, Xis have the common prob-
ability mass function (p.m.f.) given by
f xjpð Þ ¼ px 1� pð Þ1�x, x ¼ 0, 1, 0< p< 1, (1)
where p is the probability that a child is vaccinated with measles vaccine in the
population. Now we have, for any i, 1 ≤ i ≤ s
P X i½ �1 ¼ 1









Apr 1� pð Þs�r ¼ p i½ �, say,
P X i½ � ¼ 0
� � ¼ 1� p i½ �
� �
:
Obviously, p i½ � is the proportion, in ith class, of children who received the
vaccination and p is the overall proportion of children receiving the vaccine in
entire target population. Here it can be easily shown that
Xs
r¼1
p r½ � ¼ sp: (2)
3. Estimation of parameter p
For a dichotomous population, estimation of population proportion p, based on
ranked set samples have already been investigated [8–14]. A method for estimation
[15] of p using RSS for the situations where the binary variable is obtained from a
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systematic sampling, cluster sampling [5] and stratified sampling [6], are based on
simple random sampling (SRS) either at one stage or subsequent stage. In most of
the practical situations to obtain actual measurement of an observation is not
relatively easy and economical, but ranking a small subset of auxiliary information
about a sample is relatively easy, economical and reliable. McIntyre in 1952 [7] have
introduced the procedure of ranked set sampling (RSS), as an alternative, which is
highly beneficial and much superior to the standard SRS, for estimating population
parameters. In RSS procedure a set of units is randomly drawn from the population
and the selected units are ranked by using judgment method or by other means
which does not require actual measurement. Only the unit possessing lowest rank is
measured for this set of units. Next, a second set of units of the same size is drawn
as earlier and ranked; then the unit at the second lowest position is measured. This
procedure of ranking and measuring is continued until we get as many observations
as the size of the set. This entire procedure is regarded as a cycle. The process of
cycle formation will be continued until the desired sample size is obtained for
analysis.
Based on real-life primary data, in the present study, the procedure of RSS is
investigated against SRS for estimating the proportion of children aged 12–23 months
of slum and non-slum households of Guwahati, the capital city of state Assam,
India, who are not immunized with the vaccine against measles. The information on
a total of 500 (260 slum and 240 non-slum) households, were obtained after being
ranked using mother’s age 15–49 years (in months), as auxiliary variable is used as
auxiliary variable. The data of the same size is obtained by following the SRS
procedure, for the evaluation of the performance and effectiveness of the RSS
estimator compared to SRS estimator.
2. Sampling design
The study population is a representative cross-sectional sample of children aged
12–23 months to mothers aged 15–49 of Guwahati City, India. Five hundred house-
holds, following both SRS and RSS procedures, having the children of age from
6 months to 5 years were identified for the present study. Following the SRS
technique, from both slum and non-slum regions, a sample 250 households were
obtained. Among the selected 500 households under RSS, 260 were residents of
slum region whereas remaining 240 are of non-slum parts of the Guwahati City.
The variable considered in the study is the proportion of children in Guwahati City,
India who are not immunized with the vaccine against measles. It is assumed that
the case of receiving the vaccination of children usually depends on the awareness
of the child’s mother on immunization. Lower the age of a mother who has children
aged 12–23 months, lower would be the consciousness as expected. Therefore, the
age of the mother (in months) was used as a ranking variable in RSS for classifica-
tion of the sample. Information on children was obtained by a face to face interview
with the mothers. Mothers were selected through RSS conducted in Guwahati City.
The observation were divided into m sets of size four (s ¼ 4) each. The obser-
vations under RSS procedure are obtained through the following steps.
1.A simple random sample of units s2 is selected from the target population and
is distributed randomly in sets s, each with s units.
2. In each set s, the units are ranked according to the age of the mother. Since the
samples in different sets are ranked according to the age of themother (1, 2, 3, 4).
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Obviously, there is a high chance of having ties then in this situation, the
observations are ordered systematically in sequence, as explained by Terpstra
and Nelson (2005).
3.From the first set, the unit corresponds to the mother with the lowest age (in
months) is selected. From the second set, the unit corresponds to the mother
with the second lowest age is selected and so on. Finally, from sth set, the unit
corresponding to the mother with the highest age is selected. The other s(s� 1)
sampled units are discarded from the data set.
4.Steps 1–3, called a cycle, are repeated m times to obtain a ranked set sample of
size ms.
Corresponding to each selected mother, information regarding whether her
child is administrated with measles vaccination or not is collected.
Suppose X is the binary response that takes value “1” if the child is vaccinated
with measles vaccine and “0” otherwise. Let X i½ � j, i ¼ 1, 2,⋯, s, j ¼ 1, 2,⋯,m
� �
rep-
resent a ranked set sample of size ms, where X i½ � j takes the values “1” or “0”
according as the jth child in the ith ranking class is vaccinated or not. By virtue of
ranked set sampling all X i½ � j0s are independently distributed. Here for any i from 1 to
s, X i½ �1,X i½ �2,⋯,X i½ �m are independently and identically (i.i.d.) distributed. Here X i½ �1
can be regarded as the ith order statistic corresponding to a simple random sample
of s observations, say, X1,X2,⋯,Xsð Þ on X. Obviously, Xis have the common prob-
ability mass function (p.m.f.) given by
f xjpð Þ ¼ px 1� pð Þ1�x, x ¼ 0, 1, 0< p< 1, (1)
where p is the probability that a child is vaccinated with measles vaccine in the
population. Now we have, for any i, 1 ≤ i ≤ s
P X i½ �1 ¼ 1
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continuous variable. Let XRSS ¼ X 1½ �,⋯,X i½ �,⋯,X s½ �
� �
, X i½ � ¼ X i½ �1,⋯,X i½ �m
� �T and
p ¼ p 1½ �⋯, p i½ �,⋯, p s½ �
� �
. Here X i½ �1,⋯,X i½ �m are i.i.d. Binomial 1, p i½ �
� �
, i ¼ 1, 2,⋯, s.
So the joint p.m.f. of X i½ �j, j ¼ 1, 2,⋯,m is given by






x i½ � j
i½ � 1� p i½ �





i¼1x i½ � j, the number of children getting vaccinated observed in ith
ranking class of the given ranked set sample. Obviously, Zi ¼
Pm
i¼1X i½ � j � Binomial
m, p i½ �
� �
, independently for all i ¼ 1, 2,⋯, s. Then the joint p.m.f. of the whole
sample XRSS is of the form
f xRSSjpð Þ ¼
Ys
i¼1





pzii½ � 1� p i½ �
� �m�zi
: (4)
Applying standard maximum likelihood (ML) principle the ML estimate of p
under ranked set sampling, is given by
p̂RSS ¼ arg max f xRSSjpð Þ
p
:
Given the RSS data, the form of likelihood function of p is complicated and
hence the MLE of p is difficult to obtain directly. Alternatively, for i ¼ 1, 2,⋯, s, one
can separately derive ML estimate, say, p̂ i½ � of based on the likelihood function (3)







Here, it can be shown that, for each i ¼ 1, 2,⋯, s, Zim would be the maximum








¼ XRSS, say, (5)
where XRSS is the overall mean of the ranked set sample.
Let Y1,Y2,⋯,Yn are the observations drawn according to SRS design and p̂SRS be








4. Effect of imperfect ranking
The discussion done in the previous sections are based on the assumption that
the ranking procedure produces the correct order statistics. But, a perfect ranking
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mechanism is very rare in practice and hence some error in judgment ranking is
inevitable. So it is necessary to study how much robust the proposed procedure is
against when the rankings are not perfect. Estimation of p under perfect and
imperfect unbalanced RSS [13, 16, 17] are discussed.
Let X i½ � and X ið Þ denote, respectively, the i
th judgment order and ith true order
statistic while a set of s units are ordered. In the presence of ranking error, X i½ � is not
necessarily equal to X ið Þ. Let πij denote the probability that the i
th judgment order
statistic actually have the true rank j, for i ¼ 1 1ð Þs, j ¼ 1 1ð Þs. Assume that πijs satisfy
the conditions
0 ≤ πij ≤ 1, πij ¼ πji,∀ i, jð Þ,
Xs
j¼1
πij ¼ 1, ∀i,
Xs
i¼1
πij ¼ 1, ∀j:
That is, π ¼ πij
� �
is a doubly stochastic symmetric matrix of order s� s. Under
this assumption the distribution of X i½ � would be changed to Binomial (1, p ∗i½ �), for
each i ¼ 1 1ð Þs, where






where p ¼ p 1½ �, p 2½ �,⋯, p s½ �
� �0
and p∗ ¼ p ∗1½ �, p ∗2½ �,⋯, p ∗s½ �
� �0
. For the present pur-
pose we take the particular form of π as in [18, 19],
π ¼
ρ δ δ … δ








, 0< ρ< 1, δ ¼ 1� ρ
s� 1 :
Here “ρ ¼ 1” corresponds to the case of perfect ranking. Under the above prob-





















p j½ � ¼
Xs
j¼1




1� p ∗i½ �
� �
¼ s 1� pð Þ,
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mechanism is very rare in practice and hence some error in judgment ranking is
inevitable. So it is necessary to study how much robust the proposed procedure is
against when the rankings are not perfect. Estimation of p under perfect and
imperfect unbalanced RSS [13, 16, 17] are discussed.
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statistic while a set of s units are ordered. In the presence of ranking error, X i½ � is not
necessarily equal to X ið Þ. Let πij denote the probability that the i
th judgment order
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P X i½ � ¼ x
� � ¼ P X ¼ xð Þ, for x ¼ 0, 1:









πijp j½ �, bi ¼
Xs
j¼1
πij 1� p j½ �
� �
,
one can get under ranked set sampling with the presence of ranking error






















Also, for the above choice of π-matrix, it is verified that
ai ¼ δspþ ρ� δð Þp i½ � and bi ¼ δs 1� pð Þ þ ρ� δð Þ 1� p i½ �
� �
: (7)




sequence and subsequently, among two sequences aif gi¼1 1ð Þs and bif gi¼1 1ð Þs, one is
non-decreasing and the other is non-increasing. So, from Chebyshev’s inequality for



















As we know that the variance of p̂ in SRS is p 1�pð Þn , the required justification






bi ¼ s 1� pð Þ:
The justification in case of perfect ranking follows automatically by taking ρ ¼ 1
in the above proof.
5. Comparison between p̂RSS and p̂SRS
It is easy to argue that the ML estimates p̂ 1½ �, p̂ 2½ �,⋯, p̂ s½ � are statistically indepen-
dent as the variables Zi0s are independently distributed. Again, substituting the
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value Zim of p̂ i½ � in Eq. (5), the estimate p̂RSS can be shown to be identical with the
overall mean of the given ranked set sample. It is also readily verified that p̂SRS is an
unbiased estimator of p.
The comparison of effectiveness and efficiency of the estimators based on sim-
ple random samples and ranked set samples, is obtained on the basis of criteria viz.,
relative precision (RP) and relative saving (RS). The expressions for RP, RS and
MSE of the estimators are described below as
RP ¼ E p̂SRS � p
 2






RS ¼ V p̂SRS
 � V p̂RSS
 
V p̂SRS
  : (9)
6. Result and discussion
Table 1 shows the estimates of proportion of measles immunized children in
Assam, under SRS and RSS are very different but RSS based estimates 0.80 and 0.92
are very close to Census report for Assam (2012) [20] true value, which is 0.84
(rural) and 0.90 (urban), and has less variability than the SRS estimator and are
very distinct from the true values. The estimate based on RSS is found to be 58%
and 142%, for slum and non-slum region, respectively, more precision than that of
SRS. Here, smaller the value of ρ represents higher will be the ranking error in RSS.
The performance of estimates even in imperfect situation as compare to SRS, for
different choices of the ranking error probability ρ ¼ 0:2, 0:6, 0:9, shows the esti-
mates based on RSS is 48%, 50% and 56% for slum region, and 139%, 140% and
141% for non-slum, respectively, more precision as compare to SRS. RSS also shows
a saving of 37%(59%) under perfect and a minimum of 32%(58%) under imperfect
in slum (non-slum) as compare to SRS.
7. Conclusion
The present study revealed that RSS based estimates in both of perfect and
imperfect situations, performs better than SRS based estimates. It should also be
Region Criteria n SRS s m RSS perfect RSS imperfect
ρ ¼0.2 ρ ¼0.6 ρ ¼0.9
Slum Estimate 250 0.64 4 65 0.80 0.80 0.80 0.80
Variance 0.92 0.58 0.62 0.62 0.59
RP 1.58 1.48 1.50 1.56
RS 36.83 32.29 33.27 35.70
Non-slum Estimate 250 0.74 4 60 0.92 0.92 0.92 0.92
Variance 0.76 0.32 0.32 0.32 0.32
RP 2.42 2.39 2.40 2.41
RS 58.60 58.22 58.30 58.51
Table 1.
Estimate of proportion of immunized children (p), variance (in 10�3), relative precision and relative saving
(in %), in different regions of Guwahati under SRS, RSS perfect and imperfect procedures.
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a saving of 37%(59%) under perfect and a minimum of 32%(58%) under imperfect
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The present study revealed that RSS based estimates in both of perfect and
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emphasized in context of estimation of proportion of measles immunization cover-
age in slum and non-slum region of Assam, RSS based estimates for different
choices of accuracy (ρ) are not only more accurate but are more precise and effi-
cient than the SRS procedure, and also suggest that the procedure of RSS is better
than the classical SRS. Therefore, based on the obtained results one can recommend
to adopt RSS procedure in epidemiological application and in other health related
studies so that it will help in planning to build a healthy and disease free
environment.
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An association between the measles virus (MV) and classic Hodgkin lymphoma 
(CHL) was reported by our center in Beer-Sheva, starting in 2003. Our basic 
evidence on the relationship had been established by immunohistochemistry, using 
several commercial and specific experimental anti-measles antibodies in about 50% 
of our patients. It relied also on the reverse transcriptase-polymerase chain reaction 
(RT-PCR) and in situ hybridization (ISH) of MV RNA, and overall, was essentially 
descriptive. The first and only response to our thesis was advanced in 2007 in 
doublet articles, in a single issue of a Cancer Journal. Our conclusions were hereby 
dismissed. Since reservations relating the above refutation seemed self-evident, 
the subsequent publication of several of our articles was launched. They disclosed 
evidence of an association of the MV with further categories of cancers, as well as 
its absence in some distinct tumors. A mechanism by which the MV may regulate 
apoptosis in the tumor cells of CHL was also proposed. A suspected role for the 
MV in oncomodulation is advocated. We deplore, however, the absence of further 
interest in our hypothesis among world experts.
Keywords: classic Hodgkin lymphoma, measles virus, antigens, RT-PCR, 
in situ hybridization, endometrial carcinoma, breast cancer, lung cancer
1. Introduction
Classic Hodgkin lymphoma (CHL) stands out among malignant tumors, by the 
relative paucity of the tumor cells in the involved lymph nodes. These Hodgkin and 
Reed-Sternberg (H/RS) cells (Figure 1) are distributed unevenly within the major-
ity of inflammatory cells, fibrosis and necrosis [1]. It is understood that, indepen-
dent of the proportion of H/RS cells in CHL, the outcome of the malignancy will be 
favorable, with a cure rate of 75–90% [2, 3]. Such a therapeutic success is unusual 
for cancer at large.
When considering the many prognostics and risk factors regarding CHL, the 
stage of the tumor, as expected, is the most relevant. Evidence of systemic symp-
toms: fever higher than 38°C for at least a month; weight loss of more than 10% of 
body weight, lasting 6 months or more, and/or drenching night sweats, singly or 
collectively, worsen the prognosis [1]. A difference is described between genders, 
as females fare as a rule better than males, no consideration being given to a higher 
incidence of nodular sclerosis CHL in females. Indeed, children and older adult 
males with mixed cellularity CHL, especially in developing countries, get on worse 
with the disease [2, 4]. In contrast, females would be included in the bulk of CHL 
patients, aged 15–36, with a favorable outcome [5].
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Some 15-20% of human cancers are thought to arise by mechanisms which 
concern viruses, bacteria, or parasites [6, 7]. Evidence for their involvement comes 
partly from the detection of the microorganism in biopsies and partly from epidemio-
logical and animal studies. Viruses might modify cellular genes directly, as with RNA 
tumor viruses, or may affect cell proliferation, as with DNA tumor viruses, and thus 
contribute to neoplasm formation [6, 7]. As a rule, the virus is responsible for only 
a limited number of steps in the promotion or progression of cancer. In most cases, 
the precise role of cancer-associated virus is hard to decipher, due to the long delay 
from the initial viral infection [6]. In any case, the number of human beings infected 
with the above viruses is much larger by far from that of patients who develop cancer. 
Therefore, tumor viruses probably act in conjunction with additional factors [7].
Chronic inflammation may play an important role in the above processes as 
well as in other pathologic events which may lead to cancer [8]. In some cases of 
unresolved chronic inflammation, the immune response becomes maladaptive, 
hence promoting tumorigenesis [8]. A regenerative process supported by an array 
of bioactive mediators, promote cell survival, tissue remodeling, and angiogenesis. 
The mediators will also cause genomic stress and mutations [9].
A correlation between CHL and the Epstein-Barr virus (EBV) has been demonstrated 
many years ago [10, 11], with a causal relationship being established as soon as 2001 [12]. 
The incidence of EBV infection in CHL has shown a wide geographic variation, from 17 
to 30% in industrialized countries, to as high as 100% in some developing countries [13, 14].  
Several more years elapsed before the distribution of EBV infection by gender, age, and 
CHL type was determined (Figure 2) [13, 14]. Thus, EBV is expressed more frequently 
in males, notably in children from developing countries, as well as in older adults all 
over the globe, these two groups showing as a rule mixed cellularity CHL. Female CHL 
patients stand out, in general, by showing nodular sclerosis CHL with a markedly lower 
level of EBV expression and a young adult age (15–36) [15]. A small subset of young 
adult males will develop CHL after recovering from infectious mononucleosis [16]. The 
EBV is recognized as oncogenic. Specifically, its transforming potential, with cell pro-
liferation, inflammation, and apoptosis arrest, has been related to the nuclear factor-κB 
(NF-κB) and the EBV/LMP1 will further contribute to the inhibition of the H/RS cell 
apoptosis [15–19]. As noted, EBV does not play a significant role in the largest subset of 
CHL that affect young adults and most of the female CHL patients.
Figure 1. 
Section of lymph node from a patient with classic HL. Off center is a Hodgkin/Reed-Sternberg giant tumor cell 
(H&E × 360).
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The above subset of young adult female patients corresponds to that defined in 
the hallmark epidemiological studies in the early 1980s as patients with the “late 
host response model” [15–19]. These patients are considered to be submitted to the 
late exposure to a common infectious agent, the term “late” meaning that instead of 
coming across the common infectious agent for the first time in early childhood, this 
occurs at adolescence or young adulthood. The epidemiological thesis further sug-
gests that these individuals had a late encounter with the agent, since they had few 
and late contacts with other children (single child, individual family house, and child 
who skipped the kindergarten) [15]. To account for the late host response model, it is 
suggested that a common agent, probably a virus, reaches the organism for the first 
time at a stage in which the metabolism and/or the hormonal balance is markedly 
different from that of a toddler, the age at which the encounter regularly takes place. 
At this point, the internal environment has varied deeply and probably, so has the 
immune system [15–19]. Thus, it seems that the EBV plays a relatively minor role, in 
the largest subset of the CHL that is most prevalent in industrialized countries [18].
When looking for a substitute for the EBV in CHL, it was observed that none of 
the additional viruses, HHV-6, -7, -8, polyoma JC virus, SV40, HTLV-1 and -2, and 
human retrovirus 5, once considered as possible candidates, have been detected in 
CHL tissues [20–26]. The only virus to be incompletely excluded at that time was 
the HCMV. However, one distinct virus showed qualities and associations which 
recalled to various extents of those of CHL.
The “candidate” proposed by us is the measles virus (MV). It penetrates the 
organism through the oropharynx. But, since it is lymphotropic, it enters the 
adjacent lymphoid tissues. This may account for the vast majority of CHL starting 
in cervical and/or in mediastinal lymph nodes [12, 27]. Histologically, it elaborates 
multinucleated cells—the Warthin-Finkeldey polykaryons. Of note, these polykary-
ons differ largely from the H/RS cells of CHL, mainly by the number of nuclei 
(up to 70) as well as by their phenotype (they are T-lymphocytes) [28]. An acute 
measles infection is soon followed, on the one hand by a life-long specific immu-
nity, but also, paradoxically a transient cellular immune deficiency systematically 
develops. This deficiency lasts about 6 months, but at times, may last longer. The 
cellular immune deficiency which affects CHL patients is not different in principle, 
but it may be long lasting [12].
Figure 2. 
Association between age, gender, EBV expression, and classic Hodgkin lymphoma, including the types thereof.
Viruses and Viral Infections in Developing Countries
138
Some 15-20% of human cancers are thought to arise by mechanisms which 
concern viruses, bacteria, or parasites [6, 7]. Evidence for their involvement comes 
partly from the detection of the microorganism in biopsies and partly from epidemio-
logical and animal studies. Viruses might modify cellular genes directly, as with RNA 
tumor viruses, or may affect cell proliferation, as with DNA tumor viruses, and thus 
contribute to neoplasm formation [6, 7]. As a rule, the virus is responsible for only 
a limited number of steps in the promotion or progression of cancer. In most cases, 
the precise role of cancer-associated virus is hard to decipher, due to the long delay 
from the initial viral infection [6]. In any case, the number of human beings infected 
with the above viruses is much larger by far from that of patients who develop cancer. 
Therefore, tumor viruses probably act in conjunction with additional factors [7].
Chronic inflammation may play an important role in the above processes as 
well as in other pathologic events which may lead to cancer [8]. In some cases of 
unresolved chronic inflammation, the immune response becomes maladaptive, 
hence promoting tumorigenesis [8]. A regenerative process supported by an array 
of bioactive mediators, promote cell survival, tissue remodeling, and angiogenesis. 
The mediators will also cause genomic stress and mutations [9].
A correlation between CHL and the Epstein-Barr virus (EBV) has been demonstrated 
many years ago [10, 11], with a causal relationship being established as soon as 2001 [12]. 
The incidence of EBV infection in CHL has shown a wide geographic variation, from 17 
to 30% in industrialized countries, to as high as 100% in some developing countries [13, 14].  
Several more years elapsed before the distribution of EBV infection by gender, age, and 
CHL type was determined (Figure 2) [13, 14]. Thus, EBV is expressed more frequently 
in males, notably in children from developing countries, as well as in older adults all 
over the globe, these two groups showing as a rule mixed cellularity CHL. Female CHL 
patients stand out, in general, by showing nodular sclerosis CHL with a markedly lower 
level of EBV expression and a young adult age (15–36) [15]. A small subset of young 
adult males will develop CHL after recovering from infectious mononucleosis [16]. The 
EBV is recognized as oncogenic. Specifically, its transforming potential, with cell pro-
liferation, inflammation, and apoptosis arrest, has been related to the nuclear factor-κB 
(NF-κB) and the EBV/LMP1 will further contribute to the inhibition of the H/RS cell 
apoptosis [15–19]. As noted, EBV does not play a significant role in the largest subset of 
CHL that affect young adults and most of the female CHL patients.
Figure 1. 
Section of lymph node from a patient with classic HL. Off center is a Hodgkin/Reed-Sternberg giant tumor cell 
(H&E × 360).
139
A Role for the Measles Virus in Oncology
DOI: http://dx.doi.org/10.5772/intechopen.84342
The above subset of young adult female patients corresponds to that defined in 
the hallmark epidemiological studies in the early 1980s as patients with the “late 
host response model” [15–19]. These patients are considered to be submitted to the 
late exposure to a common infectious agent, the term “late” meaning that instead of 
coming across the common infectious agent for the first time in early childhood, this 
occurs at adolescence or young adulthood. The epidemiological thesis further sug-
gests that these individuals had a late encounter with the agent, since they had few 
and late contacts with other children (single child, individual family house, and child 
who skipped the kindergarten) [15]. To account for the late host response model, it is 
suggested that a common agent, probably a virus, reaches the organism for the first 
time at a stage in which the metabolism and/or the hormonal balance is markedly 
different from that of a toddler, the age at which the encounter regularly takes place. 
At this point, the internal environment has varied deeply and probably, so has the 
immune system [15–19]. Thus, it seems that the EBV plays a relatively minor role, in 
the largest subset of the CHL that is most prevalent in industrialized countries [18].
When looking for a substitute for the EBV in CHL, it was observed that none of 
the additional viruses, HHV-6, -7, -8, polyoma JC virus, SV40, HTLV-1 and -2, and 
human retrovirus 5, once considered as possible candidates, have been detected in 
CHL tissues [20–26]. The only virus to be incompletely excluded at that time was 
the HCMV. However, one distinct virus showed qualities and associations which 
recalled to various extents of those of CHL.
The “candidate” proposed by us is the measles virus (MV). It penetrates the 
organism through the oropharynx. But, since it is lymphotropic, it enters the 
adjacent lymphoid tissues. This may account for the vast majority of CHL starting 
in cervical and/or in mediastinal lymph nodes [12, 27]. Histologically, it elaborates 
multinucleated cells—the Warthin-Finkeldey polykaryons. Of note, these polykary-
ons differ largely from the H/RS cells of CHL, mainly by the number of nuclei 
(up to 70) as well as by their phenotype (they are T-lymphocytes) [28]. An acute 
measles infection is soon followed, on the one hand by a life-long specific immu-
nity, but also, paradoxically a transient cellular immune deficiency systematically 
develops. This deficiency lasts about 6 months, but at times, may last longer. The 
cellular immune deficiency which affects CHL patients is not different in principle, 
but it may be long lasting [12].
Figure 2. 
Association between age, gender, EBV expression, and classic Hodgkin lymphoma, including the types thereof.
Viruses and Viral Infections in Developing Countries
140
At the time our thesis was formulated, the type of MV neural infection known 
as subacute sclerosing panencephalitis (SSPE) was considered one of the very few 
persistent MV infections, most being CNS slow viral infections. However, it was 
difficult to grasp a possible association between MV and cancer, which would not 
account for the long lapse of time necessary for the malignant transformation. In 
that context, the absence of a persistent MV infection might be counterproductive. 
The alternative being that against all odds, MV may be oncogenic, and the MV is 
not among the consensually recognized oncogenic viruses! An additional clue to 
MV causing a persistent infection beyond the CNS is the absence of membrane 
expression of hemagglutinin MV antigens, although this lack of expression might 
be due also to the lymph node mode of fixation [29].
2. Materials and methods
The basic part of our study (2003–2004) concerned 154 patients with CHL 
diagnosed between 1975 and 2000 at the Soroka University Medical Centre in Beer-
Sheva, Israel, whose tissues were available for research. Only pretreatment biopsies 
with confirmed histological type, by two hematopathologists were included. 
Clinical data were retrieved from the patients’ charts and when those were not 
found, the details were searched in the Israel Population Registry by linkage.
2.1 Immunohistochemistry
Immunophenotyping was performed on formalin-fixed, paraffin-embedded 
(FFPE) tissues by the avidin-biotin peroxidase complex method and the 
Vectastain kit by Vector Laboratories (Burlingame, CA, USA) as described. 
The EBV/LMP1 antibody was purchased from Dako (Glostrup, Denmark); the 
anti-MV antibodies were either commercial: anti-nucleoprotein (NP)-MV; anti-
hemagglutinin (HA)-MV; anti-matrix (M)-MV; and anti-phosphoprotein (P)-MV 
were purchased from Chemicon International Inc. (Temecula, CA, USA). Further 
experimental antibodies were a gift from Birrer et al. [30]: anti-NP, H14; and from 
Schneider-Schaulies et al. [31]: anti-NP, L39/22; L39/61 or anti-HA antibodies, 
K83; L77. The antibody specificity had been demonstrated by Western blotting. 
The staining was considered positive if 10% of H/RS cells or more were positive. 
For stringency purposes, we requested positivity for two MV antigens, for a case 
to be considered positive. A murine neuroblastoma cell line permanently infected 
by MV was used as a positive control; the same cell line, but non-infected was 
used as a negative control. These cell lines were also the controls used for the 
RT-PCR and ISH assays. Twenty-five cases of non-Hodgkin lymphoma were also 
tested by IHC.
2.2 Reverse transcriptase-polymerase chain reaction
Total RNA was obtained by extraction of snap-frozen lymph node samples from 
part of our patients, when available. For this goal, EZ-RNA Total RNA Isolation Kit 
(Biological Industries Co., Beit Ha-Emek, Israel) was employed, using the manufac-
turer’s instructions. To each sample, 40 U of RNA-guard (Promega, Madison, WI, 
USA) were added. One step RT-PCR was performed with Ready To Go ™ RT-PCR 
beads (Amersham Pharmacia Biotech Europe GbmH, Freiburg, Germany). A mea-
sure of 3 μl of RNA (2-6 μg) was used for each reaction. For the primers used in this 
study, see Table 1 from Ref. [3]. Nested PCR was carried out, using SUPER-NOVA 
DNA polymerase (Roche Molecular Biochemicals, Mannheim, Germany).
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Total RNA was also retrieved from several FFPE tissues from CHL patients, 
using the Paraffin Block RNA Isolation Kit (Ambion Inc., The RNA Company, 
Austin, TX. USA) and RT-PCR followed by nested PCR carried out with 10 μl RNA, as 
described above. As controls, we used seven cases of non-Hodgkin lymphomas, one 
CHL which was negative for MV by IHC. As housekeeping genes, we used β-actin 
and protein phosphatase 2C β (pp2Cβ) considered appropriate for experiments 
related with low amounts of RNA.
To confirm our RT-PCR findings, the cDNA products of the nested PCR were 
blotted to GeneScreen (NEN Research Products, Boston, MA, USA) and hybridized 
to either an NP-MV probe (CAATCCCTGGAGATTCCTCA) or to a HA-MV probe 
(GCTGGAAGCTGACACCTTTC), labeled [γ-32 P] ATP (Amersham).
2.3 In situ hybridization on paraffin sections
The digoxigenin (DIG)-labeled antisense and sense probes to MV-specific 
mRNAs were prepared by linearizing the plasmids containing NP-MV including 
positions 105–586, and those including HA-MV encompassing positions 8147–
8482 in PGEM-T Easy Vectors (Promega), with SalI or SacII. In vitro transcription 
was performed with the DIG-RNA Labeling kit, with SP6 for NP antisense and HA 
sense probes and T7 for NP sense and HA antisense DIG-labeled probes. The quality 
of the probes was determined by dot blotting, using a DIG-DNA detection kit (Roche 
Molecular Biochemicals), according to the manufacturer instructions, with minor 
modifications. In situ hybridization was performed, using Ogata’s technique with 
certain modifications [32]. Paraffin sections were deparaffinized, rehydrated, and 
submitted to microwave in the presence of 10 mM MgCl2 buffer (pH 6) for 5 min 
at 750 W. Sections were allowed to cool down for 20 min and then digested with 
20 μg/ml proteinase K for 10 min at 37°C. They were then fixed in paraformaldehyde 
in 0.1 M phosphate buffer containing 50% formamide, 10 mM Tris-HCl (pH 7.6), 
200 μg/ml tRNA, 1 x Denhardt’s solution, 10% dextran sulphate, 600 mM NaCl, 
0.25% SDS, and 1 mM EDTA, pH 8.0. Hybridized DIG-labeled probes were detected 
by the DIG-Nucleic Acid Detection kit (Roche Molecular Biochemicals), followed 
by blocking with 1.5% of the blocking reagent included in the kit. The color reac-
tion was stopped with 10 mM Tris-HCl (pH 7.6) and 1 mM EDTA. Sections were 
then fixed in 4% paraformaldehyde in phosphate-buffered saline and stained with 
hematoxylin. In addition to the neuroblastoma cell lines used as positive and nega-
tive controls, CHL cases negative for MV by IHC and NHL served as controls.
2.4 Comparison between IHC, RT-PCR, and ISH
This was performed on a sampling of cases. For this purpose, IHC positivity to a 
single NP-MV or HA-MV antibody was considered sufficient.
2.5 Clinicopathological correlations
Emphasis was given to MV IHC and to EBV-LMP1 expression, as RT-PCR and 
ISH disclosed much less results. For contingency table analysis, the χ2 or Fisher’s 
exact test was used as appropriate.
3. Preliminary results
The lymph node tissues of 82 of 154 CHL patients were positive for at least two 
MV antigens (Figure 3). Neutralization of immunostaining was made possible by 
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MV antigens (Figure 3). Neutralization of immunostaining was made possible by 
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incubation of the primary anti-NP-MV antibody with the corresponding NP-MV 
peptide (Figure 3b). This assay confirms the specificity of the anti-NP-MV anti-
body in this context. Twenty-five cases of non-Hodgkin lymphoma (NHL) were 
totally negative for MV antigens.
A Southern blotting of the nested PCR shows several bands, some stronger, 
others faint, disclosing more hemagglutinin (HA, H) MV positivity, as compared 
with NP-MV positivity (Figure 4). Samples from 7 NHL were negative. Thus, in our 
laboratory, HA-MV RNA was positive in 4 of 15 cases, while only 2 of 16 NP-MV 
RNAs were expressed by the Southern blot in CHL.
Upon sequencing and alignment of three of the experiment products, we 
displayed an almost complete homology with the control (see [3] for details on the 
homology).
In situ hybridization on paraffin sections shows a strong cytoplasmic staining 
in the positive control (persistently MV infected murine neuroblastoma cell line) 
(upper left). The same cell line uninfected by MV was negative. An H/RS cell shows 
strong cytoplasmic positivity with NP-MV (lower left). Positive granular staining 
of several H/RS cells is disclosed in the right lower quadrant (Figure 5). Altogether, 
2 of 7 CHL sections submitted for ISH were positive for HA-MV RNAs, while 8 of 21 
were positive for NP-MV RNAs.
Figure 3. 
Classic Hodgkin lymphoma-nucleoprotein-MV expression. a. Positive cytoplasmic immunostain of Hodgkin/
Reed-Sternberg cells. b. Immunostaining following neutralization of antibody with a relevant MV peptide 
(Immunoperoxidase with DAB × 320).
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Figure 4. 
Southern blotting based on cDNA from RT-PCR: A. A few cases of CHL show bands positive for 
hemagglutinin-MV (PC—positive control). B. Isolated bands, positive for nucleoprotein-MV. C and D. Absence 
of expression of MV in non-Hodgkin lymphomas.
Figure 5. 
In situ hybridization with MV-RNA. a. Positive control, using a murine, MV-transfected cell line. b. Negative 
control, with a non-transfected cell line. c. A Hodgkin/Reed-Sternberg cell disclosing positive cytoplasm for 
MV-NP-RNA. d. H/RS cells showing a granular cytoplasmic positivity for MV-HA-RNA.
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A clinicopathological correlation was based on the immunophenotypic find-
ings, as the specificity of the antibodies had been sustained by Western blotting 
and since, in each case, the immunostain had been confirmed with more than two 
antibodies. Last, the immunohistochemical (IHC) study had released the most 
manageable results.
Table 1 shows a statistically significant expression of MV antigens in female 
patients, in nodular sclerosis (NS) CHL, as compared with mixed cellularity (MC) 
CHL. A significant correlation was exhibited between negative CD15 and p53, and 
the negative expression of MV. Table 2 displays a statistically significant expression 
of MV antigens compounded by the expression of EBV/LMP1, in NS-CHL, signifi-
cantly more than that in MC-CHL, in early clinical stages, with apoptotic index 
lower than median and with the positive expression of MDM2.
A multivariable logistic regression model of the association of prognostic factors 
with dying from CHL, in 89 patients, is shown. Stage IV, as compared with the remain-
der, carried a significantly poorer prognosis, thus confirming that our cohort was 
representative. The compound expression of MV and EBV, specifically of MV+; EBV−, 
as well as MV−; EBV− was displayed as poor risk factors in our patients (Table 3).
MV+; LMP− MV−; LMP+ p Value
Subtype NS 45 (86.5) 7 (13.5) 0.00008
MC 11 (44) 14 (56)
Stage I–IIA 22 (84.6) 4 (15.4) 0.023
IIB–IVB 22 (57.9) 16 (42.1)
BCL-2 Pos. 31 (93.9) 2 (6.1) 0.0001
Neg. 27 (54) 23 (46)
MDM-2 Pos. 36 (87.8) 5 (12.2) 0.0013
Neg. 18 (54.5) 15 (45.5)
Apop index <Median 31 (81.6) 7 (18.4) 0.024
>Median 22 (42.1) 16 (57.9)
Table 2. 
Hodgkin lymphoma—association with measles and Epstein-Barr viruses.
MV+ MV− p Value
n (%) n (%)
Total 82 (54.3) 69 (45.7)
Gender F 40 (64.5) 28 (35.5) 0.036
M 42 (47.2) 47 (52.8)
Subtype NS 58 (68.2) 27 (31.8) 0.0013
MC 21 (40.4) 31 (59.6)
CD15 pos 77 (59.7) 52 (40.3) 0.015
neg 4 (26.7) 11 (73.3)
p53 pos 72 (61.5) 45 (38.5) 0.017
neg 5 (31.3) 11 (68.8)
Table 1. 
Associations of classic Hodgkin lymphoma with the measles virus.
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4. Interim discussion
The results of the first part of our study (2004) are summarized [3]. The association 
between MV and CHL, in a descriptive investigation, does not contain, so far, causal 
elements. This linkage is sustained by older epidemiologic studies describing brain and 
spinal cord tumors, as well as CHL, which followed exposure to the MV around the time 
of birth [33, 34]. They also suggest sporadic cases of CHL regression, occurring after 
acute measles infection or an MV vaccine [35–38]. Moreover, viral childhood infections, 
including measles, have been reported to protect from CHL occurrence [39].
Early clinical correlations exhibit more females, more NS-CHL, and more early 
stage cases, among patients with positive MV expression in their lymph node tis-
sues. Nevertheless, positive MV expression in CHL seems to be related with a worse 
prognosis. One cannot refute the loss of the advantage conferred to the above vari-
ables by an MV infection, as expressed in the H/RS cells of CHL. Any mechanism 
involving the MV in CHL, if uncovered, should correlate with a worse outcome of 
the malignancy.
5. The refutation episode
Two years following the publication of the above-mentioned article and several 
months after the presentation of a poster at the Hodgkin Lymphoma Meeting in 
Kiel, a scientist, from Germany, contacted me indirectly, informing me that he 
wanted to investigate our findings. He proposed to find out whether he could repro-
duce our data in his lab. He also requested to make any fresh-frozen CHL tissues 
available to him, mainly those which showed an MV-antigen positivity.
In their labs, the German scientists had collected 44 frozen CHL samples, of 
which, only 18 were selected for their high quality RNA, as determined by the 
Agilent technology, as well as for classic H/RS cell morphology. Using UV-laser 
beam single cell microdissection, some 100 H/RS cells were pooled for each experi-
ment. Total RNA was extracted and RT-PCR was performed with primers from 
three MV genes, which were different from those we had used in Israel [40].
Five CHL-derived cell lines were found to be negative for the three MV tran-
scripts. Moreover, the 18 selected German cases did not show, either, evidence of 
any of the three viral transcripts. The GAPDH gene, used as a housekeeper gene 
for these experiments, displayed a large amount of RNA. At this point, the German 
group had received the 22 snap-frozen CHL samples from our laboratory. The cases 
had been chosen, as requested for their positive MV antigens, as shown on FFPE 
tissues. However, the selection highlighted only 7 of these cases, chosen for the high 
RNA quality and the classic H/RS cell features [40].
Factor Odds ratio 95% CI p Value
Gender 1.32 0.34–5.18 0.69
Stage 13.67 2.3–80.5 0.004
Bcl-2 0.34 0.08–1.44 0.34
MV+; EBV− 10.05 0.98–103.47 0.05
MV−; EBV+ 1.53 0.07–35.44 0.79
MV−; EBV− 15.2 1.05–220.3 0.04
Table 3. 
Multivariable logistic regression model of association of prognostic factors with dying of HL in 89 patients.
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All 25 RNA samples disclosed negative results with the three MV transcripts, as 
studied in Essen labs. Back to Israel, 5 of 12 German histological unstained slides, 
subjected to IHC, were found to express MV antigens in the H/RS cells. A similar 
discrepancy in favor of IHC was also obtained in our series (Table 4).
The German scientists invited one of my colleagues and myself to co-author 
their manuscript. At every stage, we were reluctant to accept the invitation, due to 
the concern for a permanent damage to our hypothesis. Moreover, we did not curb 
our criticism, which covered several aspects of the manuscript. Prominent among 
these was the tight selection of the cases (both those from Germany and Israel). The 
methods used in Essen differed markedly from ours, notably the single cell micro-
dissection, a different strategy for the RT-PCR and the choice of primers. Following 
our criticism, minor changes were introduced, but the German group did not go all 
the way: “….due to their worry that the manuscript will lose its sharp edge and might 
not be accepted by a highly rated journal.”
The Scott collaborators of the Essen scientists reported above selected a group 
of patients, many of whom having suffered from measles, mainly as children. We 
consider this selection as counterproductive, since these patients should have been 
protected from the development of CHL. The very fact that they were not refutes the 
prevalent thesis that exposure of a child, aged 1–4 years, to MV infection protects the 
subject from CHL at a young-adult age [41]. The Scottish group may have had their 
own agenda, which might have unsettled the question raised by us. In addition, the 
antibody used by the Scott group is problematic: the clone 49–41 was purchased by us 
from Argene-Biosoft, Varilhes, France (# 11-045). It was not an anti-nucleoprotein 
antibody, as stated, and was positive in our lab for 37 of our 72 CHL cases (data not 
shown). Moreover, not unlike the German scientists, the Scotts used the GAPDH gene 
as a housekeeping gene, and we have already mentioned why it was not appropriate.
I have to admit, that we not only considered ourselves as the minor partner, 
but that we were such indeed! We had been recurrently reassured by the German 
scientists and by then had our two names included in the manuscript as co-authors. 
However, when we read the finalized doublet articles (in addition, the article by 
Wilson et al., weighted heavily on the balance) [41], published in the International 
Journal of Cancer, we realized that we had made a huge mistake.
The days which followed the double publication were crucial, since we were not 
sure, as co-authors, whether we were entitled to carry out an “insider” censure. When 
we read the final paper, we grasped the experience in terms of a possible deception. In 
addition to the impediments mentioned above, we also noted that the housekeeping 
gene, the GAPDH, might not be an adequate choice at all, since we had shown that 
CHL is most probably of low MV-RNA abundance. In contrast, the Essen group had 
described in relation with GAPDH a large amount of RNA [40]. Moreover, of the 
seven Israeli cases, selected for the experiment in Germany, five had been shown by 
us to present a faint MV-RNA positivity only (two) or were negative (three).
NP-MV HA-MV
Positive/n (%) Positive/n (%)
RT-PCR 1/16 (6.25) 7/21 (33.3)
ISH 7/14 (50) 4/7 (57.1)
IHC 25/29 (86.2) 20/29 (68.9)
NP, nucleoprotein; HA, hemagglutinin; MV, measles virus; RT-PCR, reverse transcriptase-polymerase chain reaction; 
ISH, in situ hybridization; and IHC, immunohistochemistry.
Table 4. 
Comparison of results obtained by three assays.
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An independent putative evidence for a role of the MV in carcinogenesis is that 
part of the MV proteins that interacts with and stabilizes the Pirh2 protein, an ubiq-
uitin E3 ligase, by preventing its ubiquitination. Pirh2 indeed negatively regulates 
p53 by targeting it for degradation in the proteasome.
Altogether, our criticism of the article, in which we took officially a part, is in 
principle that the German scientists carried out an investigation, which was by their 
declared intention, a duplication of our own research [3]. However, their study was 
anything, except a duplicate of ours! It stands out independently, with major flaws, 
notably a very strong selection of cases, the use of questionable primers of a housekeep-
ing gene which is not appropriate for the expected amount of retrieved MV-RNA. It is 
of note that when confronted with our criticism regarding the manuscript, the German 
group seemed to agree, but did not modify the manuscript: “…for fear of weakening our 
data”. Moreover, they insisted on mentioning the relevance of the findings to the CHL 
pathogenesis, which was not appropriate at this stage nor was it agreed upon [40]!
At this point, we insist that the impact of the European group refutation, on 
a possible role of MV in CHL, was extremely ruinous to our position and thesis. 
Moreover, its repercussions are felt to this day: for the reasons mentioned above, not 
a single investigator has accepted to engage in this project anymore, together with us 
or independently. By so doing, the two research groups have categorically “buried” 
our hypothesis. At the same time, we felt a release from the constraints which might 
have led us freeze in our position and we allowed ourselves again to indulge in the 
research concerning the measles virus and cancer. Therefore, we first wrote a review 
on our experience, as described above [42, 43].
6. New evidence
We set out to delve into endometrial carcinoma (EC), looking for the footprints 
of the MV in this cancer. Our cohort of EC included 49 patients, 36 of whom had 
a known follow-up. Using IHC and several anti-MV antibodies, we disclosed that 
26 of the 36 (72%) did express MV antigens in tumor cells, mainly in type I EC 
(Figure 6). In addition, 16/21 of the patients displayed positivity for MV-RNA by 
ISH. When type II EC was allied with MV, then deeper myometrial invasion and a 
higher mortality were evident [44].
Our next endeavor concerned the possible role of MV in lung cancer. Our interest 
was first raised by the probable relevance of Pirh2 in lung cancer. Indeed, Pirh2, an 
E3 ubiquitin ligase, was found to be expressed in lung cancer, in which it inhibits p53 
[45]. It was later found that the P-protein of the MV inhibited the function of Pirh2 
(see description in [48]). This indirect association between lung cancer, Pirh2 and p53, 
and MV led us to the following study. We identified 65 non-small cell lung cancers, 
for which FFPE tissues were available over 10 years. We limited our study to the IHC 
analysis with several anti-MV antibodies (Figure 7). Of the cases included, 54/65 were 
positive for MV antigens. These 54 positive cases were associated with older patient 
age, with positive Pirh2 expression, as well as with an improved survival [46].
The following study concerned breast cancer and the MV-IHC expression. We 
identified 131 breast cancer cases, with preserved FFPE tissues. Of these cases, 64% were 
positive for the MV antigens (Figure 8). Positive MV expression was associated with ER 
(p = 0.018); with Ki-67 < 40% (p = 0.029); with low or intermediate grade (p = 0.037); 
with age < 50 (p = 0.039); and with p53 overexpression (p = 0.049) (Table 5). It seems, 
therefore, that the MV may play a role in the development of this cancer [47].
We have speculated whether the MV phosphoprotein, through its relation with 
the Pirh2, ubiquitin ligase, by itself negatively related with the p53 expression, may 
have more relevance, a priori, than other MV antigens to the pathogenesis of the 
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Table 4. 
Comparison of results obtained by three assays.
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An independent putative evidence for a role of the MV in carcinogenesis is that 
part of the MV proteins that interacts with and stabilizes the Pirh2 protein, an ubiq-
uitin E3 ligase, by preventing its ubiquitination. Pirh2 indeed negatively regulates 
p53 by targeting it for degradation in the proteasome.
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ing gene which is not appropriate for the expected amount of retrieved MV-RNA. It is 
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6. New evidence
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of the MV in this cancer. Our cohort of EC included 49 patients, 36 of whom had 
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analysis with several anti-MV antibodies (Figure 7). Of the cases included, 54/65 were 
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(p = 0.018); with Ki-67 < 40% (p = 0.029); with low or intermediate grade (p = 0.037); 
with age < 50 (p = 0.039); and with p53 overexpression (p = 0.049) (Table 5). It seems, 
therefore, that the MV may play a role in the development of this cancer [47].
We have speculated whether the MV phosphoprotein, through its relation with 
the Pirh2, ubiquitin ligase, by itself negatively related with the p53 expression, may 
have more relevance, a priori, than other MV antigens to the pathogenesis of the 
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MV-associated cancer [48]. We therefore purchased a robust anti-MV-phosphopro-
tein antibody (9H4): sc-101,356, Santa Cruz Biotechnology, and used it by Western 
blot, first, to determine whether we could find a variance between the different 
types of lung cancers and in addition to determine whether the normal lung tissues 
around the tumor did express the MV. But, the distribution of lung cancer types in 
our cohort was clearly in favor of adenocarcinoma, which expressed the P-MV in 11 
patients (84.6%). This was also the rate of its expression in the normal lung tissue 
Figure 7. 
Lung cancer—positive for MV. a. Adenocarcinoma. b. Squamous cell carcinoma (IHC with DAB × 240).
Figure 6. 
Endometrial carcinoma—MV expression in tumor cells and in normal endometrium. a. Cytoplasmic HA-MV 
antigen is positive. b. Positive immunostain for NP-MV antigen. c. ISH positivity for NP-MV in tumoral 
glands. d. ISH positivity of surface and glandular normal epithelium of the case shown in c.
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Figure 8. 
Breast cancer is positive for measles virus antigens. a and c. Negative controls. b and d. Positive immunostains 
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(Table 6; Figure 9). The second step was to look for the expression of the P-MV in 
a tissue microarray (one tissue microarray slide). We compared 10 lung cancers, 13 
colon cancers, 14 stomach cancers, and 15 breast cancers. Breast cancer expressed 
the MV antigen in 75% in the nucleus and 50% in the cytoplasm. Stomach cancers 
expressed the antigen in 73.7% in the nucleus and 21% in the cytoplasm. Colon 
cancers expressed the MV in 68.4% in the nucleus (Table 7). The tissue microar-
ray study had demonstrated a nuclear expression of MV antigens, of which we 
have not been aware before. This may be due on the one hand to the tiny size of 
the tissue section. On the other hand, it may be specific to the present anti-P-MV 
antibody. In any case, various immunostains have shown a marked shuttling of 
antigens between cytoplasm and nucleus in various tissue sections and with varied 
antigens [49] (Table 7).
Our experience with melanoma and benign melanocytic nevi is shown in 
Table 8. The table shows the expression of several MV antigens and of Pirh2. The 
expression of NP-MV is the strongest and resembles that of Pirh2. A similar trend, 
but with a more limited expression, is found in benign melanocytic nevi. It is of 
note that the expression of the P-protein in melanomas is the mirror image of that 
of the NP-MV antigen. This was a preliminary exercise and no follow-up is yet 
Pathology Positive (%) Negative (%)
Adenocarcinoma 11 (84.6%) 2 (15.4%)
Squamous cell carcinoma 3 (100%) 0
Large cell carcinoma 1 (100%) 0
Bronchioloalveolar carcinoma 1 (100%) 0
Table 6. 
Western blotting using a phosphoprotein-MV antibody.
Figure 9. 
Western blotting with an antiphosphoprotein-MV antibody on fresh frozen tissues of non-small cell lung cancer. 
Most cases show positive expression both in tumor tissue (T) and in nonadjacent nonneoplastic lung tissue (H). 
In a few cases, the MV expression is found in the tumor only.
Positive staining % Negative staining %
Organ Nucleus Cytoplasm Stroma Nucleus Cytoplasm Stroma
Lung 10 (52.6%) 2 (11.1%) 0 9 (47.4%) 16 (88.9%) 18 (100%)
Colon 13 (68.4%) 7 (36.8%) 4 (23.5%) 6 (31.6%) 12 (63.2%) 13 (76.5%)
Stomach 14 (73.7%) 4 (21%) 0 5 (26.3%) 15 (79%) 19 (100%)
Breast 15 (75%) 10 (50%) 2 (10%) 5 (25%) 10 (50%) 18 (90%)
Table 7. 
Tissue microarray using a phosphoprotein-MV antibody.
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available. The positivity of 23 benign nevi for NP-MV should be investigated to 
exclude evidence of a pre-malignant condition.
At this stage, we were motivated to determine whether some categories of 
tumors might be uniformly negative for MV antigens. One limitation is that these 
tumors were often showed with a restricted sampling. In our original study, we 
included 25 NHLs by IHC and 7 cases of non-Hodgkin lymphoma by RT-PCR. They 
were all negative for MV. Only later did we find an interest in ALK-positive ana-
plastic large cell lymphomas in this regard. In contrast, these lymphomas were 
predominantly positive for MV. A large scale study of seminomas showed negativ-
ity for the MV antigens. Glioblastomas and mesotheliomas were negative for the 
antigens (Samuel Ariad, personal communication). I later examined small samples 
of the following tumors which were also negative for the MV antigen: Merkel-cell 
tumors, hepatocellular carcinoma, malignant mixed mesodermal tumors, and 
desmoid tumor.
In 2010, we revised and expanded a prior study on the role of apoptosis in CHL 
[50, 51]. This was undertaken in the light of a consensual point of view: it has 
been stated that apoptosis in CHL is arrested; this is carried out not only with the 
help of the NF-κB machinery but also through the expression of EBV-LMP1 that 
inhibits apoptosis [52–55]. The consensus further determines that this apoptosis 
hindrance is necessary, since tumor cells in CHL are B cells which cannot express 
the B-cell receptor (in physiologic conditions, such cells have a strong tendency 
to die in apoptosis). Thus, apoptosis inhibition is a pre-condition for the survival 
of H/RS cells [56]. However, in our revision, we found inhibition of H/RS cells 
apoptosis in 55% of the 217 cases only. Our findings also suggested that NF-κB, 
specifically the p65 protein, as well as EBV/LMP1 expression did not correlate 
with apoptosis arrest, in contrast with the consensus view [57]. Of note, it has 
been shown that although the presence of canonical NF-κB has been considered 
to be implied, it is the noncanonical NF-κB, which is of predominant relevance 
in CHL [51]. In the revision we have shown that the most significant association 
of H/RS cell apoptosis was with p53, the negative expression of which was related 
with a high apoptotic index (p = 0.001). We looked for a link between positive MV 
expression and factors related with apoptosis. Associations with apoptotic index 
less than median (p = 0.005), with MDM2-positive (p = 0.028) and with IκB-
positive (p = 0.0001), were displayed. Viruses have a propensity to regulate the 
apoptotic mechanisms of the infected cell. We have hereby proposed a pathogenic 
mechanism, involving the MV and that is effective in the modulation of apoptosis, 
at least in CHL [51].
Antigen Level Melanoma Benign nevi P value
NP-MV Pos. 46 23
Neg. 10 1 0.16
P-protein Pos. 19 10
Neg. 36 12 0.37
HA-MV Pos. 19 7
Neg. 3 1 1.00
Pirh-2 Pos. 44 19
Neg. 12 6 0.79
Table 8. 
Melanoma and measles virus.
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7. The atypical measles syndrome
In contrast with the classic measles infection, the atypical measles syndrome 
occurs in older patients, often presenting with a heterogeneous rash, pulmonary 
infiltrates, hepatic dysfunction, and eosinophilia. The formation of immune 
complexes has been proposed as responsible for the manifestations of the syndrome 
[58]. This self-limiting disease, may show, however, long lasting, asymptomatic pul-
monary nodules. An immune waning is suspected to occur in this disorder, though 
such an event has been refuted with measles virus infection at large. Officially, 
patients with this syndrome have been reported as recently as 2015 [59].
The atypical measles syndrome (AMS) stands out when compared with classic 
measles for the following reasons.
AMS presents at an older age, often with a high and prolonged fever. A poly-
morphic rash starts in the hands and feet. In the lungs, this disorder shows nodular 
infiltrates together with swollen hilar lymph nodes. These changes may regress 
suddenly. Liver function tests are often abnormal in AMS. Eosinophilia is frequent. 
This disease entity was first described in 1963, following the vaccination with the 
formalin inactivated measles virus (FIMV) vaccine. A subsequent exposure to the 
wild type MV has often been identified. The FIMV vaccine is said to have been 
withdrawn in 1967, but new cases of AMS were still reported in 2015 [59].
Clinically, the AMS does not resemble the classic MV disease and is usually mild. 
GPs have difficulties in making the diagnosis in real time. Anti-MV antibody titers 
are higher than 1:160, which is very unusual for classic measles. In AMS, Koplik 
spots are frequent and mostly will last 5–7 days, while they last rarely more than 
2 days in the classic disease. Photophobia is rarely present in AMS. AMS is probably 
not contagious [60].
While most cases of AMS in the 1960s were associated with FIMV, the more 
recent occurrences have been associated with the live attenuated measles vaccine 
(LAV). Vaccination with FIMV had offered protection for a few months, after 
which the titers dropped suddenly [61]. We have suggested that this drop of anti-
body titers is most consistent with a humoral immunity waning. Cases of AMS with 
prior LAV vaccine have been reported, which are consistent with secondary vaccine 
failure. Such cases have been suggested to follow a prolonged exposure to an acute 
measles patient [62].
To confirm the ease by which the diagnosis of AMS is missed, 291 recruits were 
diagnosed with measles in 1987. They were young adults, with abdominal pain, 
diarrhea, and vomiting (33%); Koplik spots lasting a mean 7 days; and abnormal 
liver function tests (86%). The diagnosis of AMS was missed. Retrospectively, 
this was most certainly the diagnosis, although no anti-MV titers have been 
reported [63].
In 2015, Levine et al. reported on the status of the measles immunity, 20 years 
after the two-dose MMR vaccine was introduced. Of the cohort of recruits in 1996, 
95.6% had shown positive anti-MV antibodies. In 2007, this positive data had 
dropped to 85%. Although the authors did not dare to make the statement, this 
reflected a state of waning immunity, to our opinion [64].
To summarize this issue, we have showed that the AMS differs from typical 
measles by various features. This is probably a disorder of immunologic nature, 
involving immune complexes. The AMS is presently rare, but to our opinion, 
this may be due to a notable under-diagnosis. The association between the AMS 
pathogenesis and immune waning should be confirmed. It is not excluded that this 
disorder be related with carcinogenesis as well [65, 66], as it has been proposed that 
a persistent viral infection is required for virus-associated carcinogenesis [67] and 
that a waning immunity might lead to a persistent MV infection.
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8. Conclusions and prospects
A relationship between MV expression and CHL was provisionally established 
on IHC [positive with two antigens or more in 82 of 154 CHL patients]; on RT-PCR 
[positive in 4 of 15 cases for HA-MV RNA; for 2 of 16 NP-MV RNA], and on in situ 
hybridization [for 2 of 7 CHL with HA-MV RNA; in 8 of 21 for NP-MV RNA], as 
well as with several other malignancies. When focusing on CHL, this association 
may even be causally linked: apoptosis regulation by the MV may be one of the 
supportive mechanisms. Our findings are probably sustained by an increasing CHL 
morbidity related with a progressing occurrence of measles in young adults, in 
Israel [68], in Quebec [69], and in Connecticut [70], in which frequent outbursts of 
measles are described.
A clinicopathological correlation, based on the IHC results, was chosen, mainly 
due to the frequent results as compared with RT-PCR and in situ hybridization. In 
this part of our study, we confirmed an association between CHL and the MV. More 
females, NS-CHL cases, and more patients in the early stages of their disease were 
linked to the expression of MV in their tissues. In spite of these variables being, as 
a rule, correlated with a better prognosis, when they are associated with a positive 
measles expression, the net effect is a poor prognosis [3].
Regarding the refutation of our findings and conclusions by the German group, 
this might have been an occasion for further learning. However, the repercussions 
thereof, on our thesis and our findings, were such that no future was available for 
us in this domain. As a colleague described it, our position and our theory had been 
buried. Moreover, I never understood why it was done in that most unpleasant way.
A chapter on the atypical measles syndrome was introduced at the end of the 
study. This disorder is related with measles and with the MV, but the link has not 
been clarified completely. Most of the AMS features, clinical, radiological, and bio-
logical, differ completely from those of measles. While measles is predominantly an 
infectious disease, and is highly contagious, AMS is probably not contagious, with 
its pathogenesis probably based on the formation of immune complexes. One of 
the highlights of the AMS is an anti-measles antibody titer of 1:160 or higher, much 
beyond that found in measles. Our interest, at this point, laid in evidence pointing 
toward immunity waning, as an essential component of AMS. Moreover, in the 
presence of a sharp drop in the titer, following mainly the FIMV vaccination, as 
well as occasionally that of the LAV vaccine, the subject might be submitted to the 
protracted exposition to an acute measles patient. So far, we are not aware of cancer 
developing in the context of AMS cases, but, since this disorder is often missed, it 
might be worthwhile looking for cases of cancer within such a context [60].
The prospects and suggestions for proceeding with our research include an epide-
miologic study as well as the duplication of our basic investigation, but this once by 
scientists of good faith. The epidemiologic investigation should have 3 components: 
the first two, based on our CHL cohort, about half of which show IHC evidence of the 
MV. Of this population, we will attempt to identify, via the Israeli Ministry of Health 
Registry, patients who had contracted measles as well as those who had been vac-
cinated for MV, including vaccination details. The third will deal with AMS, based on 
the cohorts highlighted by Giladi M et al. [63], and Levine H et al. [64]. Confirmation 
in the first of the diagnosis of AMS, and research of patients with possibly MV-related 
tumors and in the second, confirmation of the relevance to immune waning.
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Israel [68], in Quebec [69], and in Connecticut [70], in which frequent outbursts of 
measles are described.
A clinicopathological correlation, based on the IHC results, was chosen, mainly 
due to the frequent results as compared with RT-PCR and in situ hybridization. In 
this part of our study, we confirmed an association between CHL and the MV. More 
females, NS-CHL cases, and more patients in the early stages of their disease were 
linked to the expression of MV in their tissues. In spite of these variables being, as 
a rule, correlated with a better prognosis, when they are associated with a positive 
measles expression, the net effect is a poor prognosis [3].
Regarding the refutation of our findings and conclusions by the German group, 
this might have been an occasion for further learning. However, the repercussions 
thereof, on our thesis and our findings, were such that no future was available for 
us in this domain. As a colleague described it, our position and our theory had been 
buried. Moreover, I never understood why it was done in that most unpleasant way.
A chapter on the atypical measles syndrome was introduced at the end of the 
study. This disorder is related with measles and with the MV, but the link has not 
been clarified completely. Most of the AMS features, clinical, radiological, and bio-
logical, differ completely from those of measles. While measles is predominantly an 
infectious disease, and is highly contagious, AMS is probably not contagious, with 
its pathogenesis probably based on the formation of immune complexes. One of 
the highlights of the AMS is an anti-measles antibody titer of 1:160 or higher, much 
beyond that found in measles. Our interest, at this point, laid in evidence pointing 
toward immunity waning, as an essential component of AMS. Moreover, in the 
presence of a sharp drop in the titer, following mainly the FIMV vaccination, as 
well as occasionally that of the LAV vaccine, the subject might be submitted to the 
protracted exposition to an acute measles patient. So far, we are not aware of cancer 
developing in the context of AMS cases, but, since this disorder is often missed, it 
might be worthwhile looking for cases of cancer within such a context [60].
The prospects and suggestions for proceeding with our research include an epide-
miologic study as well as the duplication of our basic investigation, but this once by 
scientists of good faith. The epidemiologic investigation should have 3 components: 
the first two, based on our CHL cohort, about half of which show IHC evidence of the 
MV. Of this population, we will attempt to identify, via the Israeli Ministry of Health 
Registry, patients who had contracted measles as well as those who had been vac-
cinated for MV, including vaccination details. The third will deal with AMS, based on 
the cohorts highlighted by Giladi M et al. [63], and Levine H et al. [64]. Confirmation 
in the first of the diagnosis of AMS, and research of patients with possibly MV-related 
tumors and in the second, confirmation of the relevance to immune waning.
Acknowledgements
We thank Kibbutz Sde-Boker for their support.
Viruses and Viral Infections in Developing Countries
154
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Daniel Benharroch
Department of Pathology, Soroka University Medical Center and Faculty of Health 
Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
*Address all correspondence to: danielbenharroch1@gmail.com
Conflict of interest
The author declares no conflict of interest.
Notes/thanks/other declarations
Many warm thanks : Samuel Ariad, Martin Sacks, Yonat Shemer-Avni, Yi-Yi 
Myint, Bracha Rager, Irena Klinkovich, Jacob Gopes, and Eugenia Mejirovski for 
their valuable contribution.
155
A Role for the Measles Virus in Oncology
DOI: http://dx.doi.org/10.5772/intechopen.84342
References
[1] Jaffe ES, Stein H, Swerdlow SH.  
Classic Hodgkin lymphoma. In: 
Swerdlow SH, Campo E, Harris NL, 
Jaffe ES, Pileri SA, Stein H, et al., 
editors. WHO Classification of Tumours 
of Haematopoietic and Lymphoid 
Tissues. 4th ed. update. Lyon: IARC; 
2017. pp. 435-442
[2] Fend F. Classical Hodgkin’s 
lymphoma and related lesions. In: 
Jaffe ES, Arber DA, Campo E, Harris 
NL, Quintanilla-Martinez L, editors. 
Hematopathology. 2nd ed. Philadelphia: 
Elsevier; 2017. pp. 525-545
[3] Benharroch D, Shemer-Avni Y, 
Myint Y-Y, et al. Measles virus: Evidence 
of an association with Hodgkin’s 
disease. British Journal of Cancer. 
2004;91:572-579
[4] Benharroch D, Brousset P, Goldstein J, 
et al. Association of the Epstein-Barr 
virus with Hodgkin’s disease in southern 
Israel. International Journal of Cancer. 
1997;71:138-141
[5] Alexander FE, Jarrett RF, Lawrence D, 
et al. Risk factors for Hodgkin’s disease 
by Epstein-Barr virus (EBV) status: 
Prior infection by EBV and other 
agents. British Journal of Cancer. 
2000;82:1117-1121
[6] Thorley-Lawson DA, Gross A.  
Mechanisms of disease: Persistence 
of Epstein-Barr virus and origin 
of the associated lymphomas. The 
New England Journal of Medicine. 
2004;350:1328-1337
[7] Peek RM, Crabtree JE. Helicobacter 
infection and gastric neoplasia. 
The Journal of Pathology. 
2006;208:233-248
[8] Tlsty TD, Coussens LM. Tumor 
stroma and regulation of cancer 
development. Annual Review of 
Pathology. 2006;1:119-150
[9] Kundu JK, Surth YJ. Inflammation: 
Gearing the journey to cancer. Mutation 
Research. 2008;659:15-30
[10] Knecht H, Berger C, Rothenberg S, 
et al. The role of Epstein-Barr virus in 
neoplastic transformation. Oncology. 
2001;60:289-302
[11] Niedobitek G, Meru DHJ. Epstein-
Barr virus infection and human 
malignancies. International Journal of 
Experimental Pathology. 2001;82:149-170
[12] Benharroch D, Shemer-Avni 
Y, Myint Y-Y, et al. New candidate 
virus in association with Hodgkin’s 
disease. Leukemia & Lymphoma. 
2003;44:605-610
[13] Jarrett RF, Armstrong A, Alexander E.  
Epidemiology of EBV and Hodgkin 
lymphoma. Annals of Oncology. 
1996;7(suppl):5-10
[14] Chang KL, Albujar PF, Chen YY, 
et al. High prevalence of Epstein-Barr 
virus in Reed-Sternberg cells of Hodgkin 
disease occurring in Peru. Blood. 
1993;81:496-501
[15] Gutensohn N, Cole P. Childhood 
social environment and Hodgkin’s 
disease. The New England Journal of 
Medicine. 1981;304:135-140
[16] Glaser SL. Spacial clustering 
of Hodgkin’s disease in the San 
Francisco Bay area. American 
Journal of Epidemiology. 
1990;132(Suppl):s167-s177
[17] Westergaard T, Melbye M, Pedersen JB, 
et al. Birth order, sibship size and the 
risk of Hodgki's disease in children and 
young adults: A population based study 
of 31 million person-years. International 
Journal of Cancer. 1997;72:977-981
[18] Sleckman BG, Mauch PM, 
Ambinder RF, et al. Epstein-Barr virus 
Viruses and Viral Infections in Developing Countries
154
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Daniel Benharroch
Department of Pathology, Soroka University Medical Center and Faculty of Health 
Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
*Address all correspondence to: danielbenharroch1@gmail.com
Conflict of interest
The author declares no conflict of interest.
Notes/thanks/other declarations
Many warm thanks : Samuel Ariad, Martin Sacks, Yonat Shemer-Avni, Yi-Yi 
Myint, Bracha Rager, Irena Klinkovich, Jacob Gopes, and Eugenia Mejirovski for 
their valuable contribution.
155
A Role for the Measles Virus in Oncology
DOI: http://dx.doi.org/10.5772/intechopen.84342
References
[1] Jaffe ES, Stein H, Swerdlow SH.  
Classic Hodgkin lymphoma. In: 
Swerdlow SH, Campo E, Harris NL, 
Jaffe ES, Pileri SA, Stein H, et al., 
editors. WHO Classification of Tumours 
of Haematopoietic and Lymphoid 
Tissues. 4th ed. update. Lyon: IARC; 
2017. pp. 435-442
[2] Fend F. Classical Hodgkin’s 
lymphoma and related lesions. In: 
Jaffe ES, Arber DA, Campo E, Harris 
NL, Quintanilla-Martinez L, editors. 
Hematopathology. 2nd ed. Philadelphia: 
Elsevier; 2017. pp. 525-545
[3] Benharroch D, Shemer-Avni Y, 
Myint Y-Y, et al. Measles virus: Evidence 
of an association with Hodgkin’s 
disease. British Journal of Cancer. 
2004;91:572-579
[4] Benharroch D, Brousset P, Goldstein J, 
et al. Association of the Epstein-Barr 
virus with Hodgkin’s disease in southern 
Israel. International Journal of Cancer. 
1997;71:138-141
[5] Alexander FE, Jarrett RF, Lawrence D, 
et al. Risk factors for Hodgkin’s disease 
by Epstein-Barr virus (EBV) status: 
Prior infection by EBV and other 
agents. British Journal of Cancer. 
2000;82:1117-1121
[6] Thorley-Lawson DA, Gross A.  
Mechanisms of disease: Persistence 
of Epstein-Barr virus and origin 
of the associated lymphomas. The 
New England Journal of Medicine. 
2004;350:1328-1337
[7] Peek RM, Crabtree JE. Helicobacter 
infection and gastric neoplasia. 
The Journal of Pathology. 
2006;208:233-248
[8] Tlsty TD, Coussens LM. Tumor 
stroma and regulation of cancer 
development. Annual Review of 
Pathology. 2006;1:119-150
[9] Kundu JK, Surth YJ. Inflammation: 
Gearing the journey to cancer. Mutation 
Research. 2008;659:15-30
[10] Knecht H, Berger C, Rothenberg S, 
et al. The role of Epstein-Barr virus in 
neoplastic transformation. Oncology. 
2001;60:289-302
[11] Niedobitek G, Meru DHJ. Epstein-
Barr virus infection and human 
malignancies. International Journal of 
Experimental Pathology. 2001;82:149-170
[12] Benharroch D, Shemer-Avni 
Y, Myint Y-Y, et al. New candidate 
virus in association with Hodgkin’s 
disease. Leukemia & Lymphoma. 
2003;44:605-610
[13] Jarrett RF, Armstrong A, Alexander E.  
Epidemiology of EBV and Hodgkin 
lymphoma. Annals of Oncology. 
1996;7(suppl):5-10
[14] Chang KL, Albujar PF, Chen YY, 
et al. High prevalence of Epstein-Barr 
virus in Reed-Sternberg cells of Hodgkin 
disease occurring in Peru. Blood. 
1993;81:496-501
[15] Gutensohn N, Cole P. Childhood 
social environment and Hodgkin’s 
disease. The New England Journal of 
Medicine. 1981;304:135-140
[16] Glaser SL. Spacial clustering 
of Hodgkin’s disease in the San 
Francisco Bay area. American 
Journal of Epidemiology. 
1990;132(Suppl):s167-s177
[17] Westergaard T, Melbye M, Pedersen JB, 
et al. Birth order, sibship size and the 
risk of Hodgki's disease in children and 
young adults: A population based study 
of 31 million person-years. International 
Journal of Cancer. 1997;72:977-981
[18] Sleckman BG, Mauch PM, 
Ambinder RF, et al. Epstein-Barr virus 
Viruses and Viral Infections in Developing Countries
156
in Hodgkin’s disease: Correlation of risk 
factors and disease characteristics with 
molecular evidence of viral infection. 
Cancer Epidemiology, Biomarkers & 
Prevention. 1998;7:1117-1121
[19] Glaser SL, Clark CA, Nugent RA, 
et al. Social class and risk of Hodgkin’s 
disease in young adult women in 1988-
94. International Journal of Cancer. 
2002;98:110-117
[20] Torreli G, Marasca R, Lupi M, 
et al. Human herpesvirus-6 in human 
lymphomas: Identification of specific 
sequences in Hodgkin’s lymphoma 
by polymerase chain reaction. Blood. 
1991;77:2251-2258
[21] Armstrong AA, Shield L, Gallagher 
A, et al. Lack of involvement of known 
oncogenic DNA viruses in Epstein-Barr 
negative Hodgkin’s disease. British 
Journal of Cancer. 1998;77:1045-1047
[22] Berneman ZN, Torreli G, Luppi M, 
et al. Absence of a directly causative role 
for herpesvirus-7 in human lymphoma 
and a review of human herpesvirus-6 in 
human malignancy. Annals of 
Hematology. 1998;77:275-278
[23] Cozen W, Masood R, Mack T, et al. 
Seroprevalence of Kaposi’s sarcoma-
associated herpesvirus antibody in 
young adult Hodgkin’s disease. Blood. 
1998;91:724
[24] Jarret RF, MacKenzie J. Epstein-Barr 
virus and other candidate viruses in 
the pathogenesis of Hodgkin’s disease. 
Seminars in Hematology. 1999;36:260-269
[25] Schmidt CA, Oettle H, Peng R, 
et al. Presence of β- and γ-herpes virus 
DNA in Hodgkin’s disease. Leukemia. 
2000;24:865-870
[26] Gallager A, Perry J, Shield L, et al. 
Viruses and Hodgkin’s disease: No 
evidence of novel herpesvirus in non-
EBV-associated lesions. International 
Journal of Cancer. 2002;101:259-264
[27] Gopas J, Shemer-Avni Y, Levy A,  
et al. Measles virus expression in 
Hodgkin’s lymphoma. Proceedings of 
the American Association for Cancer 
Research. 2001;42:111 (Abstract)
[28] Kamel OW, Le Brun DP, Berry GJ, 
et al. Warthin-Finkeldey polykaryotes 
demonstrate a T-cell immunophenotype. 
American Journal of Clinical Pathology. 
1992;97:179-183
[29] Griffin DE, Pan CH. Measles virus. 
In: Griffin DE, Oldstone MBA, editors. 
Measles Pathogenesis and Control. 
Berlin: Springer; 2009
[30] Birrer MJ, Bloom BR, Udem R.  
Characterization of measles 
polypeptides by monoclonal 
antibodies. Virology. 
1981;108:381-390
[31] Schneider-Schaulies S, Lieber UG, 
Segev Y, et al. Antibody-dependent 
transcriptional regulation of measles 
virus in persistently infected 
neural cells. Journal of Virology. 
1992;66:5534-5541
[32] Ogata A, Czub S, Ogata S, et al. 
Absence of measles virus receptor 
(CD46) in lesions of subacute 
sclerosis panencephalitis brains. Acta 
Neuropathologica. 1997;94:444-449
[33] Dickinson HO, Tyari TA, Parker L.  
Childhood solid tumors in relation 
to infections in the community in 
Cumbria during pregnancy and 
around the time of birth. British 
Journal of Cancer. 2002;87: 
746-750
[34] Tyari TA, Dickinson HO, Parker L.  
Childhood cancer in relation with infections 
in the community during pregnancy and 
around the time of birth. International 
Journal of Cancer. 2003;104:772-777
[35] Zygiert Z. Hodgkin’s disease: 
Remission after measles. Lancet. 
1971;1(7699):593
157
A Role for the Measles Virus in Oncology
DOI: http://dx.doi.org/10.5772/intechopen.84342
[36] Mota HC. Infantile Hodgkin’s 
disease: Remission after measles. British 
Medical Journal. 1973;2:241
[37] Zwitter M. Hodgkin’s disease: 
Therapeutic role of measles vaccine. 
American Journal of Medicine. 
1984;77:A49, A52, A64
[38] Schattner A. Therapeutic role of 
measles vaccine in Hodgkin’s disease. 
Lancet. 1984;1(8469):171
[39] Cozen W, Hamilton AS, Zaho P, 
et al. A protective role for early oral 
exposures in the etiology of young 
adult Hodgkin’s lymphoma. Blood. 
2009;114:4014-4020
[40] Maggio E, Benharroch D, Gopas J, 
et al. Absence of measles virus genome 
and transcripts in Hodgkin/Reed-
Sternberg cells of a cohort of Hodgkin 
lymphoma patients. International 
Journal of Cancer. 2007;121:448-453
[41] Wilson KS, Freeland JML, Gallagher 
A, et al. Measles virus and classical 
Hodgkin lymphoma: No evidence for a 
direct association. International Journal 
of Cancer. 2007;121:242-247
[42] Karlin D, Belshaw R. Detecting 
remote sequence homology in 
disorsered proteins: Discovery of 
conserved motifs in the N-termini of 
Mononrgavirales phosphoproteins. 
PLoS One. 2012;7:e31719
[43] Kruzniar A, van Ham RC, Pongor S, 
et al. The quest for orthologs: Finding 
the corresponding gene across genomes. 
Trends in Genetics. 2008;24:539-551
[44] Benharroch D, Klinkovich I, Piura B, 
et al. Evidence of measles virus 
antigens and RNA in endometrial 
cancer. European Journal of Obstetrics, 
Gynecology, and Reproductive Biology. 
2009;147:206-209
[45] Duan W, Gao L, Druhon LJ, et al. 
Expression of Pirh2, a newly identified 
ubiquitin protein ligase in lung cancer. 
Journal of the National Cancer Institute. 
2004;96:1718-1721
[46] Sion-Vardy N, Lazarev I, Delgado 
B, et al. Measles virus: Evidence 
for association with lung cancer. 
Experimental Lung Research. 
2009;35:701-712
[47] Ariad S, Milk N, Bolotin A, 
et al. Measles virus antigens in 
breast cancer. Anticancer Research. 
2011;31:913-920
[48] Chen M, Cortay J-C, Logan IR, 
et al. Inhibition of ubiquitination 
and stabilisation of human ubiquitin 
E3 ligase Pirh2 by measles virus 
phosphoprotein. Journal of Virology. 
2005;79:11824-11836
[49] Nihie T, Nagata K, Takeuchi K. The 
C protein of wild-type measles virus 
has the ability to shuttle between the 
nucleus and the cytoplasm. Microbes 
and Infection. 2007;9:344-354
[50] Benharroch D, Levy A, Prinsloo I, 
et al. Apoptotic index as a prognostic 
factor in Hodgkin’s disease. Leukemia & 
Lymphoma. 1999;33:351-359
[51] Benharroch D, Einav I, Feldman A,  
et al. Apoptosis of Hodgkin-Reed-
Sternberg cells in classical Hodgkin 
lymphoma revisited. Acta Pathologica, 
Microbiologica, et Immunologica 
Scandinavica. 2010;118:339-345
[52] Marafioti T, Hummel M, Foss HD, 
et al. Hodgkin and reed-Sternberg 
cells represent an expansion of 
a single clone originating from 
a germinal center B-cell with 
functional Ig gene rearrangement 
but defective Ig transcription. Blood. 
2000;95:1443-1450
[53] Kuppers R, Rajewsky K. The origin 
of Hodgkin-Reed-Sternberg cells in 
Hodgkin’s disease. Annual Review of 
Immunology. 1998;16:471-493
Viruses and Viral Infections in Developing Countries
156
in Hodgkin’s disease: Correlation of risk 
factors and disease characteristics with 
molecular evidence of viral infection. 
Cancer Epidemiology, Biomarkers & 
Prevention. 1998;7:1117-1121
[19] Glaser SL, Clark CA, Nugent RA, 
et al. Social class and risk of Hodgkin’s 
disease in young adult women in 1988-
94. International Journal of Cancer. 
2002;98:110-117
[20] Torreli G, Marasca R, Lupi M, 
et al. Human herpesvirus-6 in human 
lymphomas: Identification of specific 
sequences in Hodgkin’s lymphoma 
by polymerase chain reaction. Blood. 
1991;77:2251-2258
[21] Armstrong AA, Shield L, Gallagher 
A, et al. Lack of involvement of known 
oncogenic DNA viruses in Epstein-Barr 
negative Hodgkin’s disease. British 
Journal of Cancer. 1998;77:1045-1047
[22] Berneman ZN, Torreli G, Luppi M, 
et al. Absence of a directly causative role 
for herpesvirus-7 in human lymphoma 
and a review of human herpesvirus-6 in 
human malignancy. Annals of 
Hematology. 1998;77:275-278
[23] Cozen W, Masood R, Mack T, et al. 
Seroprevalence of Kaposi’s sarcoma-
associated herpesvirus antibody in 
young adult Hodgkin’s disease. Blood. 
1998;91:724
[24] Jarret RF, MacKenzie J. Epstein-Barr 
virus and other candidate viruses in 
the pathogenesis of Hodgkin’s disease. 
Seminars in Hematology. 1999;36:260-269
[25] Schmidt CA, Oettle H, Peng R, 
et al. Presence of β- and γ-herpes virus 
DNA in Hodgkin’s disease. Leukemia. 
2000;24:865-870
[26] Gallager A, Perry J, Shield L, et al. 
Viruses and Hodgkin’s disease: No 
evidence of novel herpesvirus in non-
EBV-associated lesions. International 
Journal of Cancer. 2002;101:259-264
[27] Gopas J, Shemer-Avni Y, Levy A,  
et al. Measles virus expression in 
Hodgkin’s lymphoma. Proceedings of 
the American Association for Cancer 
Research. 2001;42:111 (Abstract)
[28] Kamel OW, Le Brun DP, Berry GJ, 
et al. Warthin-Finkeldey polykaryotes 
demonstrate a T-cell immunophenotype. 
American Journal of Clinical Pathology. 
1992;97:179-183
[29] Griffin DE, Pan CH. Measles virus. 
In: Griffin DE, Oldstone MBA, editors. 
Measles Pathogenesis and Control. 
Berlin: Springer; 2009
[30] Birrer MJ, Bloom BR, Udem R.  
Characterization of measles 
polypeptides by monoclonal 
antibodies. Virology. 
1981;108:381-390
[31] Schneider-Schaulies S, Lieber UG, 
Segev Y, et al. Antibody-dependent 
transcriptional regulation of measles 
virus in persistently infected 
neural cells. Journal of Virology. 
1992;66:5534-5541
[32] Ogata A, Czub S, Ogata S, et al. 
Absence of measles virus receptor 
(CD46) in lesions of subacute 
sclerosis panencephalitis brains. Acta 
Neuropathologica. 1997;94:444-449
[33] Dickinson HO, Tyari TA, Parker L.  
Childhood solid tumors in relation 
to infections in the community in 
Cumbria during pregnancy and 
around the time of birth. British 
Journal of Cancer. 2002;87: 
746-750
[34] Tyari TA, Dickinson HO, Parker L.  
Childhood cancer in relation with infections 
in the community during pregnancy and 
around the time of birth. International 
Journal of Cancer. 2003;104:772-777
[35] Zygiert Z. Hodgkin’s disease: 
Remission after measles. Lancet. 
1971;1(7699):593
157
A Role for the Measles Virus in Oncology
DOI: http://dx.doi.org/10.5772/intechopen.84342
[36] Mota HC. Infantile Hodgkin’s 
disease: Remission after measles. British 
Medical Journal. 1973;2:241
[37] Zwitter M. Hodgkin’s disease: 
Therapeutic role of measles vaccine. 
American Journal of Medicine. 
1984;77:A49, A52, A64
[38] Schattner A. Therapeutic role of 
measles vaccine in Hodgkin’s disease. 
Lancet. 1984;1(8469):171
[39] Cozen W, Hamilton AS, Zaho P, 
et al. A protective role for early oral 
exposures in the etiology of young 
adult Hodgkin’s lymphoma. Blood. 
2009;114:4014-4020
[40] Maggio E, Benharroch D, Gopas J, 
et al. Absence of measles virus genome 
and transcripts in Hodgkin/Reed-
Sternberg cells of a cohort of Hodgkin 
lymphoma patients. International 
Journal of Cancer. 2007;121:448-453
[41] Wilson KS, Freeland JML, Gallagher 
A, et al. Measles virus and classical 
Hodgkin lymphoma: No evidence for a 
direct association. International Journal 
of Cancer. 2007;121:242-247
[42] Karlin D, Belshaw R. Detecting 
remote sequence homology in 
disorsered proteins: Discovery of 
conserved motifs in the N-termini of 
Mononrgavirales phosphoproteins. 
PLoS One. 2012;7:e31719
[43] Kruzniar A, van Ham RC, Pongor S, 
et al. The quest for orthologs: Finding 
the corresponding gene across genomes. 
Trends in Genetics. 2008;24:539-551
[44] Benharroch D, Klinkovich I, Piura B, 
et al. Evidence of measles virus 
antigens and RNA in endometrial 
cancer. European Journal of Obstetrics, 
Gynecology, and Reproductive Biology. 
2009;147:206-209
[45] Duan W, Gao L, Druhon LJ, et al. 
Expression of Pirh2, a newly identified 
ubiquitin protein ligase in lung cancer. 
Journal of the National Cancer Institute. 
2004;96:1718-1721
[46] Sion-Vardy N, Lazarev I, Delgado 
B, et al. Measles virus: Evidence 
for association with lung cancer. 
Experimental Lung Research. 
2009;35:701-712
[47] Ariad S, Milk N, Bolotin A, 
et al. Measles virus antigens in 
breast cancer. Anticancer Research. 
2011;31:913-920
[48] Chen M, Cortay J-C, Logan IR, 
et al. Inhibition of ubiquitination 
and stabilisation of human ubiquitin 
E3 ligase Pirh2 by measles virus 
phosphoprotein. Journal of Virology. 
2005;79:11824-11836
[49] Nihie T, Nagata K, Takeuchi K. The 
C protein of wild-type measles virus 
has the ability to shuttle between the 
nucleus and the cytoplasm. Microbes 
and Infection. 2007;9:344-354
[50] Benharroch D, Levy A, Prinsloo I, 
et al. Apoptotic index as a prognostic 
factor in Hodgkin’s disease. Leukemia & 
Lymphoma. 1999;33:351-359
[51] Benharroch D, Einav I, Feldman A,  
et al. Apoptosis of Hodgkin-Reed-
Sternberg cells in classical Hodgkin 
lymphoma revisited. Acta Pathologica, 
Microbiologica, et Immunologica 
Scandinavica. 2010;118:339-345
[52] Marafioti T, Hummel M, Foss HD, 
et al. Hodgkin and reed-Sternberg 
cells represent an expansion of 
a single clone originating from 
a germinal center B-cell with 
functional Ig gene rearrangement 
but defective Ig transcription. Blood. 
2000;95:1443-1450
[53] Kuppers R, Rajewsky K. The origin 
of Hodgkin-Reed-Sternberg cells in 
Hodgkin’s disease. Annual Review of 
Immunology. 1998;16:471-493
Viruses and Viral Infections in Developing Countries
158
[54] Kuppers R, Hansmann ML, 
Rajewsky K, et al. Clonality and 
germinal center derivation of 
Hodgkin/Reed-Sternberg cells in 
Hodgkin’s disease. Annals of Oncology. 
1998;9(suppl 5):s17-s20
[55] Kuppers R. Molecular biology of 
Hodgkin’s lymphoma. Advances in 
Cancer Research. 2002;84:277-312
[56] Bargou RC, Emmerich F, 
Krappmann D, et al. Constitutive 
nuclear factor-κB, RelA activation is 
required for proliferation and survival 
of Hodgkin’s disease tumor cells. The 
Journal of Clinical Investigation. 
1997;100:2961-2969
[57] Izban KF, Ergin M, Huang Q , et al. 
Characterization of NF-κB expression 
in Hodgkin’s disease. Modern Pathology. 
2001;14:297-310
[58] Griffin DE, Pan CH. Inactivated 
vaccines. In: Griffin DE, Oldstone 
MBA, editors. Measles Pathogenesis 
and Control. Berlin: Springer; 2009. 
pp. 194-195
[59] Melenotte C, Cassir N, Tessonier L,  
et al. Atypical measles syndrome in 
adults: Still around. BMJ Case Reports. 
2015:2015
[60] Benharroch D. Atypical measles 
syndrome—A brief review. Annals 
of Clinical Cytology and Pathology. 
2016;2:1039-1041
[61] Rauh LW, Schmidt R. Measles 
immunization with killed virus vaccine. 
Serum antibody titers and experience 
with exposure to measles epidemic. 
American Journal of Diseases of 
Children. 1965;109:232-237
[62] Hickman CJ, Hyde TB, Sowers SB, 
et al. Laboratory characterization of 
measles virus infection in previously 
vaccinated and unvaccinated 
individuals. Journal of Infectious 
Diseases. 2011;204:s549-s558
[63] Giladi M, Schulman A, Kedem R, 
et al. Measles in adults: A prospective 
study of 291 consecutive cases. British 
Medical Journal. 1987;295:1314
[64] Levine H, Zarka S, Ankol OE, et al. 
Seroprevalence of measles, mumps 
and rubella among young adults, 
after 20 years of universal 2-dose 
MMR vaccination in Israel. Human 
Vaccines & Immunotherapeutics. 
2015;11:1400-1405
[65] Wood DL, Brunell PA. Measles 
control in the United States: Problems 
of the past and challenges for the 
future. Clinical Microbiology Reviews. 
1995;8:260-267
[66] Kontio M, Jokinen S, Paunio M,  
et al. Waning antibody levels and 
avidity: Implications for the MMR 
vaccine-induced protection. The 
Journal of Infectious Diseases. 
2012;206:1542-1548
[67] Dziurzyski K, Chang SM, 
Heimberger AB, et al. Consensus on 
the role of human cytomegalovirus 
in glioblastoma. Neuro-Oncology. 
2012;14:246-255
[68] Ariad S, Lipshitz I, Benharroch D, 
et al. A sharp rise in the incidence of 
Hodgkin’s lymphoma in young adults in 
Israel. The Israel Medical Association 
Journal. 2009;11:453-455
[69] Liu S, Semensiw R, Waters C, 
et al. Time trends and sex patterns in 
Hodgkin’s disease in Canada, 1970-1995. 
Canadian Journal of Public Health. 
2000;91:188-192
[70] Chen YT, Zheng T, Chou MC, 
et al. The increase in Hodgkin’s disease 
incidence among young adults. 
Experience in Connecticut, 1935-1992. 
Cancer. 1997;79:2209-2218
Viruses and Viral Infections in Developing Countries
158
[54] Kuppers R, Hansmann ML, 
Rajewsky K, et al. Clonality and 
germinal center derivation of 
Hodgkin/Reed-Sternberg cells in 
Hodgkin’s disease. Annals of Oncology. 
1998;9(suppl 5):s17-s20
[55] Kuppers R. Molecular biology of 
Hodgkin’s lymphoma. Advances in 
Cancer Research. 2002;84:277-312
[56] Bargou RC, Emmerich F, 
Krappmann D, et al. Constitutive 
nuclear factor-κB, RelA activation is 
required for proliferation and survival 
of Hodgkin’s disease tumor cells. The 
Journal of Clinical Investigation. 
1997;100:2961-2969
[57] Izban KF, Ergin M, Huang Q , et al. 
Characterization of NF-κB expression 
in Hodgkin’s disease. Modern Pathology. 
2001;14:297-310
[58] Griffin DE, Pan CH. Inactivated 
vaccines. In: Griffin DE, Oldstone 
MBA, editors. Measles Pathogenesis 
and Control. Berlin: Springer; 2009. 
pp. 194-195
[59] Melenotte C, Cassir N, Tessonier L,  
et al. Atypical measles syndrome in 
adults: Still around. BMJ Case Reports. 
2015:2015
[60] Benharroch D. Atypical measles 
syndrome—A brief review. Annals 
of Clinical Cytology and Pathology. 
2016;2:1039-1041
[61] Rauh LW, Schmidt R. Measles 
immunization with killed virus vaccine. 
Serum antibody titers and experience 
with exposure to measles epidemic. 
American Journal of Diseases of 
Children. 1965;109:232-237
[62] Hickman CJ, Hyde TB, Sowers SB, 
et al. Laboratory characterization of 
measles virus infection in previously 
vaccinated and unvaccinated 
individuals. Journal of Infectious 
Diseases. 2011;204:s549-s558
[63] Giladi M, Schulman A, Kedem R, 
et al. Measles in adults: A prospective 
study of 291 consecutive cases. British 
Medical Journal. 1987;295:1314
[64] Levine H, Zarka S, Ankol OE, et al. 
Seroprevalence of measles, mumps 
and rubella among young adults, 
after 20 years of universal 2-dose 
MMR vaccination in Israel. Human 
Vaccines & Immunotherapeutics. 
2015;11:1400-1405
[65] Wood DL, Brunell PA. Measles 
control in the United States: Problems 
of the past and challenges for the 
future. Clinical Microbiology Reviews. 
1995;8:260-267
[66] Kontio M, Jokinen S, Paunio M,  
et al. Waning antibody levels and 
avidity: Implications for the MMR 
vaccine-induced protection. The 
Journal of Infectious Diseases. 
2012;206:1542-1548
[67] Dziurzyski K, Chang SM, 
Heimberger AB, et al. Consensus on 
the role of human cytomegalovirus 
in glioblastoma. Neuro-Oncology. 
2012;14:246-255
[68] Ariad S, Lipshitz I, Benharroch D, 
et al. A sharp rise in the incidence of 
Hodgkin’s lymphoma in young adults in 
Israel. The Israel Medical Association 
Journal. 2009;11:453-455
[69] Liu S, Semensiw R, Waters C, 
et al. Time trends and sex patterns in 
Hodgkin’s disease in Canada, 1970-1995. 
Canadian Journal of Public Health. 
2000;91:188-192
[70] Chen YT, Zheng T, Chou MC, 
et al. The increase in Hodgkin’s disease 
incidence among young adults. 
Experience in Connecticut, 1935-1992. 
Cancer. 1997;79:2209-2218
Viruses and Viral Infections 
in Developing Countries
Edited by Snežana Jovanović-Ćupić,  
Muhammad Abubakar, Ayşe Emel Önal, 
Muhammad Kashif Saleemi, Ana Božović  
and Milena Krajnovic
Edited by Snežana Jovanović-Ćupić,  
Muhammad Abubakar, Ayşe Emel Önal,  
Muhammad Kashif Saleemi, Ana Božović  
and Milena Krajnovic
This book contains information on various virus families, with the focus on viruses 
causing prevalent infections in parts of developing countries in Africa and Asia. Viral 
proteins play an important role in their replication and infection potential, and are the 
main candidates for antiviral therapy and vaccines. While some antiviral vaccines are 
available for quite some time (e.g. MMR), there are regions in the world still struggling 
with some infections. This is especially the problem in regions where the morbidity 
rate from viral infections among young children is high. This situation requires urgent 
measures to put infections under control.
Published in London, UK 
©  2020 IntechOpen 




iral Infections in D
eveloping C
ountries
ISB  978-1-838 0 969
